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2 ABBREVIATIONS AND ACRONYMS 
Standard 3-letter abbreviations for proteinogenic amino acids: 
Ala alanine 
Arg arginine 
Asn asparagine 
Asp aspartic acid 
Cys cysteine 
Gln glutamine 
Glu glutamic acid 
Gly glycine 
His histidine 
Ile isoleucine 
Leu leucine 
Lys lysine 
Met  methionine 
Phe phenylalanine 
Pro proline 
Ser serine 
Thr  threonine 
Trp tryptophan 
Tyr tyrosine 
Val valine 
Other abbreviations and acronyms: 
2-HG  2-hydroxyglutaric acid 
2-KG  2-ketoglutarate 
4-HPA  4-hydroxyphenylacetic acid 
AA amino acid 
VIII 
 
AAE amino acid enantiomer 
ACL  ATP-citrate lyase 
APCI atmospheric pressure chemical ionization 
ATP adenosine triphosphate 
BsrV broad spectrum racemase Vibrio 
CD cyclodextrin 
CE capillary electrophoresis 
CSF  cerebrospinal fluid 
DAO  D-amino acid oxidase  
E. coli Escherichia coli 
EI  electron impact ionization 
FA  fatty acid 
fc fold change 
FDR  false discovery rate 
FMOC  9-fluoroenylmethyl chloroformate 
FWHM  full widths at half maximum 
GC gas chromatography 
GC×GC comprehensive two-dimensional gas chromatography  
GlcNAc  N-acetyl-glucosamine 
HFB heptafluorobutanol 
HICA  hydroxyisocaproic acid 
HMDB  Human Metabolome Database 
HPLA  3-(4-hydroxyphenyl)-lactic acid  
HPLC high performance liquid chromatographie 
ICA independent component analysis 
IDH  isocitrate dehydrogenase 
IS internal standard 
IX 
 
LA lactic acid 
LC liquid chromatography 
LLOQ lower limit of quantification 
LOD limit of detection 
LTP  long-term potentiation 
MCF methyl chloroformate 
MDGC-MS  multidimensional gas chromatography-mass spectrometry 
MeOH methanol 
MM  master mixture 
MS mass spectrometry 
MSD  mass selective detector 
MSTUS  MS total useful signal 
MurNAc N-acetylmuramic acid 
NAA  N-Acetyl-aspartic acid 
NAFLD  non-alcoholic fatty liver disease  
NASH non-alcoholic steatohepatitis 
NBD-F  4-fluoro-7-nitro-2,1,3-benzoxadiazole 
NIST National Institute of Standards and Technology 
NMDA  N-methyl-D-aspartic acid 
NMR nuclear magnetic resonance 
PAG phenylacetylglycine 
PBP penicillin binding protein 
PCA  principal component analysis 
PCF  propyl chloroformate 
PFPA  pentafluoropropionic acid 
PG peptidoglycan 
PGA  pyroglutamic acid 
X 
 
PLA  3-phenyllactic acid  
PLOT porous layer open tubular 
PLP pyridoxal-5-phosphate 
PTV  programmed-temperature vaporization 
qMS  quadrupole mass spectrometry 
Rs resolution 
RSD  relative standard deviation 
S/N  Signal-to-noise ratios 
SCT  stem cell transplantation 
SD  standard deviations 
SIBO small intestinal bacterial overgrowth 
SIM selected ion monitoring 
TNF  tumor necrosis factor 
TOFMS time-of-flight mass spectrometry 
tR retention time 
ULOQ upper limit of quantification 
wb  to base peak width  
WCOT wall coated open tubular 
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3 MOTIVATION 
Metabolomics aims at the reliable and quantitative acquisition of the complete set of 
endogenous and exogenous small-molecule compounds present within a biological 
sample in response to environmental and genetic factors. Metabolomics methods 
should therefore be ideally capable of determining simultaneously thousands of 
organic molecules with distinctly different but also very similar physicochemical 
properties. This ambitious goal has so far eluded us, as available techniques suffer 
from insufficient selectivity and sensitivity. They do not distinguish enantiomers of 
chiral metabolites and lack in accessibility to all present metabolites. Thus, a variety 
of complementary analytical tools, including enantioselective methods, is required to 
comprehensively cover the metabolome1, 2.  
Gas chromatography coupled to mass spectrometry (GC-MS) is widely used in 
metabolomics studies. GC-MS combines high peak capacity separation, analyte-
characteristic detection, and the opportunity to structurally identify biomarkers1. 
Applied to metabolic profiling, GC-MS is used for the sensitive and selective 
determination of components of metabolite classes or metabolic pathways1. 
Commonly, however, the methods employed lack the selectivity required for the 
separation and quantitation of chiral metabolites. Chirality is not a rare phenomenon 
in the metabolome. Sugars, some lipids, most amino acids (AAs) and many organic 
acids contain one or more chiral centers. Enantiomers behave like image and mirror 
image. They are not identical but have similar chemical and physical properties with 
few exceptions. Their different interaction with a chiral environment constitutes the 
basis for their chromatographic resolution using chiral stationary phases. This is 
commonly referred to as direct approach. Diastereomers contain more than one 
chiral center with not all centers having the opposed configuration. They possess 
different physicochemical properties. This is used for indirect approaches that add 
chiral centers by derivatization. By means of these strategies the presence of both 
enantiomers of chiral metabolites, mainly AAs, has been demonstrated in all 
organisms from bacteria to human. Still, the high requirements on sensitivity and 
selectivity render the comprehensive stereoselective analysis challenging and call for 
the continued development of new methodology.  
Based on this general motivation, this doctoral thesis set out for the following aims: 
2 
 
Aim 1. Optimization of a previously developed one-dimensional gas chromatography-
quadrupole mass spectrometry method for the targeted determination of methyl 
chloroformate derivatives of selected amino acid enantiomers.  
Aim 2. Application of comprehensive two-dimensional gas chromatography - time-of-
flight mass spectrometry for improved resolution and detectability of amino acid 
enantiomers as their methyl chloroformate derivatives. 
Aim 3.  Application of one-dimensional gas chromatography in combination with both 
electron ionization quadrupole mass spectrometry and atmospheric pressure 
chemical ionization time-of-flight mass spectrometry to the untargeted detection, 
resolution and identification of metabolic enantiomers that differentiate experimental 
groups. 
Aim 4. Application of the methods developed to a mouse model of fatty acid liver 
disease with the goal of identifying urine based biomarkers in that allow the non-
invasive differential diagnosis between reversible fatty liver disease without 
inflammation and fatty liver disease accompanied by progressive inflammation, which 
leads, if not recognized and treated in time, to fibrosis, cirrhosis and, ultimately, liver 
cancer. Such biomarkers are in great need, as with the recent introduction of 
effective remedies for the treatment of viral hepatitis, fatty liver disease as one of the 
manifestations of metabolic syndrome, characterized by diabetes, hypertension, 
obesity and dyslipidemia, is expected to become the leading cause of liver cancer.  
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4 BACKGROUND 
4.1 METABOLOMICS 
The ultimate goal of functional genomics is the elucidation and prediction of the 
function and interaction of genes and their interaction in biological entities such as 
cells, tissues and entire organisms under a given set of genetic and environmental 
conditions. To that end, methods and technologies are required that allow to capture 
ideally all gene products at a given molecular level such as gene transcripts, proteins 
and metabolites in a single analysis3. The respective investigation fields are depicted 
in Figure 1, with metabolomics capturing the nonstructural phenotype of a biological 
entity1.  
 
Figure 1. The ‘omics’ cascade of investigation fields and their molecular targets and 
associated information gained. The metabolome is very predictive of phenotype. 
Adapted with permission from1. 
Genes are used to control the synthesis of proteins in organisms. Proteins regulate 
abundances of metabolites via transport and catalysis of metabolic reactions. The 
metabolome (all metabolites of a living system) is predictive of phenotype as its 
alteration reflects the response of an organism to genetic, pathogenic and other 
Genome
Transcriptome
Proteome
Metabolome
PHENOTYPE
Target Molecules Information gainedInvestigation Fields
Genomics
Transcriptomics
Proteomics
Metabolomics
What can happen
What appears to be 
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What makes it happen
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influences2. Analyses comparing and combining information gained at different levels 
of the ‘omics’ cascade suggest a high discriminatory power of metabolic profiles 
when used for characterization of organisms into groups4. 
 
4.1.1 THE FUNDAMENTALS OF METABOLOMICS 
Metabolomics and metabonomics are the two terms applied often interchangeably for 
the discipline aiming at the comprehensive, systematic and quantitative study of all 
metabolites in a living system. Materials under investigation are mostly physiological 
fluids, tissues or cells. The obtained results help to characterize metabolite function, 
interactions, reactions and their dynamic response to biological stimuli, genetic 
modification or other events5. Therefore, metabolomics generates knowledge about 
the way living systems function and provides potential for understanding the 
pathogenesis of disease6. Early diagnosis and development of novel therapeutic 
strategies are chances of a founded interpretation of metabolomics data sets. 
Furthermore, information gained by metabolomics methodologies allowed, together 
with the results from the other ‘omics’ disciplines, mapping the complex pathway 
network of energy metabolism, and understanding the underlying redox metabolism 
as well as the biosynthesis of physiologically active macromolecules and their 
precursors. Beyond, flux analyses of the metabolome aim at the detection of the 
reaction rates in the network and their regulation as response to specific biological 
circumstances.  
Metabolites are low molecular-weight molecules (typically< 1500 Da) that participate 
in metabolic reactions. Comparing physicochemical properties there are great 
differences between representatives of different metabolite classes whereas they can 
be similar for metabolites of the same class especially for isobaric metabolites like 
e.g. L-Leu and L-Ile and almost identical for enantiomers. Thus the biggest challenge 
in metabolomics studies remains the development of a method that is capable of 
capturing and resolving the whole metabolome. Currently used detection techniques 
like nuclear magnetic resonance (NMR) and mass spectrometry (MS) suffer from 
insufficient detectable concentration range 1 and selectivity, and thus do not allow to 
monitor all metabolites, not even of a simple organism like Escherichia coli (E.coli) 
holding about 750 metabolites7. The disciplines above metabolomics in the ‘omics’ 
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cascade (Figure 1) are less affected by molecular diversity as investigated 
macromolecules are basically build up from a manageable number of molecules. In 
contrast metabolomics deals with small target molecules that can be easily modified 
and transported through the whole organism.  
Metabolites can be synthesized by one or more anabolic reactions (endogenous 
metabolites) or they are exogenous and therefore are not part of any anabolic 
pathway. Metabolites can be altered and degraded by one or more catabolic 
pathways and can be excreted from the organism. The complexity of 
physicochemical properties, pathways, interactions and fluxes renders the 
acquisition, analysis and interpretation of metabolome data sets challenging. 
Different strategies, explained in the next chapter, try to tackle these problems.  
 
4.1.2 STRATEGIES IN METABOLOMICS STUDIES 
Metabolomics studies are mainly based on two different strategies: Targeted 
(Metabolic profiling, Target analysis) and untargeted analysis (metabolic 
fingerprinting, metabolic footprinting). 
Metabolic profiling methods concentrate on a number of metabolites related to a 
biochemical pathway or a metabolite class1. They often use selective sample 
preparation (e.g. extraction), separation (e.g. stationary phases with specific 
selectivity) and detection (e.g. selected ion monitoring mode of quadrupole mass 
selective detectors) to remove ‘irrelevant’ analytes and to obtain high-quality data that 
allow absolute quantification of target metabolites with high accuracy, precision and 
low LLOQs8. The objective is to investigate well-defined hypotheses. 
Targeted analysis focuses on very few metabolites like on substrates or products of 
enzymes or biomarkers of specific diseases. It aims at the direct study of primary 
effects of genetic alterations or serves as a diagnostic tool1, 9. 
Metabolic fingerprinting refers to holistic analysis of as many metabolites as possible 
and therefore is the nearest to a real metabolomics approach. It uses a 
straightforward universal sample preparation, provides low-quality data and therefore 
is only semi-quantitative. It is hypothesis-generating. The intention is to classify 
samples into groups by their metabolite patterns or ‘fingerprints’ that differ due to 
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disease, genetic or environmental perturbations1. In order to achieve this, 
chemometric or comparative visualization strategies are required to handle large and 
complex datasets10. The final goal is to identify discriminating metabolites that are 
often investigated more closely in follow-up targeted studies.  
Metabolic footprinting is a special metabolic fingerprinting approach analyzing extra-
cellular metabolites in cell culture medium to study metabolite excretion or uptake by 
cells1, 11. 
 
4.1.3 CHIRAL METABOLOMICS 
If entered into pubmed the expression ‘chiral metabolomics’ yields 24 results and the 
number increases continuously, with some publications using the term in their title12 . 
As no consistent ‘-omics’ expression was introduced so far, other names like 
enantioselective or stereoselective metabolomics can be used interchangeably. 
Subfields of metabolomics like lipidomics and glycomics reduce the scope of 
recorded metabolites. In contrast chiral metabolomics should expand the field of view 
by the resolution of stereoisomers. However, until today chiral metabolomics has 
relied exclusively on targeted analysis focusing on the separation of a few selected 
enantiomers. Researchers first competed for the development of separation 
strategies as the similarity of enantiomers in structure and physicochemical 
properties makes their resolution by conventional approaches impossible. The 
application of chiral stationary phases or alternatively the creation of diastereomers 
by a chiral derivatization reagent are established and routinely used approaches in 
chromatography, electrophoresis and NMR based chiral metabolomics. While 
biological applications have been accomplished, it became clear that not only 
selectivity but also sensitivity and linear range are major concerns in chiral 
metabolomics. Thus, preseparation steps have been included routinely in order to 
separate targets from the biological matrix. Other problems are high costs of chiral 
materials and fast aging of chiral selectors. The motivation of chiral metabolomics 
was to demonstrate the presence of rare enantiomers, and moreover to elucidate 
their biological functions. The most frequently targeted molecules in chiral metabolic 
profiling methods are AAs. The importance of the L-enantiomer is obvious as they 
are building blocks of proteins, whereas biological functions of its antipode were 
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unknown for decades for eukaryotes and are still not fully understood. Further 
metabolite classes of interest in enantioselective metabolomics have been organic 
acids13, lipids14 and metabolic degradation products of drugs15 16. A real chiral 
metabolomics approach, recording the most detailed metabolic fingerprint of a 
biological system, is the next step to go and long overdue, since the importance of 
stereo-differentiation in biochemical processes is well-known7 for a long time17. 
Today with several enantioselective methodologies being successfully tested and 
established, it is insufficient to conjointly analyze and interpret enantiomers in 
metabolic fingerprints.  
 
4.2 SIGNIFICANCE OF D-AAS AND OTHER CHIRAL METABOLITES IN ORGANISMS  
Traditionally AAs were thought to be synthesized and applied exclusively in their L-
configuration in all kingdoms of life18. Today we know that D-AAs are present in all 
kinds of organic materials even in fossils, plants and inorganic materials like e.g. 
meteorites. They are examined in fossils for age determination or in meteorites for 
the purpose of understanding the origin of life19-21. The following two chapters focus 
on existing knowledge of D-AA presence, origins and biological functions in bacteria 
and mammals including humans. These organisms comprised the D-AA sources of 
biological samples analyzed in this thesis. The last chapter of this section 
emphasizes the significance of enantiomers, others than AAs, in mammals. It 
indicates the broad scope of target molecules in chiral metabolomics.  
 
4.2.1 D-AAS IN PROKARYOTES 
Bacteria produce the highest D-AA content among all organisms and possess an 
extensive D-AA metabolism. Regulatory functions of free D-AAs and their presence 
in the peptidoglycan (PG) of the cell wall contribute essentially to the remarkable 
resistance of bacteria to physical, chemical and biological insults17. Their distribution, 
metabolism and functions in bacteria are summarized in this section. 
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4.2.1.1 DISTRIBUTION AND METABOLISM 
D-AAs can be found in the cytoplasm, in the cell wall as building blocks of the PG, in 
the periplasm, in peptides and the supernatant of bacteria17. D-AAs are released in 
the cytoplasm after their conversion from the L-configuration by several AA 
racemases, each able to catalyze the isomerization of one AA type. There are five 
types of AA racemases known. They are classified into cofactor-dependent and 
cofactor –independent. Ala racemases and Ser racemases share a similar pyridoxal-
5-phosphate (PLP)-dependent catalytic mechanism17, 22. In contrast, Glu racemases, 
Asp racemases and Pro racemases catalyze cofactor-independent conversions.  
The PG is a netlike macromolecule situated on the outside of the cytoplasmic 
membrane in almost all bacteria17. It maintains cell shape, strength and the 
resistance to osmotic pressure and is composed of linear glycan chains holding 
repeated units of a disaccharide that consists of N-acetyl glucosamine (GlcNAc) and 
N-acetylmuramic acid (MurNAc)17, 18. These strands are crosslinked by D-AA 
containing peptides. The synthesis of the PG monomers occurs in the cytoplasm 
where the, mostly D-Ala and D-Glu containing, pentapeptides are build up directly on 
a uridine diphosphate-activated MurNAc by adenosine triphosphate(ATP)-dependent 
synthetases17, 23, 24. Required D-AAs are provided with the help of D-AA 
transaminase25 and AA racemases17, 18. In the next step the peptide bound MurNAc 
is linked to GlcNAc and translocated to the periplasm where it is finally incorporated 
into the PG polymer via transglycosylation and transpeptidation by penicillin binding 
proteins (PBPs)17, 24. Besides the above mentioned most frequently found D-AAs in 
the PG, there are some bacteria known to hold other D-AAs in their cell wall like e.g. 
Enterococcus faecium holding D-Asp 26 and Lactococcus lactis, which utilizes both D-
Asp and D-Asn27. In Vibrio cholera D-Met and D-Leu have been found to replace D-
Ala on the fourth position of the peptide bridge in 3-4% of cases in stationary 
phase17. This is one effect of the remarkable production and release of D-Met, D-Leu, 
D-Val, and D-Ile in and from the periplasm, yielding in sum a D-AA concentration of 
about one millimolar in the stationary phase supernatant of these bacteria18. A broad 
spectrum racemase that was thus called BsrV (V stands for in Vibrio) was found to be 
responsible for the extensive release of these D-AA types. It is contrary to single AA 
recemases located in the periplasm and likely only active in stationary phase. 
Millimolar D-AA levels in stationary phase media are not confined to Vibrio cholera 
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but are also detected in case of other species of diverse phyla (e.g. Streptomyces 
lividans, Staphylococcus aureus and Deinococcus radiodurans). This suggests that 
many bacterial phyla encode broad-spectrum racemases, able to produce D-AAs 
different to those required typically for PG construction17, 18. Finally, there are also 
enzymes that catalyze the degradation of D-AAs like the membrane-bound, 
cytochrome-linked D-Ala dehydrogenase28. 
The bridge-peptides of the PG are not the only peptides in prokaryotes that benefit 
from the incorporation of D-AAs. Most free peptides holding D-AAs are built by 
nonribosomal peptide synthetases. There may be many more D-AA containing, 
biologically active peptides in prokaryotes, but they are probably often overlooked17. 
 
4.2.1.2 BIOLOGICAL FUNCTIONS 
Free D-AAs in bacteria are known to be utilized as carbon and energy sources for 
bacterial growth17, 28. D-AAs as components of the cell wall and of free peptides 
provide protection against degradation by proteases that catalyze mostly a cut 
between two L-AAs. Due to this protective property and the fact that most free 
bacterial peptides holding D-AAs bear antimicrobial functions, D-AAs are an 
important factor of bacterial defense mechanisms. Furthermore D-AAs bear several 
regulatory functions concerning sporulation and adaption to harsh environmental 
conditions17, 18. In 1949 D-Ala was found to be a potent inhibitor of spore germination 
and an antagonist of the highly specific germinant L-Ala in many Bacillus species. 
The promoting action of L-Ala was impeded strongly by a D-Ala portion as low as 3% 
of the present L-Ala medium concentration29. In case of a Bacillus anthracis infection 
in murine macrophages a complete inhibition of germination required the presence of 
D-Ala together with D-His30. In contrast, in Myxococcus xanthus eleven D-AA types 
including D-Ala, D-Gln, D-Asn, D-Met and D-Trp were capable to induce starvation-
independent sporulation. Among tested D-AAs only D-Asp, D-His, D-Lys and D-Pro 
did not effect starvation-independent sporulation31. D-AAs are not only building 
blocks of the bacterial cell wall, moreover they were found to manage the adaption of 
PG structure and content to stationary phase conditions 17, 18. Due to this influential 
function they also determine the shape and the strength of the cell. This remodeling 
regulation of the PG by D-AAs was investigated in detail for species releasing D-AAs 
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in the millimolar range from their periplasm to the stationary phase medium. In the 
respective study, the stationary phase PG content was doubled in a mutant lacking 
BsrV, the enzyme responsible for elevated D-AA synthesis. However, the PG of the 
wild type was 20 times more resistant to osmotic pressure and thus differed clearly in 
its structure and architecture from the mutant’s PG. The authors gathered from their 
results that D-AAs might be substrates and regulators of enzymes (PBPs) 
synthesizing and rearranging the PG network in the periplasm, and may trigger 
therefore growth inhibition when population density reaches saturation. The 
incorporation of high abundant unusual D-AAs into the cell wall was also suggested 
to contribute to the regulation of PG remodeling17, 18. A further regulatory role was 
discovered recently. It concerns biofilms being communities of bacteria. When 
biofilms age, waste products start to accumulate and nutrients become rare. 
Therefore, it becomes advantageous for biofilm-connected bacteria to leave this 
association. A mixture of D-Leu, D-Met, D-Tyr and D-Trp induced biofilm dissolution 
or could prevent biofilm formation by Bacillus subtilis at a concentration of about ten 
nanomolar. This function seems to be based on the replacement of the terminal D-
Ala in the peptide side chain of PG by the named active D-AAs, which inhibited the 
anchoring of amyloid fibers that connect cells in biofilm assembly. This effect was 
also reported for Staphylococcus aureus and Pseudomonas aeruginosa 32. 
 
4.2.2 D-AAS IN MAMMALS 
Homochirality of AAs in proteins is essential for all known organisms as it allows the 
protein its specific folding that determines its active sites and biological functions. 
However, as D-AAs were excluded from the ribosomal protein synthesis it was 
concluded that they were in general excluded from higher organisms. This 
assumption was revoked when D-AA analysis was expanded from prokaryotes to 
eukaryotic organisms. Until now D-AAs were detected in various living higher 
organisms, among others in human and other mammals in the form of free D-AAs, 
peptides and proteins33. Biochemical pathways and functions were identified and D-
AAs were suggested as biomarkers for disease and potential therapeutical targets34-
39
. The so far gained knowledge about the relevance of D-AAs in mammals is 
summarized in this chapter. 
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4.2.2.1 DISTRIBUTION AND METABOLISM 
Pätzold et al detected D-Ala , D-Asx (D-Asn+D-Asp), D-Glx (D-Gln+D-Glu) and D-Ser 
in the brain of various mammals like wallaby, mole, monkey and cow, with D-Ser 
being clearly the most abundant D-AAs in mammalian brains. The highest D-Ser 
concentration was found in the brain of monkey (4.2 µmol/g). Relative and absolute 
amounts of D-Ser were distinctly higher in the cerebrum than in the cerebellum of 
rabbit and pig40. This is consistent with the findings by Nagata et al., who found D-
Ser amounts to be high in the forebrain of rat, mouse and bull (approximately 400 
nmol/g wet weight) and low in the hindbrain. D/L ratios of Ser were approximately 
constant (~0.4) in all regions of the forebrain of rats except for the olfactory bulb 
where it was lower (~0.12)41. Significant D-Ser amounts were found to be produced 
in glial cells and neurons from L-Ser by serine racemase42. Moreover an age 
dependency of D-Ser absolute and relative levels in the fore- and hindbrain of mice 
and rat was observed 41, 43. Another D-AA found at significant concentrations in 
mammalian brains is D-Asp. High D-Asp levels were present in the cerebrum of 
young rats (≥100 nmol/g) that decreased with increasing age as did the D-Asp 
amounts in the cerebellum, kidney, liver and blood even though they were lower from 
the beginning and decreased more slowly43, 44. In contrast, in the pituitary gland D-
Asp levels increased continuously in rats over 42 weeks after birth, while in testis, 
spleen and thymus D-Asp levels increased until 14 weeks after birth43. In human 
frontal cortex D-Asp concentrations were shown to be low during lifetime but high at 
week 14 of gestation and continuously falling until birth whereas D-Ser levels stayed 
high during embryonic and postnatal life and were approximately halved in the frontal 
cortex of adolescent and aged people45. Immunostaining with a specific antibody 
revealed that D-Ala was localized to insulin producing β-cells in pancreas from rats 
46
. In addition, its location to adrenocorticotropic hormone-secreting cells of the 
anterior pituitary gland was shown47. In urine, serum and faeces D-Ala and D-Ser 
were found to be the most abundant free D-AA types in the majority of analyzed 
mammalian specimens including physiological fluids of humans48, 49,40. Urine is the 
mammalian matrix with the highest relative and absolute D-AA amounts, with D-Ala 
and D-Ser ratios around 50% and even higher in some cases (e.g. D-Ser ratios in 
urine of chimpanzee, rabbit, cat and man40, 48. Human urinary D-Ser ratios were 
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constantly high over lifetime. In rat, in contrast, excretion of D-Ser and D-Ala was age 
dependent with decreased relative and absolute amounts in urine of aged animals50. 
Moreover, high D-ornithine ratios were detected in urine specimens from mammals 
including humans. In contrast, relative D-AA blood level were found to be in the low 
percentage range except for the D-Ala ratio detected in the blood coagulate of 
wallaby (13.3%)40, 48. Hamase et al. demonstrated, that the detected allo-Ile in rat, 
mouse and dog urine referred to the D-form exclusively. Moreover, high levels of the 
D-form of Val and Ile were observed in rat urine, whereas in plasma branched D-AAs 
were not detected or detected in trace amounts except for D-Leu51. D- Amino acid 
oxidase (DAO) was the first enzyme discovered in mammalian tissues, mainly in the 
kidney, brain and liver (except for mouse liver). It is responsible for D-AA metabolism 
in mammals 52, 53. It catalyzes the catabolism of various neutral and basic D-AAs by 
oxidative deamination. The oxidative deamination of acidic D-AAs such as D-Asp and 
D-Glu is catalyzed by D-Asp oxidase, an enzyme similar to DAO that is expressed in 
the mammalian liver, kidney and the brain52, 54. Besides their enzymatic degradation 
mammalian organisms get rid of excessive D-AAs by renal excretion which explains 
high urinary D-AA contents40, 48, 51, 55. Ser racemase was the first enzyme discovered 
in mammals able to form a D-AA, namely D-Ser from L-Ser and vice versa56. The 
conversion of the stereo center with the help of the prosthetic group pyridoxal 5‘-
phosphate (PLP) of Ser racemase is shown in Figure 2. Additionally, it has been 
shown that the enzyme can catalyze the degradation of D- and L-Ser by α,β-
elimination of water, to form pyruvic acid. Ser racemase was detected predominantly 
in neurons, but also in protoplasmic astrocytes, cerebral cortex, hippocampus, 
striatum and olfactory bulb 52, 56. Recently, a second AA racemase was discovered in 
mammalian tissues namely Asp racemase. It is present mainly in brain, heart and 
testis and at low levels in the adrenal glands. Besides, its racemase function there is 
so far little known about other possible reactions catalyzed by the enzyme or 
underlying mechanisms 52, 57. 
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Figure 2. PLP-dependent reactions catalyzed by Ser racemase. Adapted with 
permission from52 
The enzymes responsible for the creation of the other detected D-AA types have not 
been discovered yet and, therefore, they may be exogenous. Main D-AA sources of 
mammalian organisms are the intestinal and oral microbial flora as well as food 
treated with bacteria for fermentation and maturation58-61. Also in non-fermented food, 
like milk, vegetable and fruit juices, D-AA have been detected at relevant quantities58, 
62, 63
.  
Besides their free form, D-AAs were also identified as constituents of mammalian 
peptides and proteins64-67. The number of detected D-AA containing mammalian 
peptides is small. Probably many of these peptides remain undiscovered as 
conventional approaches like sequencing techniques or non-stereoselective 
chromatography coupled to MS do not determine the configuration of AAs. Therefore, 
they may be easily overlooked65 . 
 
L-Serine PLP-bound L-Serine D-Serine
Dehydroalanine
+
Pyruvic acid
+
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4.2.2.2 BIOLOGICAL FUNCTIONS  
Physiological functions of D-AAs in mammals are under investigation. They are still 
not clarified for many detected D-AA types. So far researchers have been able to 
demonstrate important functions for D-Ser and D-Asp in the nervous system. D-Asp 
has been recently demonstrated to be a potent neurotransmitter68 and D-Ser was 
suggested already in 2000 as neurotransmitter69. The latter was reported to bind 
effectively to the ‘glycine site’ of the N-methyl-D-aspartic acid (NMDA) subtype of 
glutamic acid receptors and therefore is a potent co-agonist and is, in addition to the 
agonist glutamate, required for NMDA receptor activation in the brain70. NMDA 
receptors are key mediators for the excitatory transmission in the nervous system 71. 
Ca2+ dependent release of D-Ser from astrocytes enables NMDA receptor activation, 
which is obligatory for synaptic long-term potentiation (LTP) that alters synaptic 
strength, on the basis of synaptic plasticity. Therefore D-Ser contributes to learning 
and memory processes, which are inter alia considered to be based on LTP 
mechanisms71, 72. Both stereoisomers of Asp can bind to the Glu site of NMDA 
receptors and elicit thereby excitation. D-Asp was additionally found to be a precursor 
of NMDA that represents a potent agonist of NMDA receptors73, 74. NMDA was shown 
to be a product of methyl transfer from S-adenosyl-methionine to D-Asp73. D-Asp was 
detected in mammalian endocrine and neuroendocrine tissues and testis 43, 44, 75 and 
was reported to regulate the synthesis and secretion of various hormones like growth 
and luteinizing hormones73, 76, testosterone and progesterone68,77, melatonin78 and 
oxytocin79 directly or indirectly as a part of dependent events or as precursor of 
NMDA. This hormone regulation was also shown to be NMDA receptor mediated73. 
Testosterone is involved in the regulation and maintenance of spermatogenesis80. 
Therefore D-Asp levels comprise an element of spermatogenesis regulation in testis 
81, 82
. Since D-Ala was visualized to be localized to insulin producing β-cells in 
pancreas46 and to adrenocorticotropic hormone-secreting cells of the anterior 
pituitary gland and both hormones adjust blood glucose, D-Ala was suggested to be 
involved in blood glucose control47. Characterization of D-AA functions in mammals is 
an ongoing field of research and most probably there exist further D-AA activities 
awaiting discovery.  
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4.2.2.3 D-AAS AS BIOMARKERS AND POTENTIAL THERAPEUTICS 
The gained knowledge about D-AA distribution, metabolism and function led to the 
general assumption that D-AAs can serve as biomarkers and therapeutics for 
diseases affecting gut, liver, kidney or the nervous system. Indeed, researchers were 
able to demonstrate that D-AAs in physiological fluids, such as blood or urine, can be 
indicators of kidney dysfunctions34, 83. Furthermore, Ketting et.al found augmented D-
Ala ratios in urine of a patient with short bowl syndrome when compared to 
controls35. Because of their important role in the activation of NMDA receptors, D-Ser 
and D-Asp levels and those of their degrading enzymes (DAO and D-Asp oxidase) in 
the brain have been associated with diseases that are believed to be based on 
NMDA receptor dysfunction. For example decreased D-Ser levels in cerebrospinal 
fluid (CSF)36, 84, as well as increased DAO expression85 and DAO activation86 in the 
brain have been linked to schizophrenia. However, other studies failed to confirm 
these findings 52, 87, 88. Nevertheless, the administration of D-Ser in addition to other 
antipsychotics has been shown to improve schizophrenia symptomes36-38. D-Asp in 
the brain has been reported to act like an antidepressant. The respective study was 
based on experiments with mutant mice, lacking D-Asp oxidase39. 
 
4.2.3 OTHER CHIRAL METABOLITES IN MAMMALS 
Also for chiral metabolites other than AAs, enantioselective detection is a prerequisite 
for the accurate characterization of metabolic changes in the pathogenesis of 
diseases and for the meaningful use of enantiomers as diagnostic markers. To that 
end, especially small acids and hydroxy acids have been monitored. The following 
examples show that enantiomers, which were initially thought to be the ’unnatural’ 
and meaningless form of a chiral metabolite (mostly the D-enantiomer), were finally 
found to be important not only as biomarkers but also as participants in mammalian 
metabolism. D-lactic acid acidosis was detected in cases of short bowel syndrome. It 
was caused partly by bacterial overgrowth of D-lactic acid (D-LA) producing bacteria 
13, 89, 90
. As another source for the D-LA excess its production in the methylglyoxal 
pathway was suggested, which was reported to be increased in individuals with 
thiamin deficiency 89, 91. D-LA showed neurotoxic properties and the neurotoxic 
concentration was observed to be different for different patients89. Unlike the L-form, 
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D-LA was shown to be oxidized very slowly in mammalian organisms including 
humans92. However, like L-LA dehydrogenase catalyzing the formation or 
degradation of L-LA, with pyruvate as substrate or product, a respective enzyme for 
the metabolism of D-LA was characterized namely D-α-hydroxy acid dehydrogenase 
93
. Furthermore, high ratios of D-2-hydroxyisocaproic acid (D-HICA), D-3-phenyllactic 
acid (D-PLA) and D- 3-(4-hydroxyphenyl)-lactic acid (D-HPLA) were present in the 
urine of short bowel syndrome patients. The D/(D+L) ratios were around 50% for the 
latter metabolite and even higher for D-HICA (81-100%) and D-PLA (60-86%)13, 94. 
These D-forms were considered as products of bacterial AA metabolism and 
therefore, they were suggested to be indicators of bacterial overgrowth in short bowel 
disease13. The appearance of L- PLA and L-HPLA, being metabolites of L-Phe and L-
Tyr, in urine was characteristic for patients suffering from phenylketonuria or 
tyrosinaemia13, 94. In maple syrup urine disease HICA was detected in the L-
configuration94. Moreover, both pyroglutamic acid (PGA) enantiomers were detected 
in human urine specimens13. PGA results from a pH dependent intramolecular 
reaction of Glu or Gln to form the cyclic lactam. L-PGA was found to be a member of 
the γ-glutamyl cycle13, 95. The γ-glutamyl cycle, with glutathione as key metabolite, 
was suggested to be involved in AA transport95. However, Heil et al. found D-PGA to 
be the predominant enantiomer in urine (63-79%) of healthy probands. A patient that 
exhibited glutathione synthetase deficiency excreted predominantly L-PGA (>99%) 
and showed an overall increased PGA urinary level13. The origin, potential 
physiological functions and metabolism of D-PGA in mammals still await elucidation. 
The metabolism of malic acid enantiomers in rats was investigated by the 
administration of radioactive labeled L-malate or the equally labeled racemate. Both 
cases yielded comparable results including a fast metabolism of both substrates that 
was demonstrated by the excretion of radioactive carbon dioxide in the expired air. 
There was no indication for bacterial metabolism of malic acid enantiomers in the gut 
as the way of administration had little impact on the metabolic outcome96. The 
enzyme capable of metabolizing D-lactate (D-α-hydroxy acid dehydrogenase) was 
also shown to oxidize other substrates like D-malate and meso-tartrate93. For 2-
hydroxyglutaric acid (2-HG) enantiomers, there were identified two different enzymes 
catalyzing their stereoselective conversion to α-ketoglutaric acid97, 98. Mutations on 
either of the responsible genes were accompanied with the respective L- or D- 
aciduria97, 99. Mutations on the genes encoding isocitrate dehydrogenase (IDH)1or 2 
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were shown to be associated with cancer types like glioma or acute myeloid leukemia 
and resulted in the production of D-2-HG from α-ketoglutarate by the altered 
enzyme100-102. D+L 2-HG serum quantity (cut-off 2 µM) was applied as indicator for 
these mutations. The stereospecific quantification of 2-HG enantiomers led to a more 
specific biomarker namely the D/ L 2-HG ratio102. 
Albeit one enantiomer of chiral metabolites is usually the predominant in mammalian 
organisms the other was present, too. Furthermore, there were enzymes identified 
that metabolize enantiomers stereospecifically. This makes stereoselective analysis a 
necessity to achieve a more precise specification of metabolic disorders. As several 
‘unusual’ stereoisomers have been considered as bacterial metabolites they may 
serve as markers for diseases affecting the gut. The so far gained knowledge about 
antipodes of chiral metabolites demonstrates the chances of enantioselective 
techniques allowing the assignment of abundances, metabolism and functions of 
single enantiomers in mammals. Finally, chiral analysis is essential for the 
characterization of the active enantiomer of chiral drugs. They improve the 
understanding of the enantiospecific metabolism and therefore of possible side 
effects or toxicity caused by the administration of racemic drugs15, 103 . 
  
4.3 SEPARATION OF ENANTIOMERS 
4.3.1 HISTORY AND NOMENCLATURE 
History. It took until 1848 for molecular chirality to be visualized for the first time, 
although we are daily surrounded by chirality, because objects like our hands, a 
corkscrew, or a sea shell are nonsuperimposable to their mirror picture. In 1848 Louis 
Pasteur observed the spontaneous resolution of racemic sodium ammonium tartrate 
tetrahydrate during its crystallization from aqueous solution. He sorted the resulting 
two crystal forms that were nonsuperimposable and therefore chiral104, 105. He 
detected the opposite rotation of the plane of polarized light for the two solved crystal 
groups. The angle of rotation, however, was the same104. The respective property of 
enantiomers, called optical activity, had been already recognized in the early 
nineteenth century by Biot and other scientists, but they had not understood the 
cause for the rotation. Fresnel’s discovery of circularly polarized light was inevitable 
for the explanation of optical activity. Enantiomers show different refractive indices for 
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left and right circularly polarized light that overlaid results in linearly polarized light104, 
106
. Therefore, the velocity of left- and right-circularly polarized light was different after 
passing a solution with an optical active substance, leading to the rotation of the 
polarization plane of the two overlaid light rays106. These are the fundamentals of the 
first method for the determination of enantiomer ratio, which were summarized by the 
term ‘optical rotatory dispersion’. In 1874 Van’t Hoff and Le Bel independently 
postulated the tetrahedral structure of four substituents on a carbon atom and 
therefore the asymmetry of the shape in consequence of four different substituents. 
These reports provided the explanation for Pasteur’s mirror image crystals and for 
molecular chirality in general104, 105. Louis Pasteur was also the first to demonstrate 
the importance of stereochemistry in biochemical processes by showing that 
enantiomers of ammonium tartrate were metabolized with different velocity by a mold 
fungus105. The invention of gas chromatography finally provided a technique with 
sufficient resolution for the separation of enantiomers. However, the first gas 
chromatographic separation of enantiomers was not realized until 1966. Gil-Av et al. 
separated Ala, Val and Leu stereoisomers, applying an optically active stationary 
phase107, 108.  
Nomenclature. In 1891 Emil Fischer invented the so-called Fischer projection as a 
simple way of illustrating chiral structures of molecules to describe the configuration 
of an asymmetric C center. On the basis of this projection and the model molecule 
glyceraldehhyde, he introduced the Fisher nomenclature. In the Fischer projection 
horizontal bonding lie above the paper plane, vertical ones below and the asymmetric 
(chiral) center lies in the paper plane. This two-dimensional way of displaying a three-
dimensional structure is shown exemplarily in Figure 3 by applying Fisher’s rules to 
AAEs in their physiological form. Fischer assigned the (+)-stereoisomer, rotating the 
polarization plane to the right, to D- glyceraldehyde and the (-)-stereoisomer, rotating 
the polarization plane to the left, to L- glyceraldehydes. When a moiety of a chiral 
molecule, considered to be the equivalent to the Cα hydroxy group of 
glyceraldehydes, is situated on the left side of the chiral center in Fischer projection 
the configuration is described by the prefix L. When it is on the right side the prefix D 
is used. 
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Figure 3. Fisher projection, applied to the structure of AAEs. DL-configuration was 
assigned according to the example of glyceraldehyde enantiomers. R refers to the 
characteristic moiety of each AA types except Gly which is achiral. 
However, Fischer’s assignment was arbitrary as he had no means to determine the 
absolute configuration of glyceraldehyde enantiomers109. Sixty years later Bijvoet et 
al. were able to clarify by means of x-rays, using a phase lag, that Fischer’s 
assumption represented the true stereochemical situation110. Recently, the innovative 
technique of foil-induced Coulomb explosion allowing to image the positions of 
substituents of chiral centers was presented, in order to directly determine the 
absolute configuration of small molecules from the gas phase111. Nevertheless, 
Fischer’s nomenclature is only definite for one chiral center and requires the 
invention of additional prefix (e.g. allo) or terms for the description of diastereomers 
(e.g. threonic acid enantiomers are diastereomers of erythronic acid enantiomers) 
and becomes unclear for multiple asymmetric centers within a molecule. In 
consequence, the Cahn-Ingold-Prelog priority rules were defined for substituents of 
chiral C atoms as the basis for the RS nomenclature allowing a definite description of 
configuration of all chiral centers in a molecule. They include sequence rules for 
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complex moieties and are based on the positive correlation of priority with the atomic 
number. With the view from the asymmetric C atom to the moiety of lowest priority, 
the R configuration is assigned when priority of the other three moieties, decreases 
clockwise. Prefix S describes the opposed stereochemical situation. Albeit the RS 
nomenclature offers a more detailed and clear assignment of configuration, the DL 
nomenclature has prevailed for biomolecules. However, the RS system is essential 
for the description of enzymatic reaction mechanisms109. Since the analyses of this 
work focused on small metabolites, including at maximum two asymmetric C atoms, 
the DL nomenclature was used.  
 
4.3.2 PRINCIPLES OF ENANTIOMER SEPARATION  
One of the first strategies to determine AAE ratios in complex biological specimens 
employed immobilized enzymes that stereospecifically catabolize AAs. Appropriate 
detection techniques allow the sensitive quantification of produced α-ketoacids. 
However, these sensors have limitations such as short life times of the active layer 
and distinctly different sensitivity for different AA types because of individual reaction 
kinetics. The quantification of both antipodes required the immobilization of two 
different stereospecific AA oxidases112-115. Column chromatographic and 
electrophoretic approaches prevail for the separation of enantiomers and are 
generally based on two different strategies. Indirect approaches separate 
diastereomeric derivatives of target enantiomers, which possess different physical 
and physico-chemical properties, using achiral selectors or columns 108, 116, 117. Limits 
of this strategy can be the absence of chemical groups amenable for the reaction 
with chiral reagents, the occurrence of kinetic resolution or racemization during 
derivatization and a lack of availability of enantiomerically pure reagents. The latter 
problem can be solved by applying correction factors to obtain accurate quantification 
results117, 118. Direct approaches use chiral nonracemic (pseudo) stationary phases 
that form diastereomeric association complexes with derivatized or underivatized 
enantiomers. The chiral selector does not have to be enantiomerically pure117. 
Different stabilities of the two complexes, resulting in different partition coefficients, 
enable the resolution of enantiomers108, 117. In the first direct GC based approach Gil-
Av et al. applied N-trifluoroacetic –L-Ile lauryl ester groups in the liquid stationary 
phase to enable resolution of branched chain α-AAEs107. This strategy had some 
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drawbacks for the analysis of complex samples like time-consuming method 
optimization due to high sensitivity to chromatographic conditions and low selectivity 
for nonchiral chemical functionalities. Nevertheless, the direct approach is currently 
used most frequently for the gas chromatographic analysis of AAEs. Further 
limitations and chances of both strategies were discussed recently for the separation 
of AAEs116. 
 
4.3.3 OUTSTANDING METHODS FOR ENANTIOSELECTIVE METABOLIC PROFILING 
Based on the direct or indirect approach several relevant column chromatographic 
and electrophoretic methodologies were described and discussed in my diploma 
thesis and in a trend article in view of the suitability for biomedical AAE analysis. 
These publications list and comment the most commonly used chiral stationary 
phases and derivatization reagents116, 119. The following chapters highlight 
outstanding methods, performing best, not only in the resolution of AAE and other 
stereoisomers, but also with regard to precision, accuracy, sensitivity and applicability 
to biological matrices. 
 
4.3.3.1 COLUMN CHROMATOGRAPHY METHODS FOR AAE ANALYSIS 
The most innovative high performance liquid chromatography (HPLC) based 
methods for the resolution of AAEs were presented by Hamase et al. and Barbaro et 
al., who applied chiral columns for the separation of fluorescent derivatives or 
underivatized AAEs51, 120. Hamase et al. achieved resolution of all proteinogenic 
branched chain AAE and of allo-Ile enantiomers by their two-dimensional approach. 
They used a conventional reversed phase column for the first and an 
enantioselective column for the second dimension. Overall, the method showed good 
performance with appropriate within-day and day-to-day precision and recoveries 
between 95.5 and 100.2 % of AAE amounts spiked into blood plasma. Fluorescence 
detection resulted in a LLOQ of 5 fmol of injected D-AA. The method was applied to 
the analysis of rat urine, plasma and tissues and urine of dog and mouse. However, 
the method was time-consuming due to derivatization, 60 minutes of reversed phase 
analysis and five minutes of enantioselective analysis for each AAE pair51. Other two-
dimensional HPLC approaches allowed the precise and sensitive quantification of Ala 
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or Ser enantiomers after fluorescence derivatization with 4-fluoro-7-nitro-2,1,3-
benzoxadiazole (NBD-F), and 30 or 40 minutes of analysis, respectively121. Barbaro 
et al. achieved the resolution of 19 AAE pairs (thereof 16 proteinogenic AA types) 
within a single chromatographic run. Two different mass selective detectors were 
tested. The LTQ-Orbitrap XL offered high mass accuracy, whereas the triple 
quadrupole mass spectrometer showed superior limits of detection (4 - 200 ng/L 
instead of 0.4-7µg/L with the Orbitrap detector). The use of isotopically labeled AAEs 
reduced matrix effects for all analytes except for D-Ser. Therewith, the method 
proved to be the most effective for the simultaneous analysis of a large number of 
AAEs in biological specimens within 35 minutes. However, the applied chiral column 
did not allow the separation of Ile/Leu isomers. Furthermore, spike-in experiments 
revealed that the method was not applicable to the quantitative analysis of D-Ser, D-
Orn, L- and D-Trp as matrix effects hampered their accurate determination. 
Nevertheless, the method using the Orbitrap promised high potential for future 
untargeted analysis of chiral metabolomics120. 
From the published GC based methods for AAE analysis the one presented by 
Zahradníčková et al. showed notable enantioselectivity and sensitivity. It was 
validated in detail in respect of its applicability to biological specimens. An 
appropriate separation was achieved for 15 proteinogenic AAE pairs within 47 
minutes using pentafluoropropylchloroformate and pentafluoropropanol reagent for 
derivatization and Chirasil-L-Val as chiral selector. AAE were extracted from 
biological samples using a cation exchanger. Resulting limits of detection (LODs) 
ranged between 0.29 and 3.25 µM and the method showed sufficiently low relative 
standard deviations (RSDs) and good recoveries for all AAEs except for Glu, Gln, 
Asp and Asn enantiomers. Several D-AAs could be detected in samples of 
cyanobacteria122. Schurig et al. demonstrated the superior enantioselectivity of L-Val 
based chiral stationary phase when applied to AAEs as their N-pentofluoropropanoyl 
isopropyl ester derivatives using hydrogen as the mobile phase. Seventeen 
proteinogenic types of AAE pairs could be separated in less than 35 minutes with 
most of them showing baseline resolution. Histidine enantiomers required further 
modification of the imidazol-N by an ethylbutoxycarbonyl group to allow their 
separation and elution from the chiral column. The competitive counterpart of the L-
Val-tert-butylamide modified polydimethylsiloxane phase for successful AAE analysis 
were alkylated –γ-cyclodextrins (CDs), as chiral selectors, solved in (Lipodex E) or 
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linked to (Chirasil-γ-Dex) a polydimethylsiloxane backbone. Thirteen proteinogenic 
types of AAE pairs were baseline separated by Schurig’s group as their trifluoroacetyl 
ethyl ester derivatives using a Chirasil-γ-Dex kind of stationary phase and hydrogen 
as carrier gas. This selector was thermally more stable than the L-Val selector as e.g. 
racemization of all chiral centers of the glucose molecules is very unlikely. 
Furthermore, the γ-CD selector was contrary to the L-Val derivative able to separate 
β- and γ-AAs as well as N-methyl-α-AAs. Despite their excellent AAE resolution, 
Schurig et al. did not pursue the applicability of these methods to biological matrices 
and unfortunately their self-made stationary phases were not made commercially 
available123. 
 
4.3.3.2 CAPILLARY ELECTROPHORESIS METHODS FOR AAE ANALYSIS 
Han et al. presented a straightforward method for the direct analysis of the 19 
proteinogenic pairs of AAEs that can be automated due to efficient on-column 
derivatization with 9-fluoroenylmethyl chloroformate (FMOC) for UV detection. 
Applying 30 mM β-CDs in the buffer, the method achieved baseline separation of 17 
pairs of AAEs and partly separated Ala and Arg enantiomers. However, the method 
was validated exclusively for Asp and Glu enantiomers that showed good linearities 
and recoveries when spiked into human serum as well as RSDs <5.4 % for peak 
areas, as a figure of merit for interday precision. The determined LODs of Glu (4.0 
µM) and Asp (3.2 µM) were insufficient for the detection of D-Glu and D-Asp in serum 
of healthy volunteers. The limited linear range and insufficient sensitivity for the 
application to human serum remain major drawbacks of the method, although at the 
chosen pH other D-AA yielded higher peak intensities than D-Glu and D-Asp124. 
 
4.3.3.3 GC-MS METHOD FOR ORGANIC ACID ANALYSIS  
Multidimensional (heart-cut) gas chromatography-mass spectrometry (MDGC-MS) 
was successfully applied for the separation of five enantiomer pairs of organic acids 
(LA, HICA, PLA, PGA and HPLA) as their methyl esters using a modified β-CD as 
chiral selector in the second dimension. The enantiomers were separated within a 
single chromatographic run of 100 minutes using hydrogen as mobile phase. Even 
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though no validation data were reported, the application of the method to urine of 
patients suffering from inborn errors of metabolism was demonstrated and 
enantiomer ratios, characteristic for the disorders, were found13. 
 
4.4 GC-MS TECHNIQUES FOR ENANTIOSELECTIVE METABOLOMICS 
This chapter explains how the analytical techniques employed in the course of this 
thesis function and which operation modes and detectors were used. Further, it 
points out chromatographic parameters meaningful for a successful separation of 
chiral and non-chiral metabolites. 
 
4.4.1 GAS CHROMATOGRAPHY – QUADRUPOLE MASS SPECTROMETRY (GC-QMS) 
Gas chromatography is an analytical technique that is used, beyond the separation of 
complex samples, for the study of reaction kinetics or for analyte characterization by 
assessment of physicochemical properties125. It uses an inert gas as mobile phase 
that transports analytes in gas phase along the solid or liquid stationary phase126. 
Therefore, the technique is amenable only for volatile and thermally stable analytes. 
However, vapor pressure of polar analytes like AAs and other small metabolites can 
be increased by derivatization with less polar chemical groups, which allows GC 
analysis of non-volatile molecules1. Typical mobile phases in GC applications are 
helium, argon, nitrogen or hydrogen. Nowadays, capillary columns are mostly 
employed. PLOT (porous layer open tubular) columns are capillary columns with a 
solid stationary phase coated on the inner wall of the capillary, whereas WCOT (wall 
coated open tubular) capillary columns feature a liquid coating on the inner wall as 
the discriminating stationary phase. Column diameter, film thickness of the active 
layer, and column length are the key parameters affecting separation efficiency. The 
partitioning coefficient K is characteristic for the analyte-stationary phase interactions 
and therefore determines the degree of retention. It is temperature dependent 
(lnK~1/T)127. Thus, the adjustment of temperature for isothermal analysis or the 
implementation of a temperature program (recommended for analytes with a wide 
boiling point range) is an important issue in method optimization in order to obtain 
baseline separation125, 126. Chromatographic resolution is defined as follows:  
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where Rs refers to resolution, tR to retention time, wb to base peak width, 
and FWHM to full widths at half maximum. Index 1 labels the first eluting 
compound, index 2 the successive one. 
For accurate quantification of stereoisomers and other isobaric substances, a 
chromatographic resolution ≥1.5, that marks baseline separation, is required if a 
mass selective detector is applied. For a non-selective detection technique, all target 
peaks require baseline resolution for proper quantification. 
Samples are introduced onto GC columns by means of an injector. Commonly, 
split/splitless or programmed-temperature vaporization (PTV) injectors are used. In 
both cases, the sample is injected by a syringe through a septum into the liner, which 
is a small chamber in which evaporation takes place. Both injectors are able to 
perform split and splitless injection. The whole injected sample amount is transferred 
onto the column in case of splitless injection, whereas only a definite split ratio of the 
injected amount reaches the column in split mode while the remaining volume is 
purged to the split outlet. PTV injection refers to a cold injection with a subsequent 
fast temperature program and is therefore a mild injection that is suitable for targets 
of low thermal stability.  
Mass analyzers are more and more favored as detectors for GC applications of 
complex matrices as they offer high sensitivity and selectivity and help to identify 
‘unknown’ structures. Quadrupole mass spectrometric detection after electron impact 
ionization (EI) is a robust detection technique that is widely used for the analysis of 
metabolomes. Electron impact ionization is a hard ionization technique in which 
electrons are emitted with a standard energy of 70 eV. The impact of the energy-rich 
electron causes fragmentation and ionization of analytes eluting from the column. 
Consequently, obtained mass spectra usually do not contain the molecular ions but 
fragment ions indicate chemical groups and therefore provide essential information 
on molecular structure. The standardized electron energy and high reproducibility 
and robustness of quadrupole detectors facilitate structure identification as spectra 
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can easily be compared e.g. with created libraries1 using algorithms that search for 
spectral matches.  
The quadrupole detector uses four parallel rods, usually of 15 cm length, with 
constant direct current and alternating radio-frequency voltages applied to them, to 
filter ions of different masses126. The resolution of a quadrupole detector is 
dependent on the ratio of the alternating voltage and the direct current voltage and a 
ratio tightly below 6 was identified for maximal resolution. The detector can be 
applied either in scan mode, in which both alterating and direct current are 
continuously increased to allow every ion mass to pass the filter at a given time126, or 
in SIM (selected ion monitoring) mode that allows the selection of target ion masses 
in retention time windows. SIM mode is often applied to metabolic profiling, because 
it provides improved sensitivity due to a longer acquisition time per ion. Scan mode is 
used for fingerprinting analysis and during method optimization to asses an 
appropriate temperature program for a given aim.  
 
4.4.2 COMPREHENSIVE TWO-DIMENSIONAL GAS CHROMATOGRAPHY – TIME-OF-FLIGHT 
MASS SPECTROMETRY (GC×GC-TOFMS) 
Significance. To separate complex metabolomes from physiological fluids or tissues 
is challenging and one-dimensional GC methods often lack in selectivity, which 
results in coelutions. Mass spectrometric detection helps to quantify overlapping 
metabolites based on their characteristic mass fragments or (quasi-)molecular ions. 
Nevertheless, isobaric metabolites like structural isomers or stereoisomers cannot be 
differentiated by their mass spectra and require baseline separation. For metabolic 
profiling or targeted analysis selective sample pretreatment or selective detection 
techniques can help, if target monitoring is impeded by matrix peaks. However, if two 
target isomers overlap, a more selective technique which offers multiple separation 
mechanisms has to be chosen such as multidimensional GC (MDGC or GC-GC) or 
comprehensive two-dimensional GC (GC×GC). The latter technique is preferable for 
complex matrices and trace analysis due to its multiplicative peak capacity and 
improved sensitivity. In contrast heart-cut multidimensional GC allows the transfer of 
only few effluent portions of coeluting peaks to a second stationary phase. 
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Basics. The innovative analytical technique of GC×GC was invented in 1991128. It 
transfers the complete sample from the first column to the second dimension column 
by means of modulation. A schematic setup of the technique is shown in Figure 4. 
  
Figure 4. Schematic GC×GC-TOFMS setup. Adapted with permission from10, 129. 
A so-called “orthogonal” separation is based on two serially coupled stationary 
phases with distinctly different interaction mechanisms yielding a significant 
improvement of the overall selectivity. Both columns are operated typically 
temperature programmed in two individual ovens or in one shared. Analytes reaching 
the modulator are retained and therefore focused before they are released as sharp 
peaks to the second dimension analysis. Since the second dimension separation is 
very fast, nearly no peak broadening occurs until peak detection. This narrow peak 
shapes are typically accompanied by a considerable gain in peak height and 
therefore increased Signal-to-noise ratios (S/N)130. A high modulation frequency (2-8 
seconds of modulation time) is required to maintain first dimension resolution. 
Therefore, a minimum of three modulations per first dimension peak is 
recommended. Also the preceding fraction should be eluted before the next is 
released to avoid a so-called ‘wrap around’ that hampers a well-arranged and 
structured separation space. Consequently narrow short columns are used for the 
second dimension analysis keeping retention times to a few seconds131.  
Data visualization. Typically only one detector is used at the end of the set-up that 
records a continuous signal of serially linked second dimension chromatograms. The 
obtained picture is complex and difficult to interpret. For a better visualization the 
acquisition software provides contour plots or 3D plots by cutting the raw 
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chromatogram at each fraction release based on modulation time and by combining 
the individual second dimension chromatograms in parallel.  
 
Figure 5. Raw GC×GC chromatogram, contour plot and three-dimensional 
presentation. Green, orange and purple arrows indicate how the contour plot is 
constructed from the cut raw GC×GC chromatogram pieces. The arrow length in the 
raw chromatogram refers to the modulation time. Adapted with permission from10, 129. 
The resulting 3 D picture displays the retention time of the first dimension separation 
on the x-axis, second dimension retention time on the y-axis and peak intensity on 
the z-axis. In a contour plot there is no z-axis but intensity is coded by colors130, 132. 
The concept of generating a contour plot and the 3D plot, respectively, from the 
actual GC×GC raw chromatogram is depicted in Figure 5. 
Modulation. Different modulation strategies have been developed that enable two-
dimensional separation. In pulse flow modulation, analytes eluting from the first 
column into the transfer line are focused by two successive gas pressure pulses, one 
in the beginning and one in the end of the transfer line, introduced via T connecters. 
Chemical bands are stored in the modulator capillary for a few seconds before their 
re-injection into the second column133. Although the method provided effective 
sample focusing and an appropriate re-injection frequency, thermal modulation 
strategies prevailed in the short history of GC×GC. The inventors of the GC×GC 
Retention time 1st dimension Ret. t.
S
ig
n
a
l
Contour plot
GC×GC Chromatogram
3D  presentation
2
n
d
 d
im
e
n
si
o
n
R
e
t.
 t
.
29 
 
technique were the first to trap fractions applying heat to the modulator tube by a 
rotating sweeper128, 134. Cryogenic modulators induce local clocked temperature 
changes realized at two nearby capillary regions either by a periodically moving 
cooler device or by two fixed cryogenic jets using liquid CO2 for retention135-137. This 
refers to the so-called dual stage modulation, which was also realized in the set-up 
with four jets installed pairwise, which was applied in the course of this thesis. It 
mediates the injection-like launch of narrow bands by alternating cold/heat pulses. 
The jets are triggered in a way that the moment one trapping station is heated, the 
other is cooled and vice versa in the next pulse period. This is illustrated in Figure 6. 
  
Figure 6. Simplified presentation of a hot/cold pulse sequence of one modulation by 
a dual-stage four-jet modulator. Adapted with permission from10, 129. 
This pulse sequence prohibits the breakthrough of an unfocused chemical band. 
Cold nitrogen gas is produced via heat exchange with liquid nitrogen and transported 
to the cold jets and hot air is directed to the trapping region through the hot jets136. 
The omission of moving components has proven to be preferable for robust high-
throughput analysis by GC×GC. 
Detectors. All of the above explained modulators provide efficient band focusing and 
therefore narrow peaks typically between 0.1 and 0.6 s of baseline peak width131. At 
least 15 points have to be recorded to quantitatively describe a peak. For peaks 
yielded from two-dimensional analysis, detection techniques with high acquisition 
rates (at least 150 Hz) need to be chosen. Flame ionization detectors and 
microelectron capture detectors were demonstrated to meet this challenge131, 136. 
However, to reach the maximum grade of selectivity, MS detectors have to be 
employed. Mostly time-of-flight mass spectrometers (TOFMS) were applied with EI 
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and nominal mass resolution. Instruments like the here used Pegasus IV GC×GC-
TOFMS from LECO (Corporation, St. Joseph, MI, USA) are able to generate up to 
500 spectra per second and therefore accomplish precise peak mapping for accurate 
and reproducible semi-quantification or quantification applications in complex 
matrices. 
 
4.4.3 GAS CHROMATOGRAPHY – ATMOSPHERIC PRESSURE CHEMICAL IONIZATION – TIME-OF-
FLIGHT MASS SPECTROMETRY (GC-APCI-TOFMS) 
To couple GC to high-resolution  MS and gain a powerful tool for structure elucidation 
of discriminating compounds in untargeted analysis, a soft ionization technique is 
inevitable to maintain molecular shape. APCI is suited to fulfill this requirement. 
Formation of protonized molecular ions proceeds via a series of ionization and 
clustering reactions initiated by a corona discharge electrode exposed to a high 
electric field. Electrons are emitted from the tip of the needle that ionize surrounding 
nitrogen gas. After cluster formation of the nitrogen ions, the positive charge is 
transferred to water molecules from air moisture that in the following associate in 
water clusters holding an excessive proton138-140. The assimilation of such protons by 
eluting compounds finally yields the quasi-molecule ions amenable for accurate 
molecular mass analysis. The respective reactions can be displayed as follows: 
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M describes a compound subjected to soft ionization in the APCI source. 
Reproduced with permission from141 
 Although this concept was introduced already in 1973 by Horning et al., it attracked 
little attention as a GC coupling device to accurate mass detection, possibly because 
of the expensive setup using a β-emitter (63Ni) foil instead of the corona needle139, 142. 
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It took another 30 years until new variants of the interface, actually commercialized 
for LC-MS coupling, offered its universal usage for both GC and LC connection to 
MS143, 144 and initiated its breakthrough in the field of GC analysis. The promising 
coupling device was optimized and launched by Bruker Daltonics and Waters 
Corporation, simultaneously. Later, also Agilent Technologies provided an 
appropriate interface. GC-APCI-TOFMS was validated initially for profile analysis by 
researchers interested in the quantitation of pharmaceutical impurities145, phenolic 
compounds in olive oil146 or metabolites in human CSF142, 147. It offered satisfactory 
repeatability, sensitivity and ionizeable polarity scope for their objectives. Wachsmuth 
et al. established the feasibility of GC-APCI-TOFMS for the fingerprinting of 
methoximated and silylated metabolites. First, the performance of the technique was 
evaluated for 43 chemically diverse metabolites in comparison to the routinely 
applied hard (EI) and soft (chemical ionization) ion sources for the coupling of one- or 
two-dimensional GC to fast-scanning low-resolution TOF or quadrupole mass 
detection. GC×GC-EI-TOFMS was the only technique that provided wider linear 
ranges for quantitation. The new coupling performed as good as commonly used 
metabolomics instrumentations with respect to repeatability and linearity except for 
GC-EI-qMS that showed lower RSD for derivatization replicates. Moreover, APCI-
based metabolic fingerprints of different E. coli strains outperformed the comparable 
GC×GC-TOFMS study in the number of structure elucidated discriminating features. 
Six additional metabolites were assigned due to selective adduct formation in the 
APCI source and sum formula prediction based on accurate mass and isotopic 
pattern141, 148.Next, Wachsmuth et al. optimized the M-H+ yield of MeOH/MCF 
derivatives in the APCI source by continuously injecting water into the ionization 
space at a rate of 0.4 mL/h. As a consequence, the variance of fingerprints within 
experimental groups was reduced, which helped to distinguish differently treated 
cancer cells by a greater number of detected and statistically discriminating features. 
M-H+ abundance, however, was not influenced by water infusion in case of 
methoxime-trimethylsilyl derivatives149. 
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4.5 HOW TO GAIN RELEVANT ENANTIOSELECTIVE INFORMATION 
4.5.1 PRE-SEPARATION FROM THE BIOLOGICAL MATRIX 
What essentially drives method optimization in chiral metabolomics is the objective of 
baseline separating as many pairs of enantiomers as possible, to monitor their ratios 
and contents. The price that many researchers had to pay was low overall selectivity 
provided by chiral selectors and therefore high limits of detection resulting from 
moderately separated enantiomers from the biological matrix. This, however, 
hampers enantiomer determination in complex biological samples. To overcome 
these limitations, complex matrices like mammalian plasma and urine were subjected 
to achiral pre-separation steps to isolate target molecules, applying e.g. cation 
exchangers35, 40, 122 and two-dimensional thin-layer chromatography83, 150 before 
chiral AA analysis. However, such procedures are labor-intensive, time-consuming 
and not suited for untargeted analysis. That’s why chiral metabolomics still requires 
the implementation of new methods based on innovative separation techniques 
offering both appropriate enantioselectivity for a broad range of chemically diverse 
stereoisomers and high overall selectivity. 
 
4.5.2 DERIVATIZATION AND CHIRAL SELECTORS  
Since established chiral selectors offer enantiomer discrimination based on different 
interaction types, the choice of the most effective selector/derivative combination is 
crucial for the baseline separation of a given set of target enantiomers. Despite the 
great variety of chiral selectors available in particular for LC analysis, the structure/ 
resolution relation was most frequently investigated for the application of CDs and 
derivatives thereof. CD selectors were not able to differentiate native AAEs in LC 
analysis except for aromatic AAEs 151-153. Thus, the adjustment of selector/derivative 
structures was often considered. CDs are α-1,4-connected glycopyranose units 
forming a cyclic tapered cavity accessible for interior hydrophobic interactions for 
analytes able to enter this small discriminating room154-156. The diameter of the 
broader entrance was gauged to be approximately 6, 8 and 10 Å for α, β or γ−CDs 
including 6,7 or 8 sugar blocks, respectively154, 156. Cavity height was estimated to be 
5-9 Å for native α−γ CDs156. The external side allows hydrophilic interactions no 
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matter if unmodified CDs or derivatives carrying polar groups such as acetyl, 
hydroxyalkyl or thio are used116, 155.  
 
Figure 7. Chiral selector moieties are linked to the polydimethylsiloxane backbone of 
two enantioselective stationary phases typically employed for GC analysis of AAs. 
CD derivatives were introduced to increase solubility in aqueous–organic solvents 
and therefore selector concentration116. Traditionally, CDs were thought to provide 
enantioselectivity predominantly by formation of inclusion complexes155 until Sicoli et 
al. demonstrated that linear acetylated/silylated malto-oligosaccharides were also 
able to separate a number of chiral aromatic compounds, amines, alcohols and α-
AAEs. With their study they pointed out the high impact of hydrophilic interactions on 
chiral resolution. Nevertheless, CDs provided superior discrimination of enantiomers 
in most cases157. With the restricted dimension of the hydrophobic cavity and polar 
groups at its opening that further decrease its effective diameter, the stability of 
inclusion complexes mainly depends on spatial factors, hydrophobic interaction and 
hydrogen bonding116, 155. Thus, matching the chemistry and shape of both the 
selector host and the analyte guest are highly recommended to adjust their 
complementarity and thereby enhance binding affinity156. This was performed in CE, 
LC and GC based studies to improve enantioselectivity19, 151, 153, 155, 158. Additionally, 
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for the application of chiral GC the performance of L-Val based stationary phase, 
providing enantiomer discrimination by hydrogen bonding, was tested for different 
AAE derivatives, including N-perfluoroacyl-(perfluoro)alkyl esters and N-(perfluoro)-
alkyl alkoxy (perfluoro)-carbonyl esters. They resulted from the reaction of anhydrides 
or chloroformates and alcohols with amino-, hydroxy- and carboxy groups 19, 20, 122, 
158
. The Chirasil-L-Val and Chirasil-γ-Dex chiral selector moieties linked to the 
polydimethylsiloxane backbone are shown in Figure 7. The method employing 
pentafluoropropyl chloroformate and pentafluoro propionic acid for derivatization and 
Chirasil-L-Val for separation offered notable enantioselectivity. It resolved 15 pairs of 
AAEs. The fluorinated chloroformate was synthesized, because it was not 
commercially available122. Derivatization with fluorinated anhydrides in combination 
with fluorinated alcohols was investigated intensively by Zampolli et al. for the 
analysis of AAEs on both the L-Val based and a γ-CD derivative (RT-γ-DEXsa) based 
GC column. The more fluor atoms had been added to the AAEs the higher was the 
detected response, whereas overall enantioselectivity decreased with increasing 
derivative size for both column types tested. Furthermore, the derivatives including 
longer fluorinated chains showed only slightly increased retention on Chirasil-L-Val 
and even decreased retention on the γ−CD based column 19, possibly due to their 
bigger size, disabling the formation of inclusion complexes. Limitations of 
anhydride/alcohol derivatization were the hydrolyzation of Asn and Gln under acidic 
conditions yielding Asp and Glu, respectively, and the time-consuming two-step 
procedure20, 40, 48, 158. Even though Zampolli et al. realized the less laborious one-step 
procedure using fluorinated anhydrides and alcohols, this procedure caused high 
racemization rates during derivatization (10-40% of pure enantiomers isomerize 
depending on the AAE moiety)19. The group considered this phenomenon to be 
negligible for their application to space analysis19 but chiral metabolomics aims at the 
detection of D-AAs in the low percentage range, which is impeded by isomerization. 
My own attempts to elucidate the nature of racemization during one-step 
derivatization with pentafluoropropionic acid (PFPA) and heptafluorobutanol (HFB) 
indicated, that PFPA hydrolyzed to form pentafluoropropionic acid that can catalyze 
racemization. Reducing applied PFPA volume or keeping PFPA strictly under 
nitrogen reduced racemization albeit not sufficiently to allow accurate AAE analysis in 
physiological fluids158.  
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The basis of the present doctoral thesis were the experiments of my diploma thesis, 
in which I had compared the performance of three different chloroformate/alcohol 
derivatization chemistries and six anhydride/alcohol derivatization strategies for the 
GC separation of proteinogenic AAEs on a Chirasil-L-Val and an RT-γ-DEXsa 
column, respectively. Pros of the L-Val based selector were high selectivity for 
different proteinogenic AA types and short run times, whereas column bleed and the 
inability to distinguish Pro enantiomers were cons. An important consideration in the 
selection of an appropriate chiral selector is the preferred elution of the low abundant 
enantiomer prior to the enantiomer present in excess, to avoid peak masking of small 
D-AA signals by peak tailing of the nearby L-AA signal. Both chiral selectors provided 
the favored elution order. RT-γ-DEXsa showed lower column bleed based on its 
higher temperature limit and, therefore, more reliable analysis. It showed lower 
selectivity for different AA types and a lower enantioselectivity for AAs treated with 
fluorinated anhydrides and fluorinated butanol or native isopropanol than the L-Val 
based selector. Nevertheless, it offered outstanding resolution of the smallest 
derivatives tested, namely methyl alkoxy methyl esters. The respective derivatization 
reaction with MCF and MeOH in aqueous solution can be seen in Figure 8. 
Chromatographic resolution was >2.4 for ten pairs of AAEs after their treatment with 
MeOH/MCF. No racemization was detected after derivatization of single AAEs158. 
Thus, this selector/derivative combination was chosen for further method optimization 
and validation to allow its versatile application to physiological matrices. These 
attempts were the subject of the first part of this thesis.  
 
Figure 8. Derivatization reactions for metabolites (here shown for AAEs) with MeOH 
and MCF in aqueous solution for analysis by enantioselective GC-MS. 
 
 4.5.3 RACEMIZATION 
As already pointed out in the preceding chapter, prevention of accidental 
racemization is a crucial aspect of chiral metabolomics. Unintended racemization can 
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occur not only during derivatization but also during sample storage, pre-treatment or 
during chiral analysis e.g. in the GC injector. Chiral metabolomics, however, is 
interested in the outcome of enzymatically catalyzed isomerization in organisms and 
in different metabolism of stereoisomers. Conditions promoting racemization of AAs 
after sample collection are inter alia high temperature, pressure and low or high pH23, 
159, 160
. AA racemization rates depend on inductive and steric effects of the side 
chain, on the stability of the planar intermediate but also on structure independent 
factors like concentration, ionic strength of the medium and the presence of metal 
traces159, 160. Asp and Cys exhibited the highest racemization rate under acidic 
conditions (4N HCl) and a temperature of 110°C, fol lowed by Pro > Glu > Met > His > 
Leu > Lys > Phe > Ala > Tyr > Arg > Trp > Val > Ile> Ser and Thr159. Two of the most 
stable presumed planar intermediates of isomerization formed at low pH values are 
displayed in Figure 9 as well as the one proposed in my diploma thesis for the 
racemization mechanism caused by derivatization with HFB/PFPA in one step. The 
most plausible proposition of the underlying reaction mechanism for the creation of 
these intermediates is the proton catalyzed enolization23, 159. Asp racemization rate 
has been shown to be a function of pH at constant ionic strength of the solvent with a 
maximum at a pH of three and a pH independent region between pH five and eight at 
25 °C. Interconversion was also favored under alkal ine conditions at pH-values>9 160. 
The planar intermediate under alkaline conditions is formed by elimination of the 
proton bound to the α-C-atom to form a carbanion23, 161. 
 
Figure 9. Presumed stable planar intermediate of acid catalyzed interconversion of 
(A) Asp, (B) Pro or (C) an AA during HFB/PFPA derivatization. Adapted from159 
and119  
Temperature exerted an even higher impact than pH on racemization velocity160. 
Heating and alkali treatment are often applied in industrial food processing161, 162. 
Caused racemization processes of protein bound AAs affect organoleptic properties 
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and food quality. Proteins (casein) treated with 1M NaOH at 80°C for one hour 
resulted in complete racemization of Asp, Ser, Tyr, and His, while >40% of the D-
form was detected for Ala, Met, Phe, Lys and Glu. The least D-AA ratio (<35%) was 
observed for Val, Leu, Ile and Thr162. Racemization of peptide bound AAs is not only 
influenced by steric and inductive effects of their own moieties, but also by those of 
chemical groups from nearby AAs. Asn or Asp bound to Gly as part of a protein 
sequence leads to the formation of an aspartyl succinimide product that is prone to a 
racemization process based on keto-enol-tautomerism23, 163. 
The different susceptibility of chiral metabolites to isomerization bears the necessity 
of a racemization check for each stereoisomer of interest to ensure accuracy of chiral 
metabolomics results. This can be accomplished by preparation and analysis of 
single enantiomers in the same way as samples have been treated. A lack of readily 
available enantiopure standards or standards with defined enantiomer excess makes 
racemization checks often labor-intensive as enantiomer ratios need to be 
investigated beforehand by direct methods like e.g. optical rotatory dispersion. 
Furthermore, samples and chiral standards should be kept strictly at low 
temperatures. Finally, comparison of chiral metabolomics results obtained by 
techniques employing different preparation and separation strategies is highly 
recommended to check for racemization at any step of the procedure.  
 
4.5.4 IDENTIFICATION OF ENANTIOMERS AND DIASTEREOMERS 
In untargeted metabonomics the identification of unknown metabolite structures is the 
ultimate goal to clarify how biochemical processes or specific metabolites of interest 
(e.g. enantiomers) are regulated in response to experimental and/or environmental 
conditions. To this end, ideally both accurate mass measurements and detection of 
characteristic fragments are performed to gain information on possible sum formula 
using algorithms (here 'smart formula' from Bruker) and to exclude or prefer tentative 
candidates by comparing fragment spectra to respective database entries (here the 
NIST database was used). Adduct formation in the presence of specific chemical 
functionalities can assist with structure elucidation148. This is useful for identification 
of chiral and non-chiral metabolites. To confirm a structure and determine the 
configuration of stereo centers the injection of commercially available standards is 
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inevitable. However, the presence of chirality can be easily recognized if a pair of 
enantiomers was detected by either fragmentation or accurate mass measurement 
without consideration of structure or composition. Enantiomers of small metabolites 
show identical fragmentation spectra and the same molecular weight. The latter also 
applies to diastereomers, positional and conformational isomers. Therefore, it is 
helpful that spectra obtained by means of soft ionization techniques in GC-MS 
couplings (APCI and CI) include fragments in addition to the (quasi-)molecular ion. 
Isobars other than enantiomers show the same fragments and molecular masses, 
while the relative abundance of fragments differs. Thus, computational tools, able to 
screen chromatograms for equal spectra, can help to identify enantiomers. However, 
the match of spectra may be low for antipodes, if their abundance differs greatly. 
Some of the characteristic fragments detected within the high abundant spectrum 
may occur below the S/N threshold in the low abundant spectrum causing the low 
match. 
 
4.5.5 DATA ANALYSIS AND VALIDATION 
Internal standards (ISs) are commonly used in metabolic profiling to correct for losses 
during sample preparation and analysis. ISs may not be part of the original sample 
but should be similar to target molecules concerning their physico-chemical 
properties. Stable isotopic labeled IS meet this requirement the best, the more as 
they do not pose a radiation hazard. Often a single isotopically marked chiral IS is 
used for the correction of related stereoisomers because of the lack of commercially 
available racemic IS. This is appropriate if all isomers are affected equally by matrix 
effects. IS are also suitable to increase precision of semi-quantitative results in 
fingerprinting approaches. Further normalization of data is required when urine is 
investigated. Dilution of urine specimens depends on physiological and life style 
(water consumption) factors. 24h urine volume of rats from different study groups 
differed up to 15 fold and higher164. For normalization, besides 24h urine volume, 
creatinine concentration, osmolality and the 'MS total useful signal' (MSTUS) have 
been applied in MS-based metabolomics164, 165. The latter two are based on different 
strategies to estimate the total content of metabolites. To assess osmolality of a 
sample the freezing-point depression can be measured whereas MSTUS is the total 
area of peaks common to all samples164. Urinary creatinine content was most 
commonly used for data normalization in clinical chemistry and was employed in this 
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thesis164, 166, 167. It comprises a measure of the glomerular filtration rate in healthy 
individuals as creatinine is filtered exclusively. The accuracy of this measure can be 
affected inter alia by acute kidney injury166. In contrast, osmolality is the consequence 
of renal filtration, resorption and secretion. 
Computational tools perform peak picking, peak integration and aligne resulting 
feature areas over all samples. A feature is a peak defined by a single retention time 
and a single m/z. Prior to uni- and multivariate statistical analysis data are often 
reduced by exclusion of features present below a chosen cut-off. Remaining missing 
values, if distributed randomly, can be imputed by algorithms that estimate these 
values. Additionally, data are often transformed to minimize misinterpretation caused 
by heteroscedasticity. Finally, artifacts like saturated feature or double feature, 
belonging to the same signal, should be excluded before statistical analysis. There 
are various statistical testing strategies available for the interpretation of 
metabolomics data. Distribution, univariate, multivariate, correlation and classification 
tests can be chosen corresponding to the experimental set up and investigated 
questions. Often a series of techniques is employed to obtain an appropriate content 
of information for a valid discussion of the study outcome. 
In untargeted metabolomics the number of tested variables usually exceeds the 
number of analyzed samples. The number of false positives after multiple student-t-
testing is nowadays most commonly reduced by the consideration of false discovery 
rate (FDR). The FDR estimates the ratio of p-values falling below the level of 
significance by chance. To this end the average frequency of p-values from 
undifferentiated feature is calculated from the list of probability results. Thus FDRs 
are list characters. This strategy was introduced by Benjamini and Hochberg168. 
Features with a FDR >0.05 are routinely excluded from the list of significantly 
regulated features10. There are even more conservative approaches for the 
correction of multiple testing like the Sidak equation and the Bonferroni 
approximation for the adjustment of the confidence interval. The latter comprises the 
division of the confidence limit for a single comparison by the number of regarded 
comparisons to obtain the confidence border that accounts for multiple testing169, 170. 
Particularly such strict rules of sorting out bear the danger of losing significant data 
and therefore hypothesis-generating trends. 
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Multivariate analysis assists in the visualization of complex data sets and in the 
assignment of relationships between samples and variables. To that end 
unsupervised approaches like principle component analysis (PCA), independent 
component analysis (ICA) or hierarchical clustering analysis are applied to 
metabolomics data. Examples for supervised approaches are partial least squares - 
discriminant analysis, support vector machines or discriminant analysis of principal 
components171. 
There are many method parameters to be determined in the course of method 
validation. Lower and upper quantification and detection limits define linear and 
dynamic ranges. Relative standard deviations of technical and derivatization 
replicates comprise a measure of method repeatability. Analyte recoveries after 
spike-in experiments are determined to check accuracy of results. For this objective 
also a method comparison is recommended, in which the results of the method under 
investigation are compared to the outcome of an established method after analysis of 
the same sample set. Hereby Bland-Altman plots help to visualize differences of the 
data sets or the presence of a systematic bias172.
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5 EXPERIMENTAL SECTION – MATERIAL, METHODS AND 
INSTRUMENTATION 
5.1 CHEMICALS  
Isooctane, pyridine, MCF, 1M NaOH, D-norvaline, racemates of AAs and other chiral 
metabolites and their respective enantioenriched solids as well as solids of non-chiral 
metabolites were obtained from Sigma-Aldrich (Taufkirchen, Germany). N-Acetyl-1-
methoxy-L-Asp and N-Acetyl-L-Ala were purchased from Bachem (Bubendorf, 
Switzerland). Methanol (MeOH, LC–MS grade) and chloroform (HPLC grade) were 
from Fisher Scientific GmbH (Ulm, Germany). The water was purified by a PURELAB 
Plus system (ELGA LabWater, Celle, Germany). The [U-13C, U-15N] cell free AA 
mixtures were obtained from Euriso-top (Saint-Aubin Cedex, France). 
 
5.2 SAMPLE PREPARATION 
5.2.1 PRECIPITATION OF PROTEINS 
Protein precipitation was performed for the analysis of serum and liver samples. After 
20 µL of aqueous internal standard mix were added to the sample, 600 µL of cold 
MeOH (-20°C) were applied to precipitate proteins a nd the mixture was vortexed. In 
case of liver tissues these steps were performed in Precelly-Keramik-Kit 1.4 mm vials 
(Peqlab Biotechnologie GmbH, Erlangen, Germany) and the mixture was 
homogenized two times for 15 s at 5500 rpm with a 30 s pause in between before 
centrifugation. In case of serum 2-mL Eppendorf tubes were used for precipitation 
and pellet washing. Precipitated serum samples were centrifuged at 1431 x g for 4 
min at 5° C. Precipitated and homogenized liver sam ples were centrifuged at 16658 x 
g for 5 min at 5° C. The supernatant was transferre d to a 1.5-mL glass vial 
(Macherey-Nagel, Düren, Germany) and the pellet was washed twice either with 250 
µL of cold (0°C) MeOH/water (4/1) in case of serum or with 300 µL of the cold (0°C) 
solvent mixture in case of liver tissues. After each washing step the mixture was 
centrifuged at 1431 x g for 4 min at 5° C in case o f serum or at 16658 x g for 5 min at 
5° C in case of liver tissues. Combined supernatant s were evaporated in glass vials 
to complete dryness. 
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5.2.2 DERIVATIZATION WITH METHANOL/ METHYL CHLOROFORMATE 
Derivatization was performed in 1.5-mL crew cap glass vials (Macherey-Nagel GmbH 
& Co. KG, Düren, Germany). If available a maximum of 150 µL of the biological 
specimen or master mixture (MM) (compositions of MM-1 and MM-2 are listed in the 
next section 5.2.3) were derivatized together with 20 µL of an aqueous IS mixture 
including U-13C, U-15N labeled proteinogenic D- and L-AAs (IS concentrations of IS 
mix A, B and C are given in the next section 5.2.3). To allow for identical 
derivatization reagent concentrations in each reaction vial the mixture was always 
diluted with water to a constant aqueous start volume of 275 µL. In preliminary 
experiments 100 µL of a 1N NaOH aqueous solution (according to Villas-Bôas 
optimized protocol173) and 5 µL of a 5.7 µM aqueous D-norvaline standard (useable 
IS) were added instead of dilution with pure water. 
If protein precipitation had been performed, the dry residue of collected supernatants 
was resolved in 275 µL of water. Subsequently 167 µL MeOH and 34 µL pyridine 
were added. Finally, MCF was added in two portions of 20 µL each. After every MCF 
addition the solution was vortexed. Villas-Bôas reported the reaction to be completed 
within 30 s after the addition of MCF173. 300 µL chloroform were added for derivative 
extraction. The mixture was vortexed for 15 s. All biological samples were centrifuges 
at 4165 x g for 5 minutes at 5°C to improve phase s eparation and subsequently 
about 100 µL of the lower phase (organic phase) were transferred to a 1.5-mL glass 
vial with a 100-µL micro-insert (VWR, Cat. No. 548-0006). 
For metabolite standard solids dissolved in a MeOH/water mixture or in pure MeOH, 
the added water and MeOH volumes were adjusted, so that the overall water and 
MeOH content (275 and 167 µL respectively) were always kept constant for the 
derivatization reaction. 
 
5.2.3 STANDARDS AND MASTER MIX 
MM-I was composed of all proteinogenic AAEs and Gly in concentrations of 0.5 or 1 
mM. MM-II consisted of AAE detectable by the here presented chiral methods and 
Gly at 1mM each except for Phe enantiomers that were present at 0.5 mM, 
respectively. For preliminary experiments of chapter 6 and 7, 150 µL and 75 µL of 
MM-I had been derivatized, respectively. The 150-µL aliquot was derivatized using 
NaOH (according to Villas-Bôas optimized protocol173) whereas the 75-µL aliquot 
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was derivatized without NaOH (according to my derivatization procedure described 
above). Respectively 150 µL of a MM-I dilution series were derivatized to calibrate 
the GC-qMS method for spike-in experiments using NaOH. 150 µL each of the 
dilution series of MM-II were derivatized to calibrate the GC-qMS method for method 
comparisons and applications and to calibrate the chiral GC×GC-TOFMS method. 
NaOH was used to derivatize the MM-II calibration series for the first comparison of 
quantification results from chiral GC-qMS to the results of an established achiral GC-
qMS method for AA analysis. In all further calibrations with MM-II no NaOH was 
applied. AAE concentrations between 1 mM and 31 nM were applied for calibration 
with MM-II and MM-I. Some AAEs were present in the concentration range between 
500 µM and 15 nM in the dilution series of MM-I. 100 µL of MM-II were derivatized for 
GC×GC-TOFMS parameter optimization. 
Originally, the chiral GC-qMS method had been performed with 33 µL of a IS mixture 
containing U-13C, U-15N labeled AAs in a concentration range of 1.9 - 15.2 mM (IS 
mix A) in experiments of my diploma thesis. The labeled AAs had been obtained from 
algae. Thus they were present in the mix at their occurring ratios in algae. D-AA 
ratios were not determined by the supplier. Dilution of IS mix A to obtain IS mix B was 
performed in the course of chiral GC-qMS method optimization. IS mix B included 
labeled D+L-AAs in a concentration range of 0.35 - 2.83 mM. 20 µL of IS mix B were 
employed for all presented method applications in chapter 6. IS mix C refers to 
another algae extract that was solved and diluted to the D+L AA concentration range 
of 0.37-2.58 mM and 20 µL were spiked, respectively, to samples and standards of 
chapters 7 and 8. 
15 µL of aqueous stock solutions (~20 mM) were derivatized together with 20 µL of 
IS mix C for metabolite identification. Some metabolites solids were solved in MeOH 
or a MeOH/water mixture (1/4). 
 
5.3 INSTRUMENTATION 
5.3.1 QUANTITATIVE AMINO ACID ENANTIOMER ANALYSIS BY GC-QMS  
An Agilent model 6890 GC (Agilent Technologies, Palo Alto, CA) equipped with a 
split/splitless injector, and a quadrupole mass selective detector (MSD) model 5973 A 
with an EI source was employed. An RT-γDEXsa (2,3-di-acetoxy-6-O-tert-butyl-
dimethylsilyl γ-CD doped into 14% cyanopropylphenyl/86% dimethyl polysiloxane) 
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column (30m×0.25mm ID, 0.25µm film thickness) from Restek GmbH (Bad Homburg, 
Germany) was used for analyses. It was connected to a fused silica deactivated pre-
column (10m×0.25mm ID) from Agilent. Phenomenex AGO 4680 liner was used. The 
autosampler was equipped with a 10-µL syringe for sample injection. Before and 
after sample injection the syringe was washed with 5 volumes of isooctane. Samples 
were kept in a cooled tray at 5 °C. 
The originally used conditions used for AAE analysis, implemented in my diploma 
thesis, were as follows: 
 
Method I (similar to method D in158): 
Injection: 1µL; split mode ; split ratio: 1: 10 
Injector temperature: 250 °C 
Temperature program: 70°C (1 min)– 4°C/min to 150°C  (5 min)-3°C/min to 190 °C 
(30 min) 
He-flow: 2.0 mL/min 
Solvent delay: 10 min  
Transfer line temperature: 250 °C 
Detection mode: SIM  
 
They were optimized to the following settings that were used for all quantitative 
applications of AAE analysis to biological samples described in chapter 6, 7 and 8: 
 
Method II (published as method E in158): 
Injection: 1µL, splitless mode, splitless time:1 min, purge flow: 20 mL/min 
Temperature program: 70°C (1 min)– 4°C/min to 150°C  (5 min)-3°C/min to 190 °C (5 
min)  
Solvent delay: 19 min  
Transfer line temperature:  230 °C 
He-flow, detection mode and injection temperature as in method I 
 
In the following course of the thesis, these settings are designated as method I and 
method II, respectively.  
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5.3.2 QUANTITATIVE AMINO ACID ENANTIOMER ANALYSIS BY GC×GC-TOFMS 
The following instrumentation and operation information was taken from174. 
The LECO (St. Joseph, MI) Pegasus 4D GC×GC–TOFMS instrument comprised an 
Agilent Technologies Model 6890 GC, a dual-stage, quad-jet thermal modulator, a 
secondary oven coupled to a fast acquisition TOFMS providing unit mass resolution, 
a PTV injector (Gerstel, Muehlheim, Germany), and a MPS-2 Prepstation sample 
robot (Gerstel). The robot was equipped with a 10-µL syringe for sample injection. 
Between injections the syringe was washed with 5 volumes of isooctane. Samples 
were kept in a cooled tray at 5 °C. An Rt- γDEXsa column (30 m×0.25 mm ID, 0.25 
µm film thickness) from Restek (GmbH, Bad Homburg, Germany) protected by a 5 
m×0.25 mm ID fused silica deactivated guard column. (Agilent Technologies, Palo 
Alto, CA, USA) was used as the first-dimension column, while an RTx-1701 (2 m×0.1 
mm ID×0.1 µm film thickness, Restek) or a ZB-AAA (2 m×0.25 mm ID, 0.25 µm film 
thickness, Phenomenex Inc.) column served as the second-dimension column. A 
sample volume of 1.5 µL was injected in splitless mode with the temperature of the 
PTV Injector set at 50 °C for 0.5 min and then ramp ed at 12 °C/s to 250 °C. A 
chemically inert Siltek liner from Gerstel was used. The helium flow-rate was set at 
1.9 mL/min (constant flow). Modulation was accomplished every 4 s during GC×GC 
analysis and modulator hot pulse time was 0.6 s. Mass spectra were acquired from 
40 to 600 m/z at a rate of 200 spectra/s. For 1D GC–TOFMS analysis the modulator 
was turned off and mass spectra were collected at 50 spectra/s. The solvent delay 
was kept at 19 min. Transfer-line temperature was held at 260 °C. The ion source 
was operated at 200 °C and −70 eV. A positive offse t of 5 °C was used for the 
second-dimension column and a 15 °C offset relative  to the first-dimension column 
for the modulator.  
Temperature programs that were considered best for GC×GC based AAE analysis by 
the two newly tested column combinations are listed in Table 1. 
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Table 1. Optimized GC temperature programs for the column sets RT-γDEXsa/ RTX-
1701 (A) and RT-γDEXsa/ ZB-AAA (B, C), respectively. Taken from174 
Method Temperature program 
A 70°C (1 min) –2°C/min – 150°C (10 min) –2°C/min – 1 80°C (25 min)  
B 70°C (1 min) – 4°C/min – 150°C (10 min) - 3 °C/min – 190°C (15 min)  
C 70°C (1 min) – 2°C/min – 130°C (12.5 min) - 8°C/min - 150°C (4 min) - 4°C/min – 
190°C (6 min)  
 
In the following course of the thesis, these settings are designated as method A, 
method B and method C, respectively.  
 
5.3.3 ENANTIOSELECTIVE METABOLIC FINGERPRINTING 
An Agilent model 6890 GC (Agilent Technologies, Palo Alto, CA) equipped with a 
MSD model 5975 Inert XL, split/splitless injector and a MPS-2 Prepstation sample 
robot (Gerstel, Muelheim, Germany) was employed. For sample injection, a 10-µL 
syringe was used. It was washed 5 times with isooctane before and after injection. 
Prepared samples were kept in a cooled tray at 5 °C . GC parameters corresponded 
to those of method II listed in chapter 5.3.1 except for the duration of the last 
temperature plateau (here 16.5 minutes at 190°C) le ading to a total run time of 55.83 
minutes. The solvent delay was decreased to 5 minutes. The qMS was operated in 
scan mode with an m/z range of 60 to 500. The transfer line was kept at 230 °C. The 
same chiral GC column, as described in chapter 5.3.1 and 5.3.2, was connected to a 
fused silica deactivated pre-column (2m×0.25mm ID) from Agilent. 
The GC-APCI-TOFMS device consisted of an Agilent model 6890 GC instrument 
equipped with an Auto Liquid Injector (model 7683B), which was hyphenated to a 
microTOF orthogonal acceleration TOF mass spectrometer from Bruker Daltonics 
GmbH (Bremen, Germany) by an APCI source that was operated in positive mode. 
Published source and MS parameters were applied that had been optimized 
previously148. The acquired m/z ranged from 50-1000. Equal GC parameters and GC 
columns were installed as applied for the measurement of fingerprints by GC-qMS. 
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5.3.4 MISCELLANEOUS 
A Precellys® 24 homogenizer (Peqlab Biotechnologie GmbH, Erlangen, Germany) 
was employed for the homogenization of liver specimens for quantitative AAE 
analysis. Solvents were evaporated by a Combi Dancer Infra-Red Vortex-Evaporator 
(Hettich AG, Baech, Switzerland). For centrifugation a Beckman GS-15R centrifuge 
(Beckman Coulter GmbH, Brea, CA) was employed. pH indicator paper (pH: 1-14) 
from MERCK was applied. Creatinine contents of urine samples, discussed in 
chapter 8, were quantified by Dr. Wentao Zhu using LC-ESI-MS/MS as described 
previously175. 
 
5.4 SOFTWARE AND STATISTICAL TESTS 
Selected ion chromatograms for quantitative AAE analysis by GC-qMS were acquired 
by G1701DA D.02.00 SP1 MSD Productivity Chemstation from Agilent Technologies. 
Integration, calibration and quantification were performed using Micromass MassLynx 
V4.1 software from Waters (Waters Corporation, Milford, MA) with the QuantLynx 
option. FDRs and p-values based on two-sided students-t-tests for results of 
biomedical applications of chapter 6 were determined in ‘R’ using the ‘limma’ 
package. 
Raw GC×GC-TOFMS data were acquired and processed with the LECO 
ChromaTOF software version 3.34. Baseline correction, deconvolution, peak picking, 
calibration and quantification were performed by this software.  
Quantitative results of biomedical applications presented in chapter 7 were tested for 
normal distribution by the Shapiro-Wilk test in ‘R’. Furtheron, they were analyzed by 
F-tests and two-sided students-t-tests for unpaired samples and equal or different 
variances in Microsoft Excel. The diseased group was compared to the 
corresponding control group.  
To record fingerprints the same acquisition software was used as for quantitative 
AAE analysis by GC-qMS. Quadrupole mass spectra library search was performed 
with NIST library revision 5.00. GC-APCI-TOFMS data were acquired with the 
micrOTOFcontrol software embedded into HyStar version 3.2 that was provided by 
Bruker. ‘Smart formula’ of the Bruker DataAnalysis software version 4.0 was 
employed to assign tentative sum formula to unknown metabolites.  
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Raw GC-qMS chromatograms of fingerprints were processed with the Waters 
Micromass MassLynx V4.1 software using the MarkerLynx option. Peak width at 5% 
height and peak-to-peak baseline noise were not set to fixed values but appropriate 
values were determined automatically by the software for each chromatogram. 
MarkerLynx performed peak picking and assigned a unique retention time and a 
single m/z-value to each feature picked and integrated it on the chosen m/z. The 
software performed data alignment. Further data analysis including exclusion of 
features that were below the chosen count cut-off and of saturated and double 
features as well as normalization were performed in Microsoft Excel. For statistical 
analysis including Shapiro-Wilk test of normality, PCA, ANOVA, as well as two-sided 
students-t-tests and FDRs for the three comparisons: steatosis vs. controls, NASH 
vs. controls, and NASH vs. steatosis, the software ‘R’ and therein the ‘limma’ 
package were applied. Reintegration of features, considered to significantly 
discriminate investigated groups, was performed in Micromass MassLynx V4.1 
software using the QuantLynx option. 
ANOVA and two-sided students-t-tests were performed in ‘R’ with the ‘limma’ 
package for the three group comparisons with AAE concentrations and thereof 
calculated D-AA ratios (D/(D+L)-ratio) obtained from quantitative chiral GC-qMS 
analysis of mouse urine for method validation.  
 
5.5 VALIDATION METHODS 
5.5.1 LOD AND LLOQ 
To account for unlabeled AAs present as impurities in the IS mix, blank values were 
determined by derivatization of 33 µL of IS mix A (U-13C, U-15N labeled AAs in a 
concentration range of 1.9 - 15.2 mM) in quintuple in the course of my diploma thesis 
and 20 µL of IS mix B in septuple in the course of this thesis and the following 
equation was applied to calculate LODs, also known as statistical LODs176. 
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blankblank SDmeanLOD ⋅+= 3                                                           (3) 
where meanblank and SDblank are the mean AA response and its standard 
deviation. Calibration curve equations were applied to LOD responses in 
order to estimate corresponding LOD concentrations176, 177. 
The probability of considering the target analyte as a component of the sample 
although it is not present in the sample is 5% using this estimation of statistical 
LODs177. In the absence of blank values (S/N<3 for AA peak in all blank value 
measures), the concentration generating a S/N ≥ 3 was defined as LOD, also known 
as empirical LOD176. The linear range was between the lower (LLOQ) and upper limit 
of quantification (ULOQ), which define the highest and the lowest point of the 
calibration curve with an accuracy between 80 and 120%. The LLOQ was additionally 
required to yield a peak with a S/N of at least ten. 
 
5.5.2 PEARSON CORRELATION COEFFICIENT 
The Pearson correlation coefficient is a measure of the linear dependence between 
two variables X and Y. It is calculated by dividing the covariance of the two variables 
by the product of their standard deviations. It has no dimension and can vary 
between -1, indicating a perfect negative linear correlation of X and Y, and +1, which 
indicates a perfect positive linear correlation. If it is zero, there is no linear relation 
between X and Y. However, this does not mean the absence of dependence 
between the two variables, as only the linear dependence was tested. Here the 
Pearson correlation coefficient was abbreviated by the letter r. 
 
5.5.3 BLAND-ALTMAN PLOT 
A Bland-Altman plot visualizes the concordance and the disagreements of the 
outcome of two methods under comparison. It is appropriate for the validation of a 
new approach as it allows the assessment of the grade of agreement of results to 
those of an established approach in the regarded quantity range. The mean of the 
two results is plotted on the x-axis and their difference is plotted on the y-axis. 
Furthermore, the mean of all calculated differences is shown as a horizontal line. The 
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nearer it is to zero the higher the agreement of the data. There are two further 
horizontal lines present in a Bland-Altman Plot. They mark the upper and the lower 
'limit of agreement' and their positions refer to mean difference ± 1.96 times the SD of 
the differences. If the differences are normally distributed 95% of the observed 
differences are expected to lie in between these limits. The closer these limits are to 
the mean difference the better the concordance of the data. If there is a consistent 
bias in the data the mean difference is not close to zero but the SD of differences is 
low so that the three lines lie close to each other. Data of the new approach can be 
corrected by the mean difference in such a case. If one of the methods or both 
methods show low repeatability a low agreement of the data is expected172. 
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6 OPTIMIZATION, VALIDATION AND APPLICATION OF 
QUANTITATIVE AMINO ACID ENANTIOMER ANALYSIS BY GC-QMS 
6.1 INTRODUCTION 
D-AAs are excluded from ribosomal biosynthesis of proteins and, therefore, are 
believed to fulfill no biological functions. However, they are found in all species 
ranging from bacteria to humans and some important regulatory functions have been 
characterized recently. Enzymes involved in the anabolism and catabolism of free D-
AAs have been identified in certain tissues. Based on these findings, D-AAs are 
considered potential diagnostic markers for diseases affecting gut, liver, kidneys or 
the nervous system. Bacteria release large quantities of D-AAs into their environment 
and, thus, changes in D-AA serum levels are believed to reflect alterations in the 
body’s microbiota composition and/or permeability of epithelial barrier of the colon, 
which is home to most commensal bacteria that reside in a human and which exert a 
significant impact on human metabolism as noted more than 40 years ago by Linus 
Pauling 178.Hence, there is great interest in methods that allow the sensitive and 
comprehensive analysis of D-AAs in biofluids such as blood and urine. However, the 
baseline separation of low abundant D-AAs from their corresponding L-AAs has 
proven difficult and, as a consequence, most chiral methods have focused on a few 
AAE types or employed time-consuming pre-separation steps. To find a more 
efficient chiral GC-qMS based method that allows the sensitive quantification of many 
proteinogenic AAEs in a single run, a method comparison of various AAE derivatives 
on two different chiral selectors was performed in the course of my diploma thesis. 
For two newly investigated derivative /chiral selector combinations that yielded best 
enantioselectivity and peak abundances, calibration and racemization tests were 
performed. Since one, namely derivatization by HFB/ PFPA with subsequent analysis 
on a Chirasil-L-Val selector, yielded high racemization rates that could not be 
reduced sufficiently, I finally decided to optimize the other, combining MeOH/MCF 
derivatization with a γ-CD based selector. This section focuses on the optimization, 
validation and application of the method. 
 
52 
 
6.2 MATERIAL AND METHODS 
6.2.1 ANALYZED SAMPLES 
Urine from 23 healthy donors and 5 urine specimens from patients collected before 
and after curative stem cell transplantation (SCT) for non-malignant and malignant 
disorders of the immunohematopoietic system, and serum from 19 patients with 
minor liver damage and 19 serum specimens from patients exposed to SCT for the 
same reasons and a human control serum sample were provided by collaborators 
from the University Hospital of Regensburg with the approval of the institutional 
review board. From the 23 human control urine samples a urine pool was prepared. 
Serum and liver specimens from 20 mice, of which ten were fed a NASH inducing 
diet and ten were fed a control diet for two or three weeks (N=5 per group), 
respectively, were provided by Anja Thomas. The composition of the two diets, 
experimental conditions and characteristics of applied mice as well as the way of 
sample drawing were reported previously179. Also the determination of tumor necrosis 
factor (TNF) α levels in liver tissues was accomplished by Anja Thomas as it was 
reported previously 179. 
 
6.2.2 PARAMETER OPTIMIZATION 
Injection parameters were varied in the course of method optimization. Injection 
parameter of method II (splitless injection at 250°C; splitless time =1 min) resulted 
from testing three different splitless (purge) times: 0.5 min, 0.75 min and 1.0 min, 
respectively. 150 µL of MM I were derivatized and measured under the different 
injection conditions. 
 
6.2.3 METHOD VALIDATION AND QUANTIFICATION  
Spike-in experiments. In preliminary experiments three aliquots of 100 µL each of 
control serum were derivatized without protein pre-precipitation together with 20 µL of 
IS mix B, respectively, to determine AA amounts. Subsequently nine aliquots (100 µL 
each) of control serum were derivatized without protein pre-precipitation together with 
20 µL of IS mix B and either 15 or 30 or 45 µL of the spike-in mix. Thus, three spike-
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in levels were added and analyzed in triplicates. The following AAs were included in 
the spike-in mix: D-Ala, L-Ala, Gly, D-Leu, D-Thr, D-Ser, D-Met, L-Met, L-Asn, DL-
Phe. The three spike-in levels corresponded to 0.5, 1.0 and 1.5 fold quantity, added 
in case of L-AAs and DL-Phe and 2, 4 and 6 times determined quantity, added in 
case of D-AAs. Method II was employed for all analysis of spike-in experiments. 
Results were analyzed by calculating percentage recoveries (determined quantity 
divided by expected quantity and multiplied by 100%). 
Method comparison. 150 µL each of 19 serum samples from patients with minor 
liver damage were prepared as described in chapter 5.2.2 without protein 
precipitation using 1N NaOH and D-norvaline. They were analyzed using method II. 
At the same time the samples were analyzed by an established achiral GC-qMS 
method for AA quantification by a procedure described elsewhere180. D- and L- AA 
amounts found by the chiral method were summed up and relative recoveries were 
calculated by dividing the D+L-AA concentration obtained by the chiral method by the 
concentration found by achiral analysis and multiplication by 100%. 
Method comparison was repeated with 19 serum samples from patients exposed to 
SCT applying optimized sample preparation (protein pre-precipitation and dilution 
with water) to 150 µL aliquots and method II for chiral analysis and the published 
procedure for the established achiral method180. Quantitative results were compared 
by relative recoveries as explained above. 
Method comparison was also performed for the analysis of urine. Five samples from 
patients exposed to SCT were derivatized using 100 µL 1N NaOH in the reaction 
mixture and ten samples from patients exposed to SCT were prepared, replacing the 
NaOH volume by the addition of water. 150 µL aliquots and Method II were applied. 
The samples were analyzed concurrently by the established achiral GC-qMS 
approach180 and quantitative results were compared by relative recoveries as 
described above. 
Comparison of different sample preparation. Each preparation strategy was 
performed in triplicate and for each experiment 150 µL of control serum were 
prepared. Four different preparation strategies were tested: 
Preparation strategy A: Derivatization with MeOH/MCF as described in chapter 5.2.2 
without protein pre-precipitation, using 100 µL 1N NaOH.  
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Preparation strategy B: MeOH/MCF derivatization without protein pre-precipitation, 
adding 100 µL water for dilution instead of 1N NaOH. 
Preparation strategy C: Protein pre-precipitation with cold MeOH (0°C) and 100 µL 
1N NaOH as additive for MeOH/MCF derivatization. 
Preparation strategy D: Protein pre-precipitation with cold MeOH (0°C) and 
derivatization with MeOH/MCF using 100 µL water for dilution instead of 1N NaOH. 
Additionally, two 150-µL aliquots of control serum were derivatized in the presence of 
proteins, one with NaOH and one without addition of NaOH, to estimate the pH in the 
reaction mixture by pH paper before and after the second addition of MCF.  
Calibration. Calibration was performed using a 16-point serial dilution of either MM I 
for spike-in experiments or of MM II for all other quantitative analysis presented in 
chapters 6, using method II. The dilution series prepared from MM I included all 
proteinogenic AAE in a concentration range between 1 mM and 31 nM or between 
500 µM and 15 nM. The dilution series prepared from MM II included all AAE 
detectable by the here presented GC-qMS method in a concentration range between 
1 mM and 31 nM. Respectively, 150 µL of the MM dilutions were prepared together 
with 20 µL of IS mix B. LODs and LLOQs were determined as described in chapter 
5.5.1.  
Repeatability. Six 150-µL aliquots each of the urine pool and the serum control, 
respectively, were derivatized using the optimized protocols with protein pre-
precipitation in case of serum and without NaOH in the reaction mixture. They were 
analyzed by method II. 
 
6.2.4 SAMPLE PREPARATION  
Depending on available sample volume 110 -150 µL of urine from patients with renal 
failure were derivatized. Depending on available sample volume 20 -150 µL of mouse 
serum and 40.3 -59.4 mg of mouse liver were prepared and analyzed. The samples 
were prepared as described in chapters 5.2.1 and 5.2.2 with the optimized protocols. 
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6.3 RESULTS AND DISCUSSION 
The following results and discussion were published partly158. Each section, 
corresponding to published text, was cited individually. 
 
6.3.1 OPTIMIZATION OF METHOD PARAMETERS 
Figure 10 shows a representative chromatogram of MM II and IS mix B derivatized 
with MeOH/MCF and recorded by the optimized GC-qMS method performed with the 
RT-γDEXsa column and method II. 
 
Figure 10. Characteristic chromatogram of 150 µL of MM II with 20 µL of IS mix B, 
prepared and analyzed using MeOH/MCF derivatization and optimized chiral GC-
qMS analysis in SIM mode, the RT-γDEXsa column and method II (temperature 
program: 70°C (1 min)– 4°C/min to 150°C (5 min)-3°C /min to 190 °C (5 min)) 158. 
Overlapping AAE peaks are encircled. 
Four pairs of AAEs coeluted after analysis namely L-Leu/ D-Ile, L-Thr/ L-Asp, L-Ser/ 
D-Met and D/L-Phe. The signal partially overlapping with the L-Met peak refers most 
probably to a derivatization byproduct that was not assigned to any AAs. Visible peak 
intensity differences of antipodes result from distinctly different concentrations of the 
corresponding labeled enantiomers of the IS mix. No D-AAs were detected upon 
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derivatization of L-AAs with MeOH/MCF and chromatographic enantiomer resolution 
ranged between 2.5 for Leu enantiomers and 14.0 for Pro enantiomersRacemization 
checks and determination of enantiomer resolution had been performed during my 
diploma thesis119. Mass spectra of Ser and Thr enantiomers indicated their 
occurrence as three-fold MeOH/MCF derivatives. Husek reported that hydroxy 
groups of hydroxymonocarboxylic acids can be converted into alkoxycarbonyl ether 
by treatment with MeOH/MCF under certain conditions181. Low peak intensities of Ser 
and Thr enantiomers, when compared to other AAE derivatives, suggest the 
occurrence of a side product, respectively. They either vanish in the baseline or do 
not elute from the column with the applied temperature program. No further attempts 
were made to clarify the structure of yielded Ser and Thr derivatives. Linear ranges 
including ULOQs and LLOQs, regression coefficients of calibration curves and LODs 
of the method had been determined in the course of my diploma thesis119. However, 
obtained LLOQs were found to be insufficient to allow quantification of all separated 
D-AAs in serum and urine of patients suffering from diseases affecting the bowl or 
the liver119. Additionally, high LODs were found due to high blank values detected 
after the derivatization of 33 µL aliquots of IS mix A because the IS mix, gained from 
algae, contained up to 2% unlabeled AAs. Thus, my first attempt in the course of this 
thesis was to decrease LODs and LLOQs. This was achieved by the adjustment of 
the IS mix concentration. Consequently, the IS mix A containing U-13C, U-15N 
labeled D+L AAs in a concentration range of 1.9 - 15.2 mM was diluted yielding IS 
mix B including U-13C, U-15N labeled D+L AA concentration in a range of 0.35 - 2.83 
mM. An additional improvement of LLOQs was achieved by the optimization of 
injection parameters. Derivatization of 20 µL of the diluted IS mix (IS mix B) yielded 
still appropriate IS intensities with S/N> 50 enabling a valid peak area correction. 
Blank values and therefore LODs were clearly decreased when compared to those 
found after derivatization of 33 µL of IS mix A. Thus, 20 µL of IS mix B were spiked to 
all analyzed samples and standards of this chapter. Besides all proteinogenic L-AA, 
the labeled IS mix included the corresponding D-AAs at low percentages. The 
abundance of labeled D-AAs was insufficient to allow their application as ISs. Thus, 
only labeled L-AA were used as ISs in all analysis of this thesis. Switching from split 
mode (split ratio 1:10) to splitless mode increased peak intensities. A further increase 
could be achieved by increasing the splitless time. This is the time period after 
injection in which analytes are evaporated and transported onto the column. After the 
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splitless time the injection chamber is purged using a high purge flow (here 20 
mL/min). Peak areas of quantifier-ion peaks were approximately doubled when the 
splitless time was enhanced from 0.5 minutes to 0.75 minute when derivatized MM-I 
(AAEs concentrations: 1mM or 0.5 mM depending on the AA type) was injected. 
Peak areas were again approximately doubled after injection of the same derivatized 
MM-I mixture when the splitless time was enhanced from 0.75 minutes to 1.0 minute. 
Here the samples were introduced by fast autosampler injection through a cold 
needle into a split/splitless liner packed with glass wool. Thus the sample enters the 
vaporization chamber as a band of liquid that is stopped by the glass wool. The 
boiling points of the solutes (the MeOH/MCF AA derivatives) are higher than the 
boiling point of the solvent chloroform (61° C) whi ch is the usual situation of liquid 
samples for GC analysis. The complete solvent must be evaporated until the liquid 
can reach the boiling points of the analytes as the droplet temperature stays at the 
solvent boiling point until solvent evaporation is completed. The liner section in which 
glass wool is holding the sample liquid was reported to be only about 4 mm long. This 
location of the sample narrows the heat transfer from the liner wall through the gas 
phase to the sample liquid. Therefore, the time require for complete sample 
vaporization is higher than for a thermospray moving through a unpacked liner182. 
This approximately four-fold increase of peak areas, achieved by increasing the 
splitless time, can be seen in the appendix Figure S1. It shows the overlaid 
chromatogram section of MM I, analyzed with the three different splitless times, 
showing late eluting AAEs that generally occurred with low peak intensities when 
compared to early eluting AAEs. Figures of merit for quantitative analysis including 
linear ranges, square values of the sample correlation coefficients R2 and LODs 
before and after method optimization are shown and discussed in the next chapter. 
 
6.3.2 METHOD VALIDATION AND QUANTIFICATION 
Spike-in experiments. The spike-in experiments with control serum yielded good 
mean recoveries for the three spike levels and for all tested AAEs as well as for D+L-
Phe and Gly. Mean recoveries ranged between 90.3 % for L-Met and 98.1 % for D-
Thr for the lowest spike level, between 86.8 %for L-Ala and 95.5 % for D+L-Phe for 
the medium spike level, and between 96.1 % for L-Ala and 104.3 % for D-Thr for the 
highest spike level (see Figure 11). Lowest standard deviations (SDs) of mean 
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recoveries were found for the highest spike level (0.5 - 3.1 %), followed by the 
medium spike level (2.8-10.6%) and the lowest precision was detected for the lowest 
spike level (SDs: 2.9-13.9%). Thus, spike-in experiments revealed no distinct matrix 
effect dependent over- or underestimation of AA quantities albeit derivatization was 
performed in presence of proteins and NaOH. NaOH and therefore a high pH > 10 in 
the beginning of reaction with MeOH/MCF was reported to increase reaction yields of 
derivatization as deprotonated carboxy groups react faster with MCF173. 
Nevertheless, high pH-values during the exothermal reaction can promote 
racemization processes in protein/peptide bound and free AAs as well as 
proteins/peptides hydrolysis23, 183. Matrix dependent overestimation of free AAEs 
would be the consequence of these unintended but relevant side reactions whereas 
ion enhancement or ion suppression are no issues in electron impact ionization 
following GC analysis. Inclusion of AAEs into the proteins that precipitate, due to the 
significant temperature increase during the highly exothermal reaction, can cause 
matrix dependent underestimation of free AAEs. Indeed, in general the method 
tended to slightly underestimate spiked AA concentrations as can be seen in Figure 
11. 
 
Figure 11. Results of spike-in experiments with ten AAs in control serum. 
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Method comparison before optimization of sample preparation. To further check 
method accuracy, 19 serum samples were analyzed both by the enantioselective 
MeOH/MCF method and an established GC-qMS method for achiral AA analysis158, 
180
. No protein precipitation was performed before MeOH/MCF derivatization in the 
presence of NaOH. Comparison of results revealed that the enantioselective method 
overquantified the sum of free AAs (D + L). Averaged recoveries ranged between 
116.6% for Asn and 176.1% for Phe using the achiral AA method as a reference158. 
Method comparison was also performed for five urine samples to check method 
accuracy for the different biological matrix. MeOH/MCF derivatization was performed 
in the presence of NaOH and the same established method for quantitative AA 
analysis was used as reference as above. Mean recovery ranged between 105.9% 
for Ala and 125.8 % for Gly indicating overestimation of AA quantities albeit a less 
extensive than for serum. In contrast to serum, urine of healthy individuals does not 
contain any proteins but only peptides. Consequently, I hypothesized that proteins 
(as ingredients of serum) and peptides (as ingredients of serum and urine) were 
partly degraded during the highly exothermal MCF derivatization reaction performed 
under alkaline conditions. To test this hypothesis, derivatization was performed at 
alkaline or neutral pH, with or without removal of proteins before derivatization158. 
The outcome of these experiments will be discussed in the following section.  
Comparison of different sample preparations. As shown in Figure 12 A, the pre-
precipitation of proteins with cold MeOH led to a distinct decrease in detected L-AA 
amounts, whereas replacing the base by water in the reaction mixture in the 
presence of proteins showed a slight increase in concentrations. Nevertheless, 
skipping the addition of NaOH after protein precipitation caused a further decrease in 
the L-AA concentrations determined. This supported the hypothesis that protein and 
peptide degradation had occurred during derivatization with MeOH/MCF. 
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Figure 12. Results from the comparison of different preparation strategies for 
derivatization of serum with MeOH/ MCF for quantification of (A) L-AAs and (B) D-
AAs by chiral GC-qMS. (C) demonstrates preparation dependent reaction yields by 
peak areas of detected labeled (marked by an asterisk) and unlabeled AAs. 
Prior to the second addition of MCF, the solution was slightly basic in the presence of 
NaOH (pH 8); afterwards, it was slightly acidic (pH 5–6). Replacement of the base 
with water resulted in a neutral to slightly acidic pH-value (6–7) after the first addition 
of MCF and acidic conditions after the second addition (pH 1). The relatively low pH-
values can be explained by the reaction of MCF with water yielding HCl. Protein 
degradation seemed to proceed faster at acidic pH, whereas the decomposition of 
peptides seemed to be faster at pH-values >5. If the underlying mechanism were an 
acetylation of the N-terminus followed by an alcoholysis, both derivatization reagents 
(MCF and MeOH) would be protagonists of protein and peptide degradation. Albeit 
related reactions had been reported, no further efforts were made to ascertain the 
underlying mechanism184. D- and L-AAs showed similar trends for the four different 
preparation strategies (see Figure 12 A and B). L-AAs contained in proteins were 
stronger affected by racemization than free AAs185. Furthermore, Frank at al. had 
observed a higher rate of racemization during the initial hydrolysis than several hours 
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later for AAs such as Asp and Val. They had also described an elevated 
isomerization rate of protein-bound Leu that was explained by a thiazoline 
intermediate. In contrast, the racemization rate for Thr was very low159. This is 
consistent with the present results. As can be seen in Figure 12 B, the highest bias 
was observed for Leu, while D-Thr was the only analyte that did not decrease when 
proteins were removed158. Consequently, it is necessary to perform MeOH/MCF 
derivatization in the absence of proteins and NaOH in order to determine accurate 
amounts of free AAEs. Finally, the influence of the omission of NaOH on reaction 
yield and, therefore, sensitivity was evaluated. Peak areas obtained with the four 
different preparation strategies were compared (Figure 12 C). Contrary to 
expectations the sensitivity for serum analytes stayed the same or was even 
improved by the removal of proteins. This might be caused by reduced AA inclusion 
into precipitated proteins. In the original procedure proteins precipitated during the 
first addition of MCF because of high temperatures resulting from reactions with 
MCF. In the optimized procedure proteins were precipitated before derivatization and 
the protein pellet was washed two times with a MeOH/ water mixture to release 
included analytes, which might explain the slightly increased sensitivity that also 
compensates the effect of omitting NaOH158. Thus, improvement of MeOH/MCF 
derivative yield by pH enhancement, reported to be based on faster esterification of 
deprotonated carboxylic acid groups173, was approved with more abundant IS and 
AA peaks when 100 µL 1N NaOH solution were part of the reaction mixture. 
However, since a basic pH at high temperature promotes peptide hydrolysis and 
racemization of peptide bound AAs 160-162 the 100 µL of 1N NaOH solution were 
replaced by pure water to provide more accurate analysis of free AAEs in body fluids. 
Method comparison after optimization of sample preparation. Method 
comparison was repeated with 19 serum samples from GvHD patients applying the 
optimized protocol (protein pre-precipitation and dilution with water) and the 
established achiral AA method as reference method180. Analysis yielded mean 
recoveries between 87.2% and 119.3%. Contrary to serum, which contains proteins 
at relevant concentrations, urine of healthy people contains no proteins but peptides. 
Here, the protein precipitation can be skipped, but base hydrolysis of peptides can 
still occur. The method comparison in 10 urine samples confirmed that accurate 
concentrations could be obtained by the enantioselective method if the addition of 
base was replaced by water158. Averaged recoveries ranged from 77.2 % to 105.2 %. 
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Results from all method comparisons are listed for six analytes in Table 2. They 
confirmed that the altered preparation protocols for serum and urine omitted the 
release of protein and peptide bound AAEs and therefore allowed the accurate 
determination of free AAE amounts.  
Table 2. Mean recoveries of selected serum and urine amino acids in the presence 
and absence of protein and/or NaOH, respectively, for the chiral MeOH/MCF method 
in comparison to an achiral GC-MS method for AA analysis. 
 
Calibration. Replacing NaOH with water in the derivatization protocol did not affect 
linear ranges of the chiral GC-qMS method. Quantification parameters like quantifier 
and qualifier m/z, linear ranges and R2 values as well as LODs before and after 
method optimization are shown in Table 3. Calibration of L- Asp, L-Thr and L-Ser 
could be realized for the first time after optimization of the chiral GC-qMS method. 
High blank values resulting from unlabeled AA impurities of the IS mix A, including 
the ISs at high concentrations had strongly impeded linear ranges of respective 
calibration curves. Furthermore, L-Thr coeluted with L-Asp and L-Ser with D-Met. For 
L-Ser, there was found no characteristic fragment at appropriate abundance that did 
not appear in the spectrum of D-Met. Thus L-Ser occurred as a double peak, which 
made reliable integration difficult as reflected by the low regression coefficient of the 
calibration points and a remarkably high LLOQ (31.25 µM)158. To achieve calibration 
of L-Thr the quantifier m/z =132, that referred to its characteristic derivative minus 
ester moiety fragment, was replaced by m/z =147, as the overlaid spectra of Asp and 
labeled Asp both interfered with m/z =132. The m/z = 136 of labeled Thr chosen in 
Averaged Recovery [%] Ala Gly Val Pro Asn Phe
Serum (N=19)
derivatization in presence 
of proteins and NaOH
144.9 152.5 145.5 138.1 116.6 176.1
Serum (N=19)
derivatization in absence 
of proteins and NaOH
98.3 104.7 87.2 97.8 94.9 119.3
Urine (N=5)
derivatization with NaOH 105.9 125.8 117.4 116.4 120.6 110.7
Urine (N=10) 
derivatization without 
NaOH
90.4 105.2 92.3 77.2 95.8 92.7
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my diploma for correction of D- and L-Thr areas was replaced by m/z= 149 to correct 
Thr areas by the corresponding labeled fragment. As a consequence of method 
optimization, 18 AAEs could be calibrated using the respective labeled L-AA as IS 
and all LLOQs were improved. However, accurate quantification of L-Ser was 
hampered by the spectrum of D-Met.  
Table 3. Figures of merit for chiral GC-qMS analysis of amino acid enantiomers 
before (results from my diploma thesis119) and after method optimization.
 
* at least three additional points were added at the lower end of the calibration curve; 
a
 the quantifier of Thr was m/z= 132 before method optimization; after optimization 
m/z= 147 was used as quantifier for Thr enantiomers.  
In case of D-Ala, one calibration point could be added at the lower end of the 
calibration curve. The calibration curves for D+L-Phe, D-Asn and both Pro 
enantiomers could be expanded by two calibration points at their lower ends. 
Calibration curves of the remaining AAEs and Gly included at minimum three 
additional points at the lower concentration end after method optimization. Summing 
up, the number of quantifiable D-AAs in physiological fluids was clearly increased 
(from N=3 to N=4 in human control serum and from N=2 to N=8 in human control 
before  method optimization 
(results from diploma thesis)
after method optimization
AA R2 Linear  range [µM] LOD [µM] R2
Linear  range 
[µM] LOD [µM]
Ion traces
Quantifier + Qualifier
D-Ala 0.9962 0.061 -1000 0.0512 0.9996 0.031 -500 0.0229 102 + 161
L-Ala 0.9903 1.953 -1000 0.2593 0.9992 0.122* -500 0.0966 102 + 161
Gly 0.9931 31.25 -1000 2.6255 0.9992 0.977* -500 0.0237 88 + 147
D-Val 0.9976 1.953 -1000 1.0236 0.9998 0.244* -500 0.0452 130 + 98
L-Val 0.9930 1.953 -1000 0.6276 0.9998 0.244* -500 0.0178 130 + 98
D-Leu 0.9959 1.953 -1000 1.3791 0.9999 0.244* -500 0.0899 144 + 88
L-Ile 0.9941 0.977 -1000 0.0719 0.9996 0.061* -500 0.0029 144 + 88
D-Pro 0.9914 0.244 -1000 0.0156 0.9997 0.061 -500 0.0032 128 + 187
L-Pro 0.9973 0.244 -1000 0.1933 0.9999 0.061 -500 0.0468 128 + 187
D-Thr 0.9970 62.50 -1000 7.8130 0.9993 0.977* -1000 0.0791 147a + 132
L-Thr - - - 0.9975 1.953 -1000 0.7380 147a + 132
D-Asp 0.9979 15.63 -1000 4.3459 0.9996 0.122* -500 0.0098 160 + 219
L-Asp - - - 0.9987 0.977 -500 0.2764 160 + 219
D-Ser 0.9985 31.25 -1000 0.5000 0.9997 1.953* -1000 0.4459 118 + 86
L-Ser - - - 0.9912 31.25 -1000 16.4172 118 + 86
D-Met 0.9979 7.81 -1000 0.0313 0.9998 0.488* -1000 0.0402 162 + 221
L-Met 0.9920 15.63 -1000 0.6197 0.9991 0.244* -1000 0.0854 162 + 221
D-Asn 0.9977 0.977 -1000 0.2500 0.9998 0.244 -1000 0.0199 127 + 95
L-Asn 0.9977 1.953 -1000 0.0020 0.9999 0.244* -1000 0.0190 127 + 95
DL-Phe 0.9962 0.244 -1000 0.0303 0.9989 0.061 -1000 0.0415 162 + 178
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urine) due to optimized injection parameters, decreased IS concentrations and newly 
selected quantifier m/z. Nevertheless, for more reliable quantitative D-AA analysis in 
matrices like mouse and human serum or mouse liver tissues, that can include D-
AAs in the nM range or the low pmol/mg tissue range, further improvement of LLOQs 
is required. Also LODs and, therefore, the detectable number of D-AAs in 
physiological fluids and tissues were improved distinctly. Parameter optimization 
decreased not only LLOQs and LODs but also ULOQs of early eluting AAEs. In these 
cases the highest concentration point (1 mM) was saturated and had to be excluded. 
However, measuring this MM-II concentration additionally with a splitless time of 0.5 
minutes yielded exclusively unsaturated peaks of which responses fitted into the 
calibration curves, as IS areas corrected perfectly for the different injection condition. 
Calibration curves of L-Ala and Gly that were generated using a splitless time of 1.0 
min except for the highest concentration point (splitless time = 0.5 min) are displayed 
in the appendix in Figure S2. Thus, samples including D- and L- AAs at distinctly 
different concentrations were measured with both splitless times (1.0 and 0.5 min) to 
realize accurate quantification of both antipodes. Albeit time-consuming, this 
procedure was applied to samples of this chapter that included L-Ala, L-Val or Gly at 
concentrations >500µM. 
Repeatability. The optimized chiral GC-qMS method showed excellent method 
repeatability with RSDs between 0.49–11.1% and 0.70–3.87% for the replicate 
analyses (N= 6) of the urine pool and the serum control, respectively, as shown in 
Figure 13. The RSD of D-Pro (11.1%) in urine was much higher compared to the 
other analytes (0.49–4.25%), most likely due to its low level in the analyzed sample, 
which was close to the LLOQ. In general, for the low-abundant D-AAs higher 
deviations were observed than for L-AAs. L-AAs benefit from the optimal correction 
by the structurally very similar labeled L-configured ISs. D-Val, D-Leu, D-Met, D-Ser 
and D-Asn were not quantified above LLOQ in the serum sample investigated. In the 
urine sample, only D-Met could not be quantified above its LLOQ158. 
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Figure 13. Repeatability of the optimized MeOH/MCF method for the analysis of 
AAEs in urine and serum. N= 6 replicates were prepared and analyzed, respectively. 
 
6.3.3 APPLICATION TO THE DISCOVERY OF MARKERS OF FATTY LIVER DISEASE  
Due to the low quality of L-Ser calibration, which was disturbed by coeluting D-Met, 
L-Ser quantities are neither shown nor discussed in this chiral GC-qMS application.  
The progression and physiological effects of non-alcoholic fatty liver disease 
(NAFLD) were investigated intensively in the last decade due to the increasing 
incidence of the disease in developed countries179, 186, 187. About 95 % of people 
suffering from obesity are affected by NAFLD. Besides obesity, this chronic liver 
disease is often accompanied by further characteristic components of the metabolic 
syndrome like type 2 diabetes, hypertension and dyslipidaemia. Triglyceride 
accumulation in hepatocytes characterizes the first stage of NAFLD called hepatic 
steatosis. NAFLD can progress from steatosis over NASH (non-alcoholic 
steatohepatitis) to fibrosis, cirrhosis and, ultimately, liver cancer. Elevated lipid 
peroxidation and oxidative stress were reported to be key factors in the development 
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of NASH from steatosis. Continuous enhanced production and the resulting 
accumulation of reactive oxygen species promote necroinflammation in the liver, 
which causes fibrosis179, 188. The noninvasive differentiation of the early stages of 
NAFLD by imaging and molecular means remains difficult and definite diagnosis still 
requires liver biopsy. Here, the chiral GC-qMS method was applied to learn more 
about the behavior of AAE levels in the liver and serum of mouse models mimicking 
the development of NASH. Mice that were fed with the NASH inducing diet for three 
weeks had increased TNF α levels (data not shown), which indicated a beginning 
liver inflammation. However, mice fed this diet for two weeks showed no indication of 
inflammation, yet. However, they already suffered from steatosis. 
FDRs were determined for the comparisons of two weeks treated animals (controls 
versus steatosis) and the comparisons of the three weeks treated animals (controls 
versus NASH), respectively. 
The differences in content between L-AAs and D-AAs in liver tissue were remarkable. 
It comprised more than three orders of magnitude in case of Ala, Val and Pro. L-Ala, 
Gly and L-Asp quantities in liver tissues exceeded their ULOQs, whereas most D-AA 
levels of Ser, Asn, Thr and Met were below LLOQs. Quantities of all remaining AAEs 
are shown in Figure 14. L-Val and L-Pro yielded only one value below ULOQ in the 
NASH group after two weeks. For each other AAE displayed, there were found at 
least three quantifiable concentrations per group and each shown mean D-AA level 
in Figure 14 was based on five values. As a consequence of method optimization 
and the up to 16-fold improvement of LLOQs (Table 3), mean liver contents of five D-
AAs were determined for the four groups. In contrast, with the original method of my 
diploma thesis and corresponding LLOQs, only D-Ala amounts would be quantifiable 
in all of the here investigated liver samples. Therefore, the number of quantifiable D-
AAs in mouse liver samples was distinctly increased due to the adjusted IS mix 
concentration and the optimized injection method. There were observed slightly 
increased L-AA quantities in mice fed a NASH inducing diet for three weeks when 
compared to respective controls albeit no significant trend was present considering 
the FDR. A significant increase in L-AA quantities was observed in liver tissues of 
mice suffering from steatosis after the two weeks diet for Ile, Met and D+L-Phe 
(FDR= 0.027-0.033) when compared to respective controls. D-Ala, D-Leu and D-Asp 
contents were decreased in steatosis and NASH livers when compared to respective 
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controls. The mean D-Val concentration in mouse liver affected by steatosis was 
increased when compared to the mean D-Val concentration in respective control 
mouse livers. However, considering the FDR, these D-AA trends were not significant. 
Changed D-AA contents cannot be explained by changed DAO activity in the liver as 
contrary to other mammalian livers, DAO is not expressed in mouse livers52, 53. 
  
Figure 14. Mean AAE concentrations in liver tissues of a mouse model mimicking the 
development of NASH and respective control mice (N=5 per group). * 0.001< FDR < 
0.05 
.AAE trends in the corresponding serum specimens were similar to those in mouse 
liver with decreased D-AA amounts for some D-AA types and increased L-AA 
amounts in steatosis and NASH serum when compared to control sera (see Figure 
15). The difference in D- and L-AA levels was clearly lower in serum. The highest 
difference was observed for Val enantiomers comprising approximately three orders 
0
10
20
30
40
50
60
70
D-
Al
a
D-
Va
l
D-
Le
u
D-
Pr
o
D-
As
p
c 
[p
m
o
l/ 
m
g]
0.0
0.5
1.0
1.5
2.0
2.5
3.0
L-
Va
l
L-
Ile
L-
Pr
o
L-
Th
r
L-
M
et
L-
As
n
Ph
e
c 
[n
m
o
l/ 
m
g]
controls (2 weeks diet) controls (3 weeks diet)
NASH (2 weeks diet) NASH (3 weeks diet)
*
*
*
0
1
2
3
4
5
D
-
Va
l
D
-
Le
u
D
-
Pr
o
68 
 
of magnitude. The other quantifiable antipodes differed by more than two orders of 
magnitude except for Thr enantiomers that differed by only about one order of 
magnitude. This was comparable to the situation in human serum.  
 
Figure 15. Mean AAE concentrations in serum of mouse models mimicking the 
development of NASH and of respective control mice. * 0.001< FDR< 0.05. 
Consequently, all L-AAs concentrations lay within the linear ranges except for two L-
Ala concentrations that exceeded the ULOQ in mice after three weeks on the NASH 
diet. Significant serum level increases were found for Gly after two weeks of diet 
(FDR=0.044) and for L-Thr after three weeks of NASH diet (FDR=0.012) when 
compared to the respective serum levels in the control mouse group. Owing to 
method optimization and obtained improved LLOQs (Table 3), there could be 
0
100
200
300
400
500
600
700
800
900
1000
L-
Al
a
G
ly
L-
Va
l
L-
Ile
L-
Pr
o
L-
Th
r
L-
As
p
L-
M
et
L-
As
n
Ph
e
c 
[µM
]
controls (2 weeks diet) controls (3 weeks diet)
NASH (2 weeks diet) NASH (3 weeks diet)
**
0
5
10
15
20
D
-
Al
a
D-
Va
l
D
-
Le
u
D
-
Pr
o
D
-
Th
r
D-
As
p
c 
[µM
]
0
1
2
D
-
Va
l
D
-
Le
u
D
-
Pr
o
*
69 
 
determined mean serum quantities of six D-AAs for all investigated groups. Due to 
the distinctly higher LLOQs, the application of the original chiral GC-qMS method of 
my diploma thesis would only allow the quantification of D-Ala and D-Pro amounts in 
all of the here investigated mouse serum samples. Thus, also for mouse serum, 
method optimization clearly increased the number of quantifiable D-AAs.  
A statistically significant D-AA serum level decrease in NASH mice was found 
exclusively for D-Leu (FDR= 0.023). In contrast the D-Asp, D-Pro and D-Val serum 
level were enhanced in case of hepatic steatosis albeit not significantly considering 
the FDR. Accurate quantification of D-Ser, D-Met and D-Asn was not possible in 
mouse serum because of coeluting matrix compounds that disturbed corresponding 
quantifier peaks. Reports on elevated gut permeability and prevalent small intestinal 
bacterial overgrowth (SIBO) in steatosis, and the ability of bacteria to release high D-
AA amounts into their environment provide an indication for increased D-AA serum 
levels 18, 189. Moreover, decreased D-Asp oxidase activity in the NAFLD livers may be 
the reason for enhanced D-Asp serum level, however, there was observed no D-Asp 
level increase in the corresponding liver samples. Therefore, the here found D-AA 
trends in mouse serum and liver do not support the findings of increased intestinal 
permeability in NAFLD as it was reported by Miele et al.189. However, their 
conclusions cannot be negated by the here shown results as there is not yet enough 
known about D-AA metabolism in mammals that most probably influences noticeable 
D-AA quantities in physiological fluids and tissues. Determined D-AA concentrations 
in mouse liver and serum were comparable to those, previously reported, for liver and 
serum of control mice121, 190, 191. 
 
6.3.4 COMPARISON WITH PUBLISHED METHODS  
This section was adapted from158 . 
Previously reported GC methods for the separation of anhydride derivatives on a 
Chirasil-L-Val column had actually not been well suited for D-AA analysis in urine and 
serum35, 40, 48. With 935, 48 or 1040  baseline resolved racemates of proteinogenic AAs, 
these methods presented suitable enantioselectivity, however, resolution values of 
the MeOH/MCF method were superior (>2.4). Applying TFAA or PFPA for 
acetylation, and MeOH, propanol or IPA for esterification, impeded quantification of 
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several AAs (Asn, Asp, Gln, Glu, Ser, Thr and Tyr)35, 40, 48. Asn degraded to form Asp 
and, analogously, Gln degraded to form Glu. IPA/TFAA derivatives of AA carrying 
hydroxy groups lacked stability and thus hampered quantification35. With the 
MeOH/MCF method quantification of D-Asn, D-Asp, D-Ser, and D-Thr posed no 
problem except for the high LLOQs for D-Ser and D-Thr when compared to the other 
MeOH/MCF D-AAs based on low peak abundances of these hydroxy D-AAs. Another 
drawback of common methods is a rising baseline caused by strong bleeding of the 
Chirasil-L-Val column at elevated temperatures >150°C. The here applied γ-CD 
based chiral column showed no baseline enhancement up to a temperature of 
190°C. Albeit the preparation of serum including re moval of proteins was complex, 
the MeOH/MCF method exceeded formerly reported GC quantification approaches in 
efficiency. Prior to chiral analysis of anhydride derivatives on Chirasil-L-Val, 
conventional achiral analysis applying ion exchange chromatography were performed 
to either determine D+L-AA quantities 35, 48 or to isolate AAs from the biological 
matrix40. Apart from Pätzold et al., who used an IS for quantification40, D-AA 
quantities were calculated from D+L amounts using D-ratios estimated from peak 
areas of the enantiomers35, 48. Peak areas are an unreliable measure in case of the 
Chirasil-L-Val column, because the rising baseline masks later eluting L-AAs more 
than the corresponding D-AAs. Thus, accuracy of this approach is likely to be inferior 
to the MeOH/MCF method. Moreover, the latter method is the only technique 
available to date that has been shown to allow in a single analytical run the direct 
quantification of D-AAs in several matrices like human and mouse serum and urine 
and mouse liver. Among the LC methods applied to physiological fluids, the one by 
Nagata et al. showed the best performance. With 12 D-AAs amenable to 
quantification, applying Marfey’s reagent and a conventional RP-column, the method 
yielded superior enantioselectivity. Nevertheless, detection limits (4–10 µM) of D-AAs 
were much higher than those of the MeOH/MCF method (3.2–446 nM). Therefore, 
only D-Ala, D-Ser and D-Pro were detected in plasma, whereas the MeOH/MCF 
method enabled accurate quantification of four D-AAs in human control serum and 
six in mouse serum. Applying two-dimensional thin-layer chromatography for the pre-
separation of AAs from the biological matrix rendered the method of Nagata et al. 
more elaborate, but the pre-separation was required due to the low selectivity of 
fluorescence detection 83. Further, several two-dimensional HPLC approaches using 
chiral columns and fluorescence detection were also not as efficient as the 
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MeOH/MCF method, because they did not allow to separate more than one racemate 
per run because of disturbing matrix compounds121, 192, 193. Only the multi-loop two-
dimensional HPLC system of Hamase et al. enabled resolution of four racemates of 
branched AAs in one run 51. LLOQs of two-dimensional LC methods were similar to 
LLOQs of the MeOH/MCF method51, 121, 192, 193, but the here presented GC–qMS 
method excelled in selectivity, robustness and efficiency, as matrix compounds could 
rarely disturb the analysis of human serum and urine due to mass spectrometric 
detection in SIM mode. From the other column chromatography methods, presented 
as outstanding methods for AAE quantification in biological matrices in chapter 
4.3.3.1, only the chiral LC-MS/MS method by Barbaro et al. outperformed the chiral 
MeOH/MCF GC-qMS in sensitivity and efficiency as the resolution of 16 pairs of 
proteinogenic AAEs was realized in 35 minutes120. Nevertheless, the method showed 
several drawbacks like Leu enantiomers coeluting with Ile enantiomers, inaccurate 
quantification of D-Ser, D-Orn, L- and D-Trp enantiomers and the unfavorable elution 
order of D-AAs eluting after L-AAE resulting in distinctly broader peaks for D-AAs 
than for L-AAs. Therefore LODs and LLOQs of D-AAs were higher than those of L-
AAs in most cases in contrast to the here presented GC-qMS method. Finally the 
chiral LC-MS/MS method was validated for the application to lake water, which is a 
less complex biological matrix than mammalian physiological fluids and tissues120. 
However, there were three pairs of overlapping peaks in chromatograms of the chiral 
GC-qMS method, which disturbed quantification of L-Ser, L-Leu and D-Ile. The use of 
GC×GC-TOFMS should solve this problem and improve resolution from biological 
matrix compounds. Moreover, it should increase the number of AAEs amenable to 
quantitative analysis due to improved peak shapes owing to modulation and fast 
second dimension separation194. 
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7 IMPLEMENTATION OF ENANTIOSELECTIVE GC×GC-TOFMS FOR 
QUANTITATIVE AMINO ACID ANALYSIS IN URINE AND SERUM  
This chapter was adapted from 174. Each section, corresponding to published text, 
was cited individually. 
 
7.1 INTRODUCTION 
The overlapping peak pairs D-Ile/L-Leu, L-Thr/L-Asp, and L-Ser/D-Met impeded the 
quantification of D-Ile, L-Leu and L-Ser by the chiral GC-qMS method. Further, 
LLOQs achieved for some D-AAs and resolution of AAEs from other biological matrix 
components were insufficient for reliable quantitative AAE analysis in serum. Both, 
the orthogonal separation characteristics and the narrower peaks obtained by cryo-
focusing make GC×GC-TOFMS an attractive remedy to overcome the 
aforementioned limitations of chiral GC-qMS194. 
Junge et al. were the first to apply GC×GC to the separation of AAEs as their ethyl 
chloroformate derivatives in samples of beer by coupling a Chirasil-L-Val column with 
a low-polarity column in the second-dimension195. The present study expanded the 
scope of GC×GC-based AAE analysis by applying a combination of an Rt-γDEXsa 
chiral first-dimension column with an RTx-1701 or a ZB-AAA column as second-
dimension column not only to the separation but also the quantitative measurement 
of AAEs in physiological fluids after derivatization with MeOH/MCF174. 
 
7.2 MATERIAL AND METHODS 
7.2.1 ANALYZED SAMPLES 
A set of 48 urine and 43 serum specimens, which had been collected from patients 
before and after curative SCT for non-malignant and malignant disorders of the 
immunohematopoietic system, was used to validate the GC×GC-TOFMS method 
with the Rt-γDEXsa/ZB-AAA column set by comparing determined AAE amounts with 
the results obtained by the chiral GC-qMS method. Urine specimens were not treated 
with preservatives but were frozen at −20 °C as qui ckly as possible after sampling to 
avoid bacterial growth. Further, 25 serum specimens from patients with liver cirrhosis 
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and 16 control sera were analyzed by the validated GC×GC-TOFMS method to 
demonstrate relevance for medical diagnostics. At the time of blood drawing, none of 
the patients had been treated with peptide antibiotics or other drugs that might affect 
D-AA serum levels. For the evaluation of method repeatability a human serum control 
was obtained. Serum specimens were stored at −80 °C . Specimens were provided 
by collaborators at the University Hospital of Regensburg with approval from the 
institutional review board174. 
 
7.2.2 SAMPLE PREPARATION 
Serum samples were prepared with the optimized procedures including protein pre-
precipitation with 600 µL of cold MeOH (-20°C) and two washing steps of the pellet 
with MeOH-water (80% MeOH; 0°C) with subsequent der ivatization of the dried 
residue of the collected MeOH-water phases. The following volumes were added for 
derivatization: 275 µL of water, 167µL of MeOH, 34 µL of pyridine and 40 µL of MCF 
that was added in two portions to the reaction mixture. Derivatives were extracted 
into 300 µL of chloroform. The optimized procedure for the derivatization of urine 
included the addition of water to a constant start volume of 275 µL and the 
subsequent addition of the above listed derivatization reagent volumes. Sample 
aliquots of 150 µL and 20 µL of IS mix C were used for quantitative analysis by 
GC×GC-TOFMS and GC-qMS. Prepared MM aliquots for preliminary experiments 
were noted in chapter 5.2.3. 
 
7.2.3 INSTRUMENTAL SET-UP AND APPLIED METHODS  
The LECO (St. Joseph, MI) Pegasus 4D GC×GC–TOFMS instrument included the 
following components: an Agilent Technologies Model 6890 GC with a PTV injector, 
a dual-stage, quad-jet thermal modulator and a secondary oven coupled to a fast 
acquisition TOFMS providing unit mass resolution (Gerstel, Muehlheim, Germany). 
An Rt-γDEXsa column (30 m×0.25 mm ID, 0.25 µm film thickness) from Restek 
(GmbH, Bad Homburg, Germany) protected by a 5 m×0.25 mm ID fused silica 
deactivated guard column (Agilent Technologies, Palo Alto, CA, USA) was used as 
the first-dimension column and an RTx-1701 (2 m×0.1 mm ID×0.1 µm film thickness, 
Restek) or a ZB-AAA (2 m×0.25 mm ID, 0.25 µm film thickness, Phenomenex Inc.) 
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column were employed as second-dimension columns, respectively. A sample 
volume of 1.5 µL was injected in splitless mode with the temperature of the PTV 
Injector set at 50 °C for 0.5 min and then ramped a t 12 °C/s to 250 °C. A chemically 
inert Siltek liner from Gerstel was used. The helium flow-rate was set at 1.9 mL/min 
(constant flow). Modulation was accomplished every 4 s. Mass spectra were acquired 
from 40 to 600 m/z. For 1D GC–TOFMS analysis the modulator was turned off. The 
solvent delay was 19 min. Transfer-line temperature was held at 260 °C. The ion 
source was operated at 200 °C and −70 eV. A positiv e offset of 5 °C was used for the 
second-dimension column and a 15 °C offset relative  to the first-dimension column 
for the modulator. Applied temperature programs for the first column oven are given 
in Table 1. 
 
7.2.4 QUANTIFICATION AND METHOD VALIDATION 
Calibration. For AA identification, EI spectra were compared to the EI spectra of the 
validated GC-qMS method. Calibration was performed with the Rtγ-DEXsa/ZB-AAA 
column set using a 16 point-serial dilution of MM II. It contained all AAs, whose 
elution from the RTγ-DEXsa column as MeOH/MCF-derivatives could be detected, 
over a concentration range of 31 nM to 1 mM each. Applied IS concentrations of IS 
mix C are given in chapter 5.2.3. As the labeled AAs had been gained from algae, 
they were present in the mix at their naturally occurring ratios in algae. Most D-AAs 
were detected in the labeled mix but their abundance was too low (< 3.4% of the 
respective L-AA area) to be suitable as ISs. Thus, the stable isotope-labeled L-AAs 
were used to correct areas of the corresponding D- and L-AA in quantitative 
measurements. Correspondingly, stable isotope-labeled Gly, the only natural 
nonchiral AA, was used for correcting Gly area integrals174. LLOQ was defined as 
described in chapter 5.5.1. Data analysis of calibration measurements was performed 
by Dr. Martin Almstetter. 
Repeatability. Eight aliquots of the human control serum were prepared and 
analyzed to test method repeatability174.  
Method comparison. Accuracy was checked by comparing results with those 
obtained by the validated chiral GC-qMS method for AAE analysis. Relative 
recoveries were determined for urine (N = 48) and serum (N = 43) by dividing the 
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enantiomer amount determined by GC×GC-TOFMS by the respective amount 
measured by chiral GC-qMS and multiplying by 100. Mean recoveries and Pearson 
correlation coefficients were calculated. Additionally, Bland-Altman plots were 
generated, which display for each specimen analyzed the difference in concentration 
versus the mean of the concentrations determined by the two methods and, 
therewith, assesses agreement between methods172, 196, 197 as explained in chapter 
5.5.3. Since it takes too much space to show all Bland-Altman plots, the mean 
difference was divided by the averaged mean of all couples and multiplied by 100. 
These values were named ‘mean deviation’174. 
 
7.3 RESULTS AND DISCUSSION 
Initial experiments focused on the evaluation of two different column combinations for 
the GC×GC separation of MeOH/MCF derivatives of AAEs. In GC×GC the length of 
the second-dimension is kept short to allow the elution of analytes within one 
modulation period. Length of the first-dimension column, in contrast, is not limited. 
Therefore, the chiral Rt-γDEXsa column was always chosen as first-dimension 
stationary phase, as the resolution of enantiomers improves with increasing length of 
the chiral column. Secondly, the Rt-γDEXsa phase reacted sensitive to high 
temperatures >190 °C, yielding reduced enantioselec tivity and accelerated column 
degradation (data not shown). Therefore, a fast second-dimension enantioselective 
separation at high elution temperatures of AAEs, eluting late from the non-chiral 
columns would be unfavorable for AAE resolution174. 
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7.3.1 RT®-γDEXSA/RTX®-1701 COLUMN SET  
 
Figure 16. Characteristic GC×GC-TOFMS chromatogram of the AAE MM II using the 
Rt-γDEXsa (30m x 250 µm x 0.25 µm)/Rtx-1701 (2m x 100 µm x 0.1 µm) column 
combination and the optimized temperature program (method A) : 70°C (1 min) –
2°C/min – 150°C (10 min) –2°C/min – 180°C (25 min),  a constant He flow of 1.9 
mL/min, a modulation rate of 4s and a positive offset of 5°C for the Rtx-1701 column. 
Coeluting D-Ile and L-Leu isomers were encircled. 
Initially, a 2-m midpolarity 14% cyanopropylphenyl/86% dimethyl polysiloxane RTx-
1701 capillary column with an inner diameter of 100 µm served as the second-
dimension column. This narrow bore column and the intended high He-flow limited 
applied temperature programs to flat temperature ramps and generally low 
temperatures. During fast temperature ramps and temperatures >180°C the GC x GC 
device was not able to continuously provide the required pressure to maintain the 
high constant He-flow of the enantioselective method. Consequently, a method 
comparable to the chiral GC-qMS method could not be tested. Nevertheless, low 
temperatures were favorable for enantiomer resolution in the first-dimension. A 
characteristic chromatogram of MM II obtained under optimized temperature program 
(method A, Table 1) is shown in Figure 16. The RTx-1701 column compensated for 
the lack of selectivity of the Rt-γDEXsa for L-Thr/L-Asp and L-Ser/D-Met, 
respectively, and allowed their baseline resolution in the second-dimension. 
However, L-Leu and D-Ile still coeluted. MeOH/MCF-Phe enantiomers were not 
resolved at all by the chiral Rt-γDEXsa column and, therefore, could not be separated 
by the RTx-1701 column either174. 
 
Ala Gly
Val
Leu
Ile
Phe
Pro
Asp Met
Thr
Asn
Ser
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7.3.2 RT®-γDEXSA/ZB-AAA COLUMN SET 
Previously, Kaspar et al. had demonstrated the successful separation of Leu and Ile 
as their propyl chloroformate (PCF) derivatives on a 15-m ZB-AAA capillary column 
that reportedly consists of 50% phenyl/50% dimethyl polysiloxane180, 198. Therefore, 
the ZB-AAA column was tested next as second-dimension column. 
Figure 17. Characteristic GC×GC-TOFMS chromatogram of the AAE MM II using the 
Rt-γDEXsa (30m x 250 µm x 0.25 µm)/ ZB-AAA (2 m×250 µm x 0.25 µm) column 
combination and a comparable temperature program to the optimized GC-qMS 
method (method B): 70°C (1 min) – 4°C/min – 150°C ( 10 min) - 3 °C/min – 190°C (15 
min). A constant He flow of 1.9 mL/min, a modulation rate of 4s and a positive offset 
of 5°C for the Rtx-1701 column were applied. Overla pping D-Ile and L-Leu isomer 
peaks were encircled. 
A representative chromatogram of MM II obtained with a temperature program 
(method B, Table 1) comparable to the previously optimized GC-qMS method II is 
pictured in Figure 17. Again L-Thr/L-Asp and L-Ser/D-Met, which coeluted from the 
chiral column, were resolved completely in the second-dimension. In addition, partial 
resolution of D-Ile and L-Leu was observed. Following optimization of the 
temperature program (method C, Table 1), baseline separation was achieved for all 
analytes except for the Phe enantiomers. This is demonstrated by first and second-
dimension retention times in Table 4 and by a 2D chromatogram of MM II in Figure 
18 A as compared to a respective measurement in 1D mode (Figure 18 B). 
Ala Gly
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Figure 18. (A) Characteristic GC×GC-TOFMS chromatogram of the AAE MM II using 
the Rt-γDEXsa/ZB-AAA column combination and the optimized temperature program 
(method C): 70°C (1 min) – 2°C/min – 130°C (12.5 mi n) - 8°C/min- 150°C (4 min) - 
4°C/min – 190°C (6 min) in 2D mode and in (B) 1D mo de after modulation was 
turned off. Each peak pair, that was not baseline separated after 1D separation but 
was baseline separated by the second dimension was encircled, respectively. 
The 1D GC-TOFMS measurement yielded 3 coeluting peak pairs and the D-Ile/L-Leu 
peak pair that was partly separated using GC method C (Table 1), reflecting the 
insufficient selectivity of the Rt-γDEXsa column. Selectivity was improved by using 
thermal modulation and the different separation properties of the second-dimension 
ZB-AAA column. Enhanced resolution of enantiomers that were separated by a 
temperature program on the chiral first-dimension column was achieved due to the 
fast and therewith approximately isothermal separation on the second-dimension 
column. It allows additional separation of enantiomers even though the second-
dimension selector provides no stereo-specific retardation. This can be seen for the 
enantiomers of Leu, Ile, and Pro in Figure 18 A174. 
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Table 4. First and second-dimension retention times and fragment ion masses used 
for quantification of MeOH/MCF AAE-derivatives by GC×GC-TOFMS employing the 
column sequence: Rt-γDEXsa (30m x 250 µm x 0.25 µm)/ ZB-AAA (2 m×250 µm x 
0.25 µm) and method C: 70°C (1 min) – 2°C/min – 130 °C (12.5 min) - 8°C/min- 
150°C (4 min) - 4°C/min – 190°C (6 min).  
 
7.3.3 QUANTIFICATION AND METHOD VALIDATION 
Calibration. Calibration curves were generated for absolute quantification of AAEs. 
Table 4 lists fragment ion masses chosen for quantification. Values for linear range, 
R2 and repeatability are shown in Table 5. For direct comparison, Table 5 also 
includes the values obtained for 1D-GC-qMS. GC×GC-TOFMS calibration curves 
were linear with the square values of the Pearson correlation coefficient r ranging 
between 0.9938 and 0.9992, which is comparable, albeit inferior to the 1D GC-qMS 
method, whose R2 values ranged from 0.9956 to 1.0000. LLOQs were in the range of 
0.03–2 µM174. While those for GC-qMS ranged from 0.03 to 31.25 µM. The most 
AA 1
st retention 
time (s)
2nd retention 
time (s)
Quantifier
analyte + U-13C,15N-labeled IS
D-Ala 1916 2.105 102 + 105
L-Ala 1976 2.110 102 + 105
Gly 2172 2.250 88 + 90
D-Val 2180 2.895 130 + 135
L-Val 2372 2.890 130 + 135
D-Leu 2572 3.810 144 + 150
L-Leu 2660 3.255 144 + 150
D-Ile 2648 3.530 144 + 150
L-Ile 2764 2.480 144 + 150
D-Pro 3004 3.445 128 + 133
L-Pro 3176 2.660 128 + 133
D-Thr 3512 1.705 147 + 149
L-Thr 3592 1.620 147 + 149
D-Asp 3536 1.995 160 + 164
L-Asp 3596 1.890 160 + 164
D-Ser 3644 1.605 118 + 121
L-Ser 3712 1.610 118 + 121
D-Met 3708 2.455 162 +167
L-Met 3740 2.455 162 + 167
D-Asn 3812 1.770 127 + 132
L-Asn 3864 1.770 127 +132
Phe 3900 3.280 162 + 171
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striking improvement was achieved for L-Ser, whose LLOQ could be reduced by 
three orders of magnitude from 31.25 µM to 0.031 µM due to the baseline separation 
of L-Ser from D-Met by the second-dimension column. In the GC-qMS method the 
mass spectrum of coeluting D-Met had interfered with the calibration of L-Ser leading 
to a flat calibration curve and a remarkably high LLOQ. In contrast, LLOQs for D-Met 
and L-Met deteriorated from 0.488 µM and 0.244 µM for GC-qMS to 1.953 µM and 
0.977 µM, respectively, for GC×GC-TOFMS as their lowest calibration points did not 
fit, with an accuracy between 80 and 120%, into the calibration curves. This was 
possibly a consequence of the lower repeatability of the method when compared to 
the chiral GC-qMS method (see Table 5). 
Table 5. Comparison of linear ranges, R2 values and relative standard deviations 
(RSDs) for AAE analysis in serum by GC×GC–TOFMS and GC–qMS. 
 
RSD of analytes that were <LLOQ in the investigated serum were not listed.              
* At least two additional calibration points were included at the lower end of the 
GC×GC calibration curve compared to the GC–qMS calibration curve174. 
GC×GC-TOF-MS GC-qMS
AA Linear range (µM) R2 RSD (%; N=8) Linear range (µM) R2 RSD (%; N=6)
D-Ala 0.031 -1000 0.9971 12.15 0.031 -500 0.9998 1.10
L-Ala 0.061 -1000 0.9974 2.16 0.122 -500 0.9996 0.95
Gly 0.031* -1000 0.9979 3.78 0.977 -500 0.9996 0.87
D-Val 0.244 -500 0.9971 - 0.244 -500 0.9999 -
L-Val 0.061* -500 0.9961 3.81 0.244 -500 0.9999 0.81
D-Leu 0.244 -1000 0.9974 - 0.244 -500 1.0000 -
L-Leu 0.061 -1000 0.9954 1.28 - - -
D-Ile 0.061 -1000 0.9970 - - - -
L-Ile 0.061 -1000 0.9973 3.07 0.061 -500 0.9998 0.87
D-Pro 0.031 -500 0.9988 4.52 0.061 -500 0.9998 1.31
L-Pro 0.061 -500 0.9970 3.38 0.061 -500 0.9999 0.73
D-Thr 0.122* -500 0.9986 - 0.977 -1000 0.9996 -
L-Thr 0.061* -500 0.9980 3.53 1.953 -1000 0.9988 1.62
D-Asp 0.031* -1000 0.9938 16.64 0.122 -500 0.9998 3.87
L-Asp 0.061* -1000 0.9990 3.18 0.977 -500 0.9994 0.70
D-Ser 0.244* -1000 0.9987 - 1.953 -1000 0.9999 -
L-Ser 0.031* -1000 0.9991 2.37 31.25 -1000 0.9956 -
D-Met 1.953 -1000 0.9988 - 0.488 -1000 0.9999 -
L-Met 0.977 -1000 0.9992 2.56 0.244 -1000 0.9996 1.06
D-Asn 0.061* -1000 0.9973 9.93 0.244 -1000 0.9999 -
L-Asn 0.031* -1000 0.9983 3.43 0.244 -1000 0.9999 1.02
DL-Phe 0.061 -1000 0.9978 3.41 0.061 -1000 0.9995 1.13
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Repeatability. Octaplicate analysis of a serum specimen yielded relative standard 
deviations (RSDs) below 5% except for D-Ala (12.2%), D-Asp (16.6%), and D-Asn 
(9.9%), whereas hexaplicate 1D-GC–qMS analysis yielded in general RSDs < 4%174 
that are shown in Table 5. The SDs of octaplicate serum analysis by GC×GC were 
significantly different (P-Value <0.05) based on the result of the F-Test when 
compared to the replicate serum analysis (N=6) by GC-qMS for D-Ala, Gly, L-Val, L-
Ile, L-Pro, L-Asp, L-Met, L-Asn and DL-Phe. 
Method comparison. For evaluation of method accuracy, 48 urine and 43 serum 
specimens were analyzed by both GC×GC-TOFMS and the 1D-GC-qMS method that 
had been validated by comparison to an established non-chiral GC-qMS method for 
quantitative AA analysis. Determined D+L amounts of free AAs had been compared 
by averaged recoveries.  
Table 6. Comparison of quantitative AAE data obtained by the chiral GC–qMS 
method and the GC×GC–TOFMS method. Mean recoveries, mean deviations, and 
Pearson correlation coefficients (r) were listed for all analytes whose urine and serum 
concentrations, respectively, fell within the linear ranges of both methods for N≥20 
specimens. 
 
*Analyte was affected by matrix overlaps that impeded accurate quantification. 
Urine Serum 
AA N
Mean
Recovery
(%)
Mean
deviation
(%)
r N
Mean
Recovery
(%)
Mean
deviation
(%)
r
D-Ala 48 93.9 -3.8 0.9892 43 90.3 -12.0 0.9752
L-Ala 48 101.3 1.8 0.9935 43 104.4 4.2 0.9067
Gly 47 101.9 1.1 0.9983 41 104.8 4.5 0.9964
D-Val <20 - - - <20 - - -
L-Val 48 105.6 5.6 0.9937 43 111.1 10.6 0.9159
D-Leu 47 78.4 -17.6 0.9704 <20 - - -
L-Ile 48 114.5 18.5 0.9955 43 129.4 25.4 0.9909
D-Pro 25 116.4 22.1 0.8186 34 91.3 -11.2 0.9873
L-Pro 48 101.7 5.9 0.9931 42 114.8 12.6 0.9571
D-Thr -* -* -* -* <20 - - -
L-Thr 48 93.3 -21.1 0.9823 43 72.2 -44.1 0.3691
D-Asp 45 81.6 -21.4 0.9185 <20 - - -
L-Asp 45 84.2 -10.6 0.9888 43 115.6 15.0 0.9938
D-Ser 48 89.8 -5.2 0.9773 -* -* -* -*
L-Ser 34 81.5 -8.8 0.9911 42 74.7 -29.1 0.8725
D-Met <20 - - - <20 - - -
L-Met 44 111.9 0.2 0.9125 42 101.2 0.2 0.9697
D-Asn 48 85.8 -10.3 0.9881 -* -* -* -*
L-Asn 48 100.9 4.9 0.9990 43 103.1 3.4 0.9841
Phe 48 105.1 8.0 0.9978 43 103.3 2.9 0.9665
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Here, mean recoveries were calculated using the data generated by chiral 1D-GC-
qMS as reference. Mean recoveries, mean deviations as results of the Bland-Altman 
plots, and Pearson correlation coefficients are shown in Table 6. Only analytes 
detected in N ≥20 urine and serum specimens, respectively, were evaluated. Mean 
recoveries between 80% and 120% and absolute values of mean deviations below 
15% were defined as quality criteria for the accuracy. These criteria were fulfilled for 
both enantiomers of Ala, Ser, and Asn, as well as for Gly, L-Val, L-Pro, L-Asp, L-Met, 
and D+L-Phe in the analysis of urine. Urinary concentrations of D-Val and D-Met 
were below the LLOQ for either method in most of the investigated specimens. 
GC×GC-TOFMS yielded slightly higher (mean deviation of 18.5%) urinary L-Ile 
concentrations. Nevertheless, both mean recovery (114.5%) and the correlation 
coefficient (R = 0.996) between the methods were excellent. Compared to 1D-GC–
qMS, GC×GC-TOFMS gave slightly lower urinary concentrations for L-Thr and D-Asp 
with mean deviations of -21.1% and -21.4%, respectively, whereas mean recoveries 
were 93.3% and 81.6%. Note that superior concordance was observed for L-Met 
(mean deviation of 0.2%) despite a low correlation coefficient of 0.913. 
Figure 19. Bland–Altman plots for the analysis of (A) L-Ala and (B) D-Pro in serum 
show good agreement between GC–qMS and GC×GC, while the Bland–Altman plots 
for (C) L-Thr and (D) L-Ile show proportional error in agreement between the two 
methods174.  
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For D-Thr, a method comparison was not possible, because a highly abundant 
urinary matrix compound had interfered with its 1D-GC-qMS analysis. The low values 
of concordance observed for D-Leu, D-Pro, and D-Asp resulted from urinary levels 
close to the respective LLOQs of either method, and in the case of D-Pro and D-Asp 
due to insufficient LLOQs for the GC-qMS method. Similar results were obtained for 
the analysis of serum. Accuracy was high for both enantiomers of Ala and Pro, and 
for Gly, L-Val, L-Asp, L-Met, L-Asn, and D+L-Phe. In Figure 19 A and B, Bland-
Altman plots demonstrate good agreement between GC-qMS and GC×GC-TOFMS 
for the serum levels of L-Ala and D-Pro. Serum levels of D-Val, D-Leu, D-Thr, D-Asp, 
and D-Met in most of the analyzed specimens were below LLOQ for either method. 
Again a slight overestimation of L-Ile (129.4%) by GC×GC-TOFMS was observed. 
Bland-Altman plots of L-Thr and L-Ile serum analysis displayed in Figure 19 C and D 
picture exemplary low concordances with the reference GC-qMS method. The plots 
show a proportional error and in case of L-Ile also a systematic error and can be 
classified as Bland-Altman plot types E and D, respectively, as recently defined by 
Kaspar et al.196. Type D describes increasingly positive differences at high 
concentrations whereas type E describes increasingly negative differences. 
Apparently lower L-Thr amounts determined by GC×GC-TOFMS result from L-Thr 
overquantification by GC-qMS analysis that was affected by a coeluting serum 
compound, which appeared at elevated levels in serum specimens of one patient and 
resulted in the 7 outliers visible in Figure 19 C. Systematically lower L-Ser 
concentrations were found by GC×GC–TOFMS for concentrations below 330 µM for 
both urine and serum, whereas concentrations above 330 µM determined in urine 
were systematically increased. A flat calibration curve of the GC-qMS method with a 
high y-axis interception caused by overlapping D-Met, and a serum matrix peak are 
responsible for this trend. The GC×GC approach provides more reliable L-Thr and L-
Ser results as matrix compounds were separated from targets in the second-
dimension. However, their accuracy could not be ascertained because of the lack of 
both a validated reference method and a certified standard for Ser and Thr 
enantiomers. Furthermore, a serum matrix peak interfered with the quantification of 
D-Ser using both 1D and 2D GC. Finally, a coeluting serum matrix compound 
impeded GC-qMS analysis of D-Asn, but the adequately resolved GC×GC peak and 
accurate urine analysis indicate accuracy of D-Asn serum analysis174. 
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7.3.4 APPLICATION TO SERUM SPECIMENS FROM PATIENTS WITH LIVER CIRRHOSIS 
An exemplary application of GC×GC-TOFMS to diagnostics was performed by 
analyzing serum specimens from N= 16 healthy probands and N= 25 patients with 
liver cirrhosis. The clear trend of increased serum levels of D-AAs in liver cirrhosis 
patients is visible in Figure 20.  
 
Figure 20. Mean concentrations of AAEs in serum specimens of patients suffering 
from liver cirrhosis and of healthy probands. 0.001 <*P-value < 0.05, **P-value< 
0.001. 
Only D-Asp concentrations were not increased when compared to the respective 
mean concentration of the control group. D-Val, D-Leu, and D-Thr were found above 
the LLOQ only in some of the serum specimens of cirrhosis patients. D-Ile and D-Met 
were detected in none of the samples, and D-Ser could not be measured because of 
the interference by a unknown serum matrix component as mentioned above. The 
null hypothesis comprising that the data are normally distributed, could not be 
rejected according to the p-values (>0.05) resulting from the Shapiro-Wilk test. 
Compared to the controls, significantly elevated serum concentrations of D-Pro (P = 
0.013) and D-Ala (P = 0.00008) were observed as determined by a two-tailed 
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student’s t-test. Mean D-Asn concentrations were not tested because of an 
insufficient number (N = 2) of values above LLOQ in the control group. Determined 
concentrations of D-Ala, D-Pro and D-Asn + D-Asp in control sera were in good 
agreement with respective serum levels reported previously for healthy volunteers48 
199
. L-AA serum levels were significantly decreased in liver cirrhosis specimens as 
shown in Figure 20: L-Ala (P = 0.0051), L-Ile (P = 0.036), L-Ser (P = 0.0099), L-Asn 
(P = 0.0011), L-Val (P = 0.00028), and L-Leu (P = 0.0003). The increased D-AA 
serum levels observed for liver cirrhosis reflect the loss of intact liver parenchyma 
and, hence, a reduced enzymatic capacity to catalyze D-AA decomposition174. 
 
7.3.5 COMPARISON OF ENANTIOSELECTIVE GC×GC-TOFMS WITH GC-QMS 
The quantification parameters determined for GC×GC-TOFMS and GC-qMS are 
shown in Table 5. Linear ranges, square values of the sample correlation coefficient 
R2, and RSDs for replicate AAE analysis of a serum sample (N = 8) were compared. 
LODs are not given, because the IS mix contained up to 2% unlabeled AAs that 
appeared as blank values in the chromatograms as reported in chapter 6. Since 
blank values affect LODs, this parameter was not considered for method comparison. 
GC×GC-TOFMS yielded distinctly lower LLOQs for Gly, L-Val, and both enantiomers 
of Thr, Asp, Ser, and Asn. Chromatographic band focusing in the thermal modulator 
and fast second-dimension separation yield narrow peaks and, thus, enhance 
detection sensitivity194. Analytes eluting late from the chiral column showed an 
improved LLOQ in GC×GC-TOFMS, because column bleed in contrast to GC-qMS 
was separated from all analytes in the second-dimension. Linearity of calibration 
curves was good for both methods. Peak resolution was improved by coupling two 
columns with orthogonal separation characteristics. All target analytes were resolved 
adequately from matrix peaks except for D-Ser in serum, whereas D-Asn and both 
enantiomers of Thr and Ser were disturbed by matrix compounds in GC-qMS 
analysis. Separation of D-Met/L-Ser and L-Thr/L-Asp, respectively, which had 
coeluted from the chiral column, was accomplished with the GC×GC approach. 
Separation of D-Ile/L-Leu was possible but required decreased operation 
temperatures for both columns and, as a consequence, increased analysis time from 
44 to 66 minutes. Analysis time of 2D data took also longer. Automatic peak 
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assignment by comparison of found mass spectra with given standard spectra was 
sometimes incorrect, such as for D-Val and Gly that dissociated into similar ions and 
featured almost identical first-dimension retention times. Another problem resulted 
from the slightly earlier elution of ISs compared to the respective analytes as shown 
in Figure 21. Since the base fraction peak of the labeled AA appeared one 
modulation before the analyte maximum, the analyte-to-standard area ratio was 
different for each fraction. Thus, peaks from all modulations had to be integrated to 
determine the response.  
 
Figure 21. Extracted ion chromatogram of L-Val quantification masses. Peak 
envelopes (dashed lines) of L-Val and U-13C, U-15N labeled L-Val are indicated to 
demonstrate their position shift and the varying analyte-to-internal standard area ratio 
for each fraction174. 
As the software mostly integrated the major analyte fractions, the remaining fractions 
had to be integrated manually and summed up, leading to a significant increase in 
data analysis time, as highly abundant L-AAs and ISs may yield ten and more 
modulations (visible in Figure 21). These problems reflect the complexity of GC×GC-
TOFMS data handling, because more parameters including a mass spectral match 
factor need to be considered in combining all modulated peaks. Due to the impact of 
noise, low abundant modulated peaks suffer from an insufficient spectral match and, 
therefore, are not integrated automatically. Reproducible manual inclusion of a great 
number of sub-fraction integrals is a challenging task and contributes to higher RSDs 
for GC×GC-TOFMS quantitative data as compared to the excellent repeatability of 
chiral GC-qMS analysis (RSDs < 4%). In this study, a large sample volume (150 µL) 
was derivatized and extracted and splitless injection was used to increase 
intentionally peak intensities in an effort to facilitate detection of D-AAs. As a 
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consequence, we observed broad peaks, peak tailing, and in turn a great number of 
modulations for L-AAs and stable isotope-labeled ISs. Optimally, each first-dimension 
peak should be sampled three to five times, which was the case for D-AAs. The 
correction of the area integral of a D-AA with a stable isotope-labeled L-AA that 
generates ten or more modulations is not optimal and, consequently, lowers 
repeatability of D-AA quantification results as reflected in comparatively great RSDs 
for D-Asp (16.6%), D-Ala (12.2%), and D-Asn (9.9%), whereas RSDs for the other 
target analytes were <5%. Comparable peak tailing was observed for L-AAs and ISs, 
whereas it was barely visible for D-AAs. This also indicates that correction of area 
integrals of D-AAs by labeled L-AAs is unfavorable as the differences in 
concentration may be as great as three orders of magnitude. A set of stable isotope 
labeled D-AAs for D-AA area integral correction would probably improve precision of 
quantification results, but is not available at present.  
The same number of proteinogenic AA types eluted from the Rt-γ-DEXsa column in 
GC×GC analysis as in GC–qMS analysis. Reasons for the failure to detect the 
proteinogenic AAs Glu, Gln, Cys, Lys, His, Arg, Tyr, and Trp remain to be elucidated, 
but may be due to chemical or thermal derivative instability as reported for propyl 
chloroformate derivatized Arg 180, or strong interactions with the CD core leading to 
strong retardation and broad peaks that vanish into the baseline. Anyway, the 
presented GC×GC approach bears the potential to be expanded to enantiomers of 
other small organic acids due to higher peak capacity compared to 1D GC 
separation. Enantiomers of lactic acid and 3-methyl-2-oxo-valeric acid were found to 
be perfectly resolved in the chromatogram of a serum sample (data not shown). They 
were identified by searching for equal mass spectra and their comparison to 
fragmentation spectra of analyzed standards174. There were found even more peak 
pairs with identical mass spectra in serum but their structural identity was not 
clarified. Even though GC×GC offered better sensitivity and resolution of AAEs, I 
decided to apply GC-qMS for the first chiral fingerprinting approach because high 
repeatability of responses is inevitable for a good group separation.
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7.3.6 COMPARISON OF CHIRAL GC×GC–TOFMS TO PUBLISHED METHODS 
In chapter 6.3.4 there was discussed the superior performance of the chiral GC-qMS 
method over other published methods for the quantitative analysis of AAEs in 
physiological fluids. No other 1D GC method had been reported to quantify more than 
5 D-AAs in serum and urine without pre-separation of AAs from biological matrix 
compounds174. To date, Barbaro et al. had presented the most effective quantitative 
1D-LC method that allowed the baseline resolution of 16 pairs of proteinogenic AAEs 
in 35 minutes; however, accurate quantification could be realized for only 12 D-AAs 
in lake water samples. The applicability of this highly sensitive LC-MS/MS method to 
more complex biological matrices like mammalian physiological fluids was not 
demonstrated120. Nagata et al. had demonstrated the applicability of their LC method 
to plasma samples. The method was able to baseline separate 12 pairs of AAEs, 
however, due to poor sensitivity (LODs ranged from 4 to 10 µM), only 3 D-AAs were 
detected in blood plasma83. Two-dimensional HPLC performed by Hamase et al. 
yielded comparable LLOQs to GC-qMS and GC×GC-TOFMS analysis, namely 0.25 
µM for all investigated AAEs, comprising branched aliphatic AAs. The method 
enabled direct quantification of 4 D-AAs in physiological fluids 51. Consequently, the 
optimized GC×GC-TOFMS method presented here for the determination of AAEs in 
physiological fluids is at present to the best of my knowledge the most effective 
technique for AAE analysis of mammalian physiological fluids, enabling quantification 
of eight D-AAs in serum or urine in a single chromatographic run174. 
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8 CHIRALOMICS: ADDING A NEW DIMENSION TO METABOLOMICS 
8.1 INTRODUCTION 
Metabolic fingerprinting aims at the detection of metabolite patterns in tissues or 
biofluids that distinguish two or more experimental groups. The ideal fingerprinting 
method should be capable of detecting and resolving the constituents of 
metabolomes in their entirety. However, due to the great chemical variety between 
metabolite classes, the structural similarity within metabolite classes and the broad 
range of metabolite abundance, no analytical method has succeeded in attaining this 
objective to date. 
Among the most powerful tools in metabolomics are GC-MS based techniques1, 200. 
Thus far, however, untargeted GC-MS methods treat enantiomers as single features 
despite the fact that stereoisomers of chiral metabolites do not only differ in 
abundance, as shown in the preceding chapters for AAEs, but also possess different 
biological functions51, 116, 158, 174, 201. That makes the separation of stereoisomers a 
necessity in the correct interpretation of abundance changes of chiral metabolites. 
Chirality is not a rare phenomenon in the metabolome, as all sugars, most AAs and 
related amines, many organic acids and some lipids feature one or more 
asymmetrical C atoms.  
The progression and physiological effects of NAFLD were investigated intensively in 
the last decade186, 187. NAFLD can progress from steatosis to NASH (non-alcoholic 
steatohepatitis), fibrosis, cirrhosis and, ultimately, liver cancer. The noninvasive 
distinction of the early stages of NAFLD by both imaging and molecular means 
remains challenging and definite diagnosis requires liver biopsy and histopathological 
examination. To learn more about metabolic changes and, in particular, those 
affecting chiral metabolites that potentially distinguish steatosis from NASH, I applied 
chiral fingerprinting using enantioselective GC-qMS to detect MeOH/MCF derivatized 
features in urine specimens of mouse models mimicking both diseases, followed by 
GC-APCI-TOFMS for the assignment of significant features to known metabolites. 
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8.2 MATERIAL AND METHODS 
8.2.1 MOUSE MODELS AND ANALYZED SAMPLES 
Urine specimens were obtained from 3 groups of female C57BL/6 mice (N=6 each) 
that had been fed one of three diets, respectively, for 14 weeks starting in week 13: 
The standard diet #V1534-0 of Ssniff (ssniff R/M-H), a hepatic steatosis inducing 
high-fat diet (similar composition as the Ssniff standard diet, but containing 30% fat), 
and a NASH initiating western-type diet (containing 16.1 % (w/w %) protein, 38 % fat, 
0.2 % cholesterol, 30.9 % sugar, 5.5 % starch, 3.3 % ash, and 2.7 % fibre). Urine 
specimens were stored at -20°C. 
 
8.2.2 SAMPLE PREPARATION 
Urine volumes of 50-100 µL were derivatized depending on the volume available. 
Urine available in excess of 100 µL for four and two mice on standard and high-fat 
diet, respectively, were combined to yield a total volume of 475 µL of a urine pool. 
Samples were prepared with the optimized protocol including the dilution of the 
sample together with 20 µL of IS mix C, applying pure water, to a constant start 
volume of 275 µL and the successive addition of 167 µL MeOH, 34 µL pyridine, two 
portions of 20 µL MCF and 300 µL of chloroform as extracting agent. After the 
addition of each MCF portion the reaction mixture was vortexed. MeOH/MCF 
derivatives were extracted into chloroform by vortexing the extraction mixture for 15 
s. Subsequently the extraction mixtures were centrifuged at 4165 x g for 5 minutes at 
5°C to improve phase separation and about 100 µL of  the lower phase (organic 
phase) were transferred to an insert. Samples were randomized for sample 
preparation and sample analysis.  
 
8.2.3 ANALYSIS OF SAMPLES 
Derivatized and randomized samples were analyzed by three different GC-MS 
devices, namely the GC-qMS that was applied for fingerprinting analysis in scan 
mode, the GC-qMS used for quantitative AAE analysis in SIM mode and the GC-
APCI-TOFMS to enable identification of unknown features. The Rt-γDexsa column, 
was employed, respectively. Between fingerprint analyses by GC-qMS and GC-
APCI-TOFMS, respectively, chloroform blanks were run to avoid baseline 
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disturbances by late eluting compounds. In addition, an MM II aliquot was analyzed 
before and after the analysis of mouse urine by GC-APCI-TOFMS to check if the 
M+H ions of AAEs were the most abundant ions in respective mass spectra as their 
formation strongly depended on moisture in and around the ion source149. As the 
M+H+ m/z was the most abundant m/z for AAEs, injection of water into the ion source 
was omitted. Finally, creatinine contents of the 18 urine samples, were quantified by 
Dr. Wentao Zhu using LC-ESI-MS/MS as described previously175. 
 
8.2.4 DATA ANALYSIS 
The whole data analysis procedure, including the identification of significantly 
differentiating features, is visualized in Figure 22.  
 
Figure 22. Scheme of the pipeline implemented for the identification of significantly 
differentiating metabolites in enantioselective fingerprints. 
 
Fingerprinting data resulting from the measurement of 18 urine samples from three 
groups (steatosis, NASH and controls; N=6 per group) by chiral GC-qMS (see 1., 
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Figure 22) were subjected to MarkerLynx analysis. MarkerLynx performed peak 
picking and assigned a unique retention time and a single m/z-value to each picked 
feature and integrated it. Furthermore, the software performed data alignment (see 
2., Figure 22). Exclusively, features detected in at least four out of 18 samples were 
applied for data analysis with the additionally prerequisite that the feature was found 
in at least three samples of one of the groups. This filter refers to the detection of a 
feature in at least half of the group members in contrast to its failed detection in 
another group, which I considered to indicate a tentative biomarker. Furthermore, the 
cut-off four out of 18 possible counts was chosen in order to fulfill the criterion for 
imputation of missing values for PCA by ‘R’. The used ‘R’ algorithme was able to 
impute at maximum 80% of missing values. Additionally, saturated signals were 
excluded. Peak areas were normalized to the area of the internal standard (U-13C-
15N-L-Pro, m/z=133), the used sample volume and the urinary creatinine 
concentration. The resulting feature list was subjected to statistical analysis in ‘R’ 
(see 3., Figure 22). Features that yielded a FDR <0.05 for ANOVA and at least one of 
the three comparisons: steatosis vs. controls, NASH vs. controls, and NASH vs. 
steatosis and those that were found at least in three samples of one group but were 
missing in another group were considered to be significantly discriminating. These 
features were reintegrated together with the IS in QuantLynx (see 4., Figure 22), 
except for double feature. Double features belong to the same metabolite and were 
accidently appointed by MarkerLynx. The double feature with the lower abundant ion 
was excluded from further analysis. Additionally, all picked AAEs were reintegrated 
for method validation. For some AAEs, the picked m/z-values belonged to the 
coeluting labeled AAE. These AAEs were reintegrated on the corresponding 
fragment of the unlabeled AAE. All reintegrated peak areas of peaks with a S/N >8 
were normalized by IS area, used sample volume and creatinine content and 
subjected to R for statistical reanalysis (see 5., Figure 22). Significantly differentiating 
features were assigned on the basis of the same criteria as listed above for 
preliminary statistical results. 
 
8.2.5 IDENTIFICATION STRATEGIES 
The sixth step in data analysis as depicted in Figure 22 was the identification of 
significantly differentiating features. For this purpose, a Visual Basic script was used 
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to recalibrate the m/z-values obtained by GC-APCI-TOFMS analysis employing the 
known m/z-values of eight U-13-C,15-N labeled AAs. After recalibration, the m/z shift 
was <5 mDa. Due to the presence of retention time shifts between the 
chromatograms recorded by GC-qMS and GC-APCI-TOFMS, the linear function of 
retention times of the uniformly 13-C and 15-N labeled AAs was used to find the 
respective peak in the GC-APCI-TOFMS chromatogram. The ‘smart formula’ option 
of the Bruker software was applied to M+H+ ion (refers to the most abundant m/z) to 
assign tentative sum formula. Sum formulas that fulfilled the criteria of m/z bias <5 
mDa and mSigma value <50 in case of separated peaks and <100 in case of 
overlapping and low abundant peaks (S/N <50), which accounts for a good match of 
theoretical and detected isotope pattern, were further considered for identification. 
Metabolites that corresponded to the obtained sum formulas after deletion of the 
proton and possible derivatization groups were searched in the Pubchem compound 
database and in the Human Metabolome Database (HMDB). The MeOH/MCF 
derivatization modifies carboxylic acids, amino groups and partly hydroxy groups. 
Thus, a sum formula was mostly assigned to more than one metabolite since 
different chemical groups and different isomers can be assumed. A further indication 
for the actual structure was obtained by NIST database search based on the 
spectrum recorded by qMS in scan mode. Finally, tentative identifications were 
confirmed by analysis of corresponding standards (see 7., Figure 22). Relative 
retention times, normalized to the retention time of the IS and the mass spectrum 
were compared. I focused primarily on the identification of small organic acids (e.g. 
TCA cycle metabolites), non-proteinogenic AAs and AA derivatives, with a special 
emphasis on chiral candidates. When the injection of a racemate confirmed the 
identification of one antipode and the other was also found with a S/N>8 above the 
cut-off in the chromatograms of the urine specimens, the peaks were integrated in 
QuantLynx, normalized and added to the list of reintegrated features. When the 
confirmation of chiral metabolites failed after standard injection, the gained 
information on retention times and mass spectrum was used to search the 
enantiomers in the chromatograms (see 8., Figure 22). Peaks passing the cut-off 
were integrated by QuantLynx, normalized and added to the list of reintegrated 
features (see 9., Figure 22). This should avoid that low abundant stereoisomers that 
were not picked sufficiently or that were integrated incorrectly remain undiscovered.  
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8.2.6 TREATMENT OF LACTONES, HYDROXY ACIDS, DIACIDS AND ALLO-ILE 
Furthermore, area integrals of two derivatives or a derivative and its lactone, 
originating from the same hydroxy acid, respectively, were summed up, normalized 
and added to the list of reintegrated features. D-allo-Ile, which had been identified as 
one of the differentiating features, was initially integrated on m/z=88. This m/z was 
present in the mass spectrum of allo-Ile. However, the ratio of m/z=88 to the more 
characteristic fragment with m/z=144 (molecule minus ester moiety) was not constant 
in the urine specimens, indicating a coeluting compound. Therefore, D-allo-Ile was 
additionally reintegrated on m/z=144, which was the highest m/z in its spectrum. 
Finally, I searched in the chromatograms for saturated medium-chain dicarboxylic 
acids, as their urinary levels have been reported to be highly elevated in disordered 
fatty acid (FA) metabolism202, 203. If characteristic fragments were found in the qMS 
data, the M+H mass was found with a ∆m< 5mDa in the microTOF data and 
identified peaks were present above the cut-off, the respective standards were 
injected. Confirmed diacids were integrated, normalized and added to the extended 
list of features. This final enlarged list of (re)integrated features was subjected to 
repeated statistical reanalysis in R (see 10. Figure 22).  
 
8.2.7 PCA ANALYSIS 
For principal component analysis (PCA), missing values were imputed with the help 
of the R package “missMDA”. PCA was performed in R with normalized, log2 
transformed areas of all significantly differentiating features after univariate statistical 
analysis of the final extended feature list. Double features were excluded. In case of 
two- and three-fold derivatized malic acid only the summed areas were used as it 
was done for 2-HG lactone and 2-HG three-fold derivative.  
 
8.2.8 METHOD VALIDATION 
Quantitative AAE analysis of mouse urine was performed in the way it was described 
in chapter 5.3.1 and 5.4 in order to compare quantitative with semi-quantitative AAE 
results for method validation.  
From the 475 µL of prepared urine pool six 75-µL aliquots were derivatized according 
to the same procedure as applied to the urine samples, to assess repeatability of the 
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fingerprinting method. Eight chosen peaks of the pool measures were integrated in 
QuantLynx on the m/z picked by MarkerLynx. Additionally the IS (U-13C-15-N 
labeled L-Pro) was integrated in the same way and RSDs of response values were 
calculated.  
 
8.3 RESULTS AND DISCUSSIONS 
8.3.1 DATA ANALYSIS AND ZERO VALUES 
Automatic peak picking in the total ion chromatograms acquired for the 18 
investigated urine specimens yielded 1077 features. However, 31.3 %, 23.3 % and 
10.9% of the features were picked in only one, two or three chromatograms, 
respectively. Nevertheless, plotting mean areas, in group and count sorted boxplots, 
of all features that were picked at least three times in a group, showed that peak 
picking and automatic integration by MarkerLynx were not arbitrary as the minimum 
value, the first quartile and the median decreased continuously with decreasing 
counts, indicating that the likelihood of being picked decreased as a function of signal 
intensity (see Figure 23). Implementing the cut-off of four out of 18 possible values 
with at least three in one group, 258 features remained. Following exclusion of four 
saturated, albeit redundant signals, 254 features remained for statistical analysis. 
FDRs <0.05 for ANOVA and at least one of the three group comparisons were 
obtained for 22 features, while 85 features were deemed significantly differentiating 
as they had no values in one group and ≥ three values in another group and the 
overall count number was ≥ four. Thus, as a result of the third step of data analysis 
(Figure 22) 107 features were considered to differentiate the groups. After the 
exclusion of seven ‘double features’ 100 differentiating features were reintegrated. 
Additionally seven AAEs that were not found to differentiate the groups, however, 
that were present above the count cut-off were reintegrated for method validation and 
to provide closer insights into AAE trends in steatosis and NASH. 
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Figure 23. Group and group count sorted boxplots of mean areas of features that 
were picked and integrated by MarkerLynx above the cut-off for controls (green), 
steatosis (blue) and NASH (red). Not all outliers were displayed as the shown range 
of mean areas was restricted to the range of boxplots, to make trends of quartiles 
visible. The number of features included in each boxplot was given in brackets. 
In Figure 23 the outliers and the increased third quartiles and maximum values of the 
’three counts boxplot’ of the control and the NASH group indicated inaccurately 
picked and/or integrated features and were the reason why manual reintegration was 
sought. Reintegration clearly reduced the number of zero values from 975 to 233 
corresponding to 50.6% and 12.1% zero value percentages, respectively, of 1926 
possible values for 107 reanalyzed features. Consequently, the resulting matrix 
provided more testable features for statistical analysis. 96 features were considered 
as significantly discriminating features after reintegration either due to FDR<0.05 for 
ANOVA and at least one of the three group comparisons (85 features) or because 
≥three values were present in one group in contrast to zero values in another group 
(eleven features) being the result of the fifth step of data analysis of Figure 22. Thus, 
from 107 reintegrated features eleven were not considered to significantly 
discriminate the groups. Four of these eleven features belong to AAEs that were not 
significantly discriminating already after initial statistical analysis. Consequently 
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seven initially discriminating features were excluded following reintegration. Three 
AAEs that had been picked on the m/z of their labeled counterpart were finally shown 
to significantly differentiate the groups, owing to reintegration on the respective 
unlabeled m/z. After addition of eleven additional features of interest to the list 
(summed areas of metabolites yielding 2 derivatization products, low abundant 
stereoisomers, lactones and medium-chain diacids) and repeated statistical 
reanalysis (10. in Figure 22), 106 features were finally considered as significantly 
differentiating features: 92 according to the FDR<0.05 obtained for ANOVA and at 
least one the three group comparisons and 14 features because they were missing in 
one group while ≥three values were detected in another group or in case of the D-
malic acid derivatives because of one count in the steatosis group and six counts in 
the control group which I also considered a tentative biomarker. Only one of the 
additional features of interest, namely L-threo-isocitric acid γ-lactone, did not 
discriminate the groups significantly. 
 
8.3.2 GROUP SEPARATION AND SIGNIFICANT DIFFERENCES 
One characteristic fingerprint each is displayed in Figure 24 for control, steatosis and 
NASH, respectively. The shown chromatograms correspond to the analysis of 100 µL 
of derivatized urine and the displayed abundance range was adjusted to the 
creatinine content found in the samples. It is obvious, that the intensity of many 
peaks was decreased in steatosis and NASH as compared to the control group. 
Identified metabolites, confirmed by the injection of standards, with a S/N>8 are 
labeled in the chromatogram of the steatosis group.  
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Figure 24. Characteristic GC-qMS TIC chromatograms obtained by derivatization of 
100 µL each of representative urine samples from the (A) control, (B) steatosis and 
(C) NASH group, respectively. Intensity ranges that were displayed were adjusted to 
the creatinine content in the respective urine specimen. The IS and identified 
metabolites with a S/N>8 in the chromatogram of the steatosis group were labeled. 
Of the 92 features that significantly differentiating the groups according to statistical 
analysis, 81 yielded a FDR <0.05 for the comparison steatosis vs. controls. 
Normalized area integrals of 72 from the 92 features were decreased (fold 
changes(fcs)<1) for the steatosis group when compared to controls. For the NASH 
vs. controls comparison, 69 of the 92 features yielded a FDR <0.05. Again, the 
majority of mean area integrals namely 74 of 92 features were decreased in the 
NASH group according to the fcs. Sixty-one features significantly differentiated both 
the steatosis and the NASH group from controls. Finally, the NASH vs. steatosis 
comparison revealed 35 features with FDRs<0.05. Normalized peak areas in the 
NASH group were mostly decreased when compared to those of the steatosis group. 
Table 7 lists fcs and FDRs of metabolites that were confirmed by standard injection. 
Table S2 lists fcs and FDRs of all feature that differentiated the groups and that were 
10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00
1000000
2000000
3000000
4000000
5000000
6000000
7000000
8000000
9000000
Abundance
TIC: R4_fil2.D\data.ms
10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00
200000
400000
600000
800000
1000000
1200000
1400000
1600000
1800000
2000000
2200000
2400000
2600000
2800000
3000000
Time-->
TIC: G1_fil2.D\data.ms
10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00
1000000
2000000
3000000
4000000
5000000
6000000
7000000
8000000
Time-->
Abundance
TIC: B5_fil2.D\data.ms
Ac
o
n
iti
c
ac
id
+
IS
 
 
 
 
 
+
L-
Pr
o
A
C
Abundance
Abundance
Abundance
Time
M
a
lo
n
ic
ac
id
DL
-
3-
M
et
hy
l-2
-
o
x
o
v
al
er
ic
 
ac
id
Su
c
ci
n
ic
ac
id
Ita
c
o
n
ic
ac
id
Ph
e
n
yl
ac
et
ic
ac
id
DL
-
Ci
tr
a
m
a
la
te
(2f
o
ld
 
de
riv
.
)
2-
He
x
e
n
e
di
o
ic
 
ac
id
D-
M
al
ic
 
ac
id
(2-
fo
ld
 
de
riv
.
)
L-
M
a
la
te
(2-
fo
ld
 
de
riv
.
)
+
 
L-
Va
l
D-
a
llo
-
Ile
Pi
m
e
lic
a
ci
d
αα αα
-
K
et
o
gl
u
ta
ric
a
ci
d
L-
Ile
H
ip
pu
ric
ac
id
Ci
tr
ic
ac
id
D-
As
p L-
Th
r
+
 
L-
As
p
N-
Ac
e
ty
l-D
-
As
p
DL
-
Ph
e
N
-
Ac
et
yl
-
L-
As
p
DL
-
th
re
o
-
Is
o
c
itr
ic
ac
id
D
-
2-
H
G
(3-
fo
ld
 
de
riv
.
)
L-
2-
HG
 
la
c
to
n
e
D
-
2-
HG
 
la
c
to
n
e
L-
2-
HG
(3-
fo
ld
 
de
riv
.
)
Fu
m
a
ric
ac
id
(o
r
M
a
le
ic
ac
id
)
D-
Va
l
Time
B Abundance
Time
4-
Hy
dr
o
x
yp
he
n
yl
ac
et
ic
 
ac
id
Ad
ip
ic
ac
id S
u
be
ric
a
ci
d
99 
 
subjected to sf analysis. Table S3 lists fc and FDRs of additionally identified 
metabolites of particular interest. A clear group separation as a result of PCA of 
significantly differentiating features is visible in Figure 25.  
 
Figure 25. PCA based on log2 transformed normalized areas of all integrated 
features that differentiated significantly the groups, based on univariate statistical 
analysis. In case of two- and three-fold derivatized malate only the summed area 
values were used as it was done for 2-HG lactone and three-fold derivative. Missing 
values were estimated with the R package “missMDA”. The variance explained by 
PC 1 and PC 2, respectively, is given in brackets. 
The three groups formed tight clusters and were separated along PC 1, which 
accounted for 67.4% of the total variance. The NASH group was further separated 
from the steatosis and the control group along PC 2, which accounted for 26.9% of 
the total variance. Combined, PC1 and PC2 accounted for 94.3% of the total 
variance. 
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steatosis / controls NASH / controls NASH / steatosis
Nr identified metabolite identified by ret.t [min] m/z fc (counts) FDR fc (counts) FDR fc (counts) FDR
2 Fumarate(or Maleic acid) NIST; sf; std 11.55 113 0.04 2.94E-02 0.13 3.21E-02 3.45 >0.05
4 Malonic acid NIST; sf; std 12.77 101 0.55 2.97E-06 0.67 1.41E-04 1.21 >0.05
5 DL-3-Methyl-2-oxovaleric acid std 13.36 85 0.92 >0.05 0.66 8.05E-03 0.71 >0.05
7 Succinic acid NIST; sf; std 14.44 115 0.14 1.62E-06 0.41 1.62E-04 2.93 4.63E-02
11 Itaconic acid NIST; sf; std 16.37 127 0.16 ( 1/ 6 ) 1.69E-02 0.33 ( 6/ 6 ) 2.60E-03 2.12 ( 6/ 1 ) >0.05
14 Phenylacetic acid NIST; sf; std 16.88 91 1.72 8.54E-04 0.80 >0.05 0.46 2.56E-04
20 Adipic acid std 19.59 114 0.52 1.67E-02 0.74 >0.05 1.43 >0.05
22 DL-Citramalate(2-fold) NIST; sf; std 20.13 117 1.38 1.24E-02 1.92 1.84E-05 1.39 3.93E-03
23 trans-2-Hexenedioic acid NIST; sf; std 20.25 74 10.52 1.59E-07 1.52 >0.05 0.14 2.27E-07
26 D-Val std 21.29 130 1.15 >0.05 0.31 9.78E-03 0.27 6.04E-03
28 L-Val std 22.21 130 0.56 3.07E-05 0.66 7.09E-04 1.18 >0.05
- L-Malate (2-fold) NIST; sf; std 22.26 71 0.04 1.06E-02 0.11 2.01E-02 2.87 >0.05
30 Pimelic acid NIST; sf; std 22.57 125 0.44 9.82E-06 0.16 5.85E-07 0.38 1.45E-02
33 D-allo-Ile sf; std 23.53 144 0.86 >0.05 0.22 1.78E-03 0.26 1.42E-02
34 α-Ketoglutaric acid NIST; sf; std 24.42 115 0.05 2.67E-03 0.16 8.05E-03 3.25 >0.05
35 L-Ile std 24.93 144 0.49 1.45E-04 0.63 3.48E-03 1.29 >0.05
39 N-Acetyl-L-Ala std 26.58 86 0.21 ( 1/ 4 ) n. av. n. av. ( 0/ 4 ) n. av. n. av. ( 0/ 1 ) n. av.
40 Suberic acid std 26.87 129 1.40 >0.05 0.63 >0.05 0.45 3.47E-02
41 N-Acetyl-D-Ala std 27.06 86 0.28 ( 4/ 5 ) n. av. n. av. ( 0/ 5 ) n. av. n. av. ( 0/ 4 ) n. av.
48 cis (/trans) -Aconitate NIST; sf; std 29.80 153 0.33 9.82E-06 0.57 1.19E-03 1.75 >0.05
49 L-Pro std 29.86 128 0.63 8.01E-05 0.76 4.87E-03 1.22 >0.05
59 Citric acid (3-fold) NIST; sf; std 34.73 175 0.05 1.12E-06 0.33 8.97E-05 6.67 >0.05
61 D-Asp std 35.59 160 0.45 9.45E-03 0.48 2.88E-02 1.08 >0.05
64 L-Thr std 36.76 147 1.23 >0.05 1.57 2.18E-03 1.27 >0.05
65 L-Asp std 36.77 160 0.52 1.83E-04 0.57 8.53E-04 1.09 >0.05
- D-2-HG-γ-lactone sf; std 37.47 85 0.22 1.61E-05 0.57 4.31E-03 2.61 3.09E-02
67 N-Acetyl-D-Asp NIST; std 37.85 102 0.18 8.40E-06 0.25 5.06E-05 1.34 >0.05
69 N-Acetyl-L-Asp NIST; sf; std 38.62 102 0.10 5.00E-06 0.25 7.79E-05 2.39 >0.05
75 4-Hydroxyphenylacetate(1-fold) NIST; sf, std 39.50 107 2.89 7.10E-05 1.83 3.38E-02 0.63 2.15E-02
- L-2-HG-γ-lactone std 40.33 85 0.08 5.42E-04 0.31 6.55E-03 3.93 >0.05
85 DL-Phe std 41.77 162 0.69 1.38E-03 0.69 2.30E-03 1.01 >0.05
89 DL-threo-Isocitrate(4-fold) sf; std 44.25 129 0.88 >0.05 1.46 8.20E-03 1.66 4.09E-03
94 Hippuric acid NIST; sf; std 48.81 77 0.21 7.89E-08 0.02 1.46E-08 0.11 4.63E-02
97 D-Malate (2-fold+3-fold) std + std 22.00; 29.30 103; 75 0.06 ( 1/ 6 ) >0.05 0.12 ( 4/ 6 ) >0.05 1.93 ( 4/ 1 ) >0.05
98 L-Malate (2-fold+3-fold) NIST; sf; std + std 22.20; 30.73 103; 75 0.09 4.78E-03 0.22 1.41E-02 2.30 >0.05
99 D-2-HG (3-fold+lactone) std + std 33.52; 37.47 71; 85 0.21 1.27E-05 0.56 3.48E-03 2.62 2.92E-02
100 L-2-HG (3-fold+lactone) std + std 34.24; 40.34 71; 85 0.10 6.07E-04 0.33 7.27E-03 3.22 >0.05
Table 7. Standard confirmed differentiating metabolites, their retention times, integrated m/z, FDRs and fold changes (fc). For analytes 
with less than three quantifiable values (S/N>8) in at least one group the counts of compared groups were noted in brackets. The 
number of functional groups derivatized in metabolites that carry hydroxy groups was noted in brackets next to the metabolite name. 
n. av. refers to not 
available for the calculation 
of fcs due to <three 
quantifiable values in one 
of the compared groups. 
The R ‘limma’ package can 
determine adjusted p-
values (FDRs) if ≥ one 
value was available as it 
estimates a SD from the 
SDs of the other features. 
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The loadings plot of the PCA with numbered significantly differentiating features is 
shown in the appendix (Figure S3; corresponding discriminating features are listed 
with respective numbers in Table 7, Table S1, Table S2 and Table S3). Thus, 
stereoselective fingerprints of mouse urine specimens allowed the differentiation of 
steatosis from NASH in a non-invasive way. This had been also reported by Klein et 
al., who had observed a less clear but visible separation by ICA of NMR spectra 
signals204. From the identified and standard confirmed enantiomers, all stereoisomers 
of hydroxy dicarboxylic acids clearly contributed to the separation along PC 1, while 
D-Val and D-allo-Ile contributed to the separation along PC 2. Isomers of medium 
chain (C6) unsaturated dicarboxylic acids and hippuric acid contributed to the 
separation along both PC 1 and PC 2.  
 
8.3.3 IDENTIFICATION RESULTS 
From 96 features that were considered to be significantly differentiating after 
reintegration and statistical reanalysis (5. in Figure 22) seven were proteinogenic 
AAEs and another feature represented D+L-Phe. Retention times and mass spectra 
of proteinogenic AAEs were known from the quantitative GC-qMS method. The 
remaining 88 discriminating peaks, recorded by GC-APCI-TOFMS, were subjected to 
sf analysis (see sf results in Table S1). This proved to be an effective tool for 
metabolite identification in complex biological matrices148. For 77, a sum formula was 
obtained that could be assigned to one or more metabolites found in mammals or 
bacteria after deletion of the proton and possible derivatization groups. For the 
remaining eleven features the respective peaks were low abundant in the 
chromatograms recorded by APCI-TOFMS and obtained formula did not fit with 
molecules that were known as endogenous metabolites of mammals or bacteria. The 
different abundances of some features after APCI-TOFMS analysis when compared 
to EI-qMS analysis can be explained by different ionization efficiency in APCI which 
depends on metabolite structure. Another three features were finally assessed as 
‘double features’ following their identification by standard injection (see Table S1). 
For 39 of the 74 remaining elemental formulas a stereoisomeric metabolite could fit 
(namely enantiomers, diastereomers, cis/trans-isomers). For 25 of these 
stereoisomers a standard was commercially available. 
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controls steatosis NASH
chiral metabolite config mean SD mean SD mean SD resolution elution 
order racemization
3-Methyl-2-oxovalerate D+L 0.0283 0.0052 0.0261 0.0068 0.0187 0.0021 0.2 unk. -
Citramalic acid (2-fold) D+L 0.0261 0.0018 0.0361 0.0073 0.0502 0.0064 0.4 unk. -
Citramalic acid (3-fold)        D n.d. n.d. n.d. n.d. n.d. n.d. 3.3 unk. -
L n.d. n.d. n.d. n.d. n.d. n.d.
Malic acid (2-fold )             D 0.0091 0.0065 0.0012 0.0005 0.0011 0.0003 1.9 D,L n.d.
L 0.1259 0.1201 0.0050 0.0017 0.0144 0.0044
Malic acid (3-fold )
D 0.0041 0.0012 n.d. n.d. n.d. n.d.
10.2 D,L n.d.
L 0.0432 0.0420 0.0010 0.0004 0.0052 0.0023
allo-Ile D 0.0089 0.0023 0.0077 0.0043 0.0020 0.0009 7.1 D,L n.d.
L n.d. n.d. n.d. n.d. n.d. n.d.
N-Acetyl-Ala D 0.0027 0.0012 0.0008 n.d. n.d. n.d. 2.7 L,D 16%
a
L 0.0042 0.0027 0.0009 0.0002 n.d. n.d.
2- HG-γ-lactone D 0.3873 0.1213 0.0842 0.0327 0.2195 0.0566 17.2 D,L 0.95% 
b
L 0.0388 0.0231 0.0031 0.0011 0.0120 0.0045
2-HG (3-fold )                D 0.0526 0.0149 0.0107 0.0038 0.0306 0.0077 5.9 D,L 0.38% 
b
L 0.0056 0.0028 0.0015 0.0002 0.0027 0.0006
N-Acetyl-Asp D 0.0098 0.0032 0.0018 0.0005 0.0024 0.0006 6.7 D,L n.d.
L 0.0727 0.0257 0.0075 0.0028 0.0179 0.0041
threo-ICA-γ-lactone D n.d. n.d. n.d. n.d. n.d. n.d. 2.1 L,D n.d.
L 0.1401 0.0080 0.1714 0.0319 0.1729 0.0582
threo-ICA (4-fold ) (D+)L 0.1174 0.0219 0.1034 0.0196 0.1715 0.0407 0.1 unk. -
Table 8. Mean reintegrated normalized areas, SDs, resolution, elution order and results of racemization checks for standard confirmed 
chiral metabolites. In case of hydroxy acids the number of derivatized functional groups is given in brackets. 
  
 
 
n.d. refers to ‘not 
detected’; 
unk. refers to unknown; 
a
 the L-enantiomer 
standard (>99.9%) was 
derivatized four times 
and yielded a mean D-
enantiomer area ratio 
(D/(D+L-area)) of 16%; 
b
 derivatization of the L-
enantiomer standard 
(enantiomer excess was 
not determined by the 
supplier) yielded a D-
enantiomer area ratio of 
0.95% for the 2-HG 
lactone peaks and 
0.38% for the 2-HG 
three-fold derivatives 
(S/ND-form <8) 
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After standard injection and the proceedings used for confirmed and rejected 
stereoisomers (8. in Figure 22) in sum 18 features were found to describe 
stereoisomers that were no proteinogenic AAEs. These features corresponded to 3 
cis/trans isomers and 12 chiral metabolites (see Table 7). The discrepancy between 
the number of features and the respective number of assigned metabolites resulted 
from the formation of two derivatives or lactones from hydroxy acids by partial 
derivatization of hydroxy groups or internal esterification. Eight of the 12 chiral 
metabolites namely two-fold derivatized L-malic acid, D-allo-Ile, both enantiomers of 
N-Acetyl-Asp (NAA) and one-fold derivatized 2-HG-γ-lactone enantiomers as well as 
unseparated two-fold derivatized DL- citramalate and DL-threo-ICA were identified 
and confirmed due to sf analysis of 88 features. The other four stereoisomers namely 
D-malic acid (two derivatives), both N-acetyl-Ala enantiomers and DL-3-methyl-2-
oxovaleric acid as well as three-fold derivatized L-malic acid were identified due to 
racemate injection of tentatively identified chiral metabolites. The identity of features 
that were initially assigned to N-acetyl-Ala enantiomers and DL-3-methyl-2-oxovaleric 
acid could not be confirmed. Anyway they were present in the chromatograms at 
other retention times and were added as additional features to the list of reintegrated 
features for second statistical reanalysis (10., Figure 22). The peak of DL-3-methyl-2-
oxovaleric acid had been integrated inaccurately by MarkerLynx and was therefore 
not under the significantly differentiating features after first statistical analysis and low 
abundant N-Acetyl-Ala enantiomers had not been picked above the cut-off. This 
applied also for D-malic acid. Injection of racemic malic acid recovered the 
appearance of two-fold and three-fold derivatives. Standard injection of racemic 
threo-ICA and 2-HG yielded four peaks, respectively, as lactonization had occurred. 
Additionally, standards of 2-HG-γ-lactone and threo-ICA-γ-lactone enantiomers were 
injected to confirm lactone identification. Averaged normalized area integrals, 
standard deviations, elution order, resolution, and the outcome of racemization 
checks of identified enantiomer pairs other than proteinogenic AAs were summarized 
in Table 8. Quantitative and semi-quantitative AAE results are visualized in Figure 26. 
Configuration of two-fold derivatized citramalate and 3-methyl-2-oxovaleric acid could 
not be specified due to failed enantiomer separation. Injection of MeOH/MCF 
citramalate racemate showed that the three-fold derivatized stereoisomers were 
baseline separated, however, they were not detected in urine samples. Albeit threo-
ICA enantiomers were not separated, the detection of exclusively the L-configured 
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threo-ICA γ-lactone in urine indicated that the open form occurred mainly in L-
configuration as stereo centers were not affected by lactonization that occurred inter 
alia as an artifact of MCF derivatization. There were two baseline-separated features 
under the significantly differentiating (see Table S1, feature Nr 72 and 77) with similar 
mass spectra belonging most probably to two stereoisomers that remained 
unconfirmed. Eleven non-stereoisomeric organic acids could be confirmed by the 
injection of standards (Table 7). Two of them were adipic and suberic acid. Their 
features were not under the significantly regulated features after first statistical 
analysis but were additionally searched in the chromatograms for the following 
reason. We found four features that were distinctly elevated in the steatosis group 
when compared to the other groups that were identified as unsaturated medium-
chain dicarboxylic acids (feature Nr. 16, 23, 24, 42 in Table 7, S1 and Table S2). 
Increased urinary excretion of saturated and unsaturated medium-chain dicarboxylic 
acids had been reported at enhanced or inhibited fatty acid metabolism202, 203. Hence 
we were interested in the identification and behavior of related saturated diacids. 
Three of the four mentioned features were identified as hexenedioic acid isomers. 
However the confirmation of identification and the detection of the position and 
configuration of the double bond could be accomplished only for the commercially 
available trans-2-hexenedioic acid. The remaining of the four features was tentatively 
identified as an isomer of octenedioic acid.  
 
8.3.4 ARTIFACTS OF MCF DERIVATIZATION  
As already mentioned in the preceding section lactonization of hydroxy acids 
occurred inter alia as an artifact of MCF derivatization. Nevertheless, lactones exist in 
equilibrium with their open form in aqueous solutions. On which side the equilibrium 
lies is pH-dependent with the lactone being favored at acidic conditions. Furthermore, 
the position of the equilibrium highly depends on structural features such as lactone 
ring size, side groups, etc.205-208. An equilibrium between the two forms is reached 
faster in mammalian organisms with the help of serum paraoxonases. These 
enzymes can catalyze both the hydrolysis of the cyclic esters and lactonization208 . 
However, lactonization was reported previously as an artifact of derivatization at 
acidic conditions209, 210. Area integrals of the open form and the lactone of 2-HG 
enantiomers were added up, respectively, as they were highly correlated (r= 0.97 for 
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the D-forms ; r= 0.96 for the L-forms) . It was not clear, if the slightly higher lactone to 
open form ratios in the samples when compared to respective enantiomer ratios after 
standard derivatization occurred due to spontaneous lactonization during sample 
storage or due to endogenous occurrence of lactone enantiomers. In contrast the 
ratio of L-threo-ICA γ-lactone to its open form was distinctly higher in mouse urine 
than in the chromatograms of threo-ICA enantiomer standards. Moreover the L-
lactone levels showed no linear correlation to the levels of the corresponding open 
form in the urine samples (r= -0.1). Consequently L-threo-ICA-γ-lactone was treated 
as an individual feature of interest in statistical analysis (Table S3). 
The injection of fumaric acid and trans-aconitic acid resulted in the detection of two 
peaks with similar mass spectra, which indicated that MCF derivatization had induced 
the conversion of trans- into cis-isomers and vice versa as similar observations were 
made after the injection of the respective cis-isomers. The purity of the standard 
solutions had been checked by non-chiral GC-qMS analysis of the MSTFA silylated 
standards (data not shown). Because of the different biological functions and sources 
of the cis- and trans-isomers, the abundance changes of these metabolites were not 
considered for interpretation. Cis- or trans-aconitic acid coeluted with the IS but its 
mass spectrum did not interfere with the m/z=133 used for area integral correction. 
There was detected a single peak for trans-2-hexenedioic acid during the analysis of 
the derivatized standard solution. Thus, MCF derivatization induced cis-trans 
conversion was most probably structure dependent and did not proceed in the 
medium-chain diacid. However, the possibility of cis- and trans-isomer coelution 
could not be excluded in case of 2-hexenedioic acid as the cis-isomer was not 
commercially available. 
A further drawback of MCF derivatization can be concluded from the observation of 
hydroxy groups being not derivatized in all molecules of malic acid and citramalic 
acid. In both cases the two-fold derivative with the unmodified hydroxy group was the 
predominant one and eluted first. There was observed only a minor abundance 
difference for the two malic acid derivatives (two-fold/(two-fold+three-fold derivative)-
ratio=0.56; N=7 standard injections) whereas in case of citramalic acid the two-fold 
derivative was much more abundant than the three-fold derivative (two-fold/(two-
fold+three-fold derivative)-ratio=0.98; N=5 standard injections). Even though mass 
spectra obtained from the injection of derivatized Ser and Thr standards indicate a 
106 
 
three-fold derivatization, the low abundances of these AAEs after standard 
derivatization, suggest the existence of the two-fold derivatized forms that, however, 
were not detected within the used run time. Thus, the incomplete derivatization of 
hydroxy groups by MCF limited peak intensities. This impeded the detection of 
biologically low abundant D-malic acid. In case of citrmalic acid it hampered the 
determination of its predominant configuration in mouse urine. 
Finally, racemization of N-acetyl-Ala enantiomers was observed. It was most 
probably promoted by high temperatures and low pH during derivatization with MCF 
and MeOH. This phenomenon will be discussed in more detail in the following 
section. A minor racemization of 2-HG enantiomers could not be excluded (see Table 
8). 
 
8.3.5 METHOD VALIDATION 
The pooled urine was applied to investigate the repeatability of the fingerprinting 
method, including preparation and GC-qMS analysis (N=6) as well as the technical 
repeatability (N=6) using uniformly 13-C,15-N-labeled L-Pro as IS. This IS was 
chosen for integral area correction as it eluted approximately after half of the analysis 
time. A total of eight peaks were chosen to cover a broad scope of m/z-values, 
retention times, and peak intensities. The RSDs (displayed in Figure 27) were always 
below five percent for the derivatization replicates except for one early and one late 
eluting metabolite, which were identified as succinic acid (RSD= 9.3) and hippuric 
acid (RSD= 7.5), respectively. The response of the chosen eight peaks showed RSD 
below three percent after repeated injection of one derivatized pool aliquot, except for 
one early eluting compound (RSD=3.3) that remained unidentified. These results 
attested to the ability of the IS to correct for losses during sample preparation and for 
fluctuations of injected volume and other technical conditions. 
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Figure 26. Mean concentrations of (A) D-AAs and (B) L-AAs, relative to creatinine 
contents, respectively, in the control group (N=5), the steatosis group (N=6), and the 
NASH group (N=6), determined by the quantitative GC-qMS method of chapter 6. (C) 
D-AA ratios were calculated from AAE quantities. (D) Shows semi-quantitative results 
for the three groups (N=6 respectively) of 12 AAE that were picked above the cut-off. 
They were reintegrated and areas were corrected by isotopically labeled L-Pro. 
*0.001 <FDR < 0.05, **FDR< 0.001 and FDRANOVA< 0.05, respectively, for 
quantitative data and for semi-quantitative data after third statistical analysis. 
For identified stereoisomers, pure enantiomer standard solutions were measured to 
ensure that the appearance of their antipode in urine is of biological nature and not 
the result of racemization during MCF derivatization. The exact enantiomer excess of 
the applied L-HG standard has not been determined by the supplier (Sigma). An area 
percentage of 0.95% and 0.39% were found for the D-enantiomer (relative to the D+L 
area) of the 2-HG-γ-lactone and the three-fold derivatized open form, respectively.  
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Figure 27. RSDs of response values of 8 peaks in the chromatograms generated by 
GC-qMS in scan mode of six MeOH/MCF derivatized aliquots of the urine pool. 
Injection replicates refer to six injections of one MeOH/MCF derivatized aliquot of the 
urine pool. Identified and standard confirmed metabolites were marked. * peak that 
significantly differentiated groups. 
For the open form the signal of the D-enantiomer had a S/N<8 so that the determined 
area may be inaccurate. The appearance of the D-signals indicated either a slight 
racemization during derivatization or a minor impurity of the standard. No 
racemization was detected for the other enantiomers identified except for N-Acetyl-L-
Ala. This racemization was most probably catalyzed by pyridine as the mean area 
percentage of the D-enantiomer decreased from 16% to 0.1% when the pyridine 
amount was decreased in the reaction mixture from 34 µL to 4 µL (data not shown). 
However, reducing the applied pyridine amount decreased the derivative yield 
distinctly. The reduction of reaction yield was dependent on the metabolite structure 
(data not shown). Finally, the AAE trends between the groups revealed by semi-
quantitative chiral GC-qMS analysis were in good agreement with the results 
obtained by the validated quantitative GC-qMS method for AAE analysis, visualized 
in Figure 26. MarkerLynx had failed to pick above the cut-off seven of the low 
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abundant D-AAs as well as L-Ser. The S/N in scan mode was distinctly lower than in 
the more sensitive selected ion monitoring, performed for quantitative AAE analysis. 
L-Ser coeluted with D-Met and the software picked an m/z of the D-Met spectrum in 
some chromatograms (below the cut-off) but no m/z of the Ser spectrum probably 
because of the similar retention time. Nevertheless, the fingerprinting method proved 
suitable for the semi-quantitative analysis of chiral and non-chiral metabolites in 
urine. 
 
8.3.6 BIOLOGICAL INTERPRETATION  
Urinary metabolite profiles represent the summed metabolite trends of all organs and 
tissues and, therefore, a concrete assignment of observed differences between the 
groups to changes in specific tissues or pathways is difficult. Moreover, decreased 
urinary metabolite levels, can either indicate decreased metabolite contents in all 
tissues or a higher requirement of the metabolite as a substrate of activated 
pathways and vice versa. Therefore decreased urinary amounts of L-malic acid, citric 
acid, 2-ketoglutarate (2-KG) and succinic acid in the steatosis group (see Table 7) 
could indicate the activation of the TCA cycle in tissues which is consistent with the 
findings of An et al. who observed increased TCA cycle intermediate levels in the 
liver of obese rats whereas their urinary excretion was decreased211. In contrast 
Thomas et al. observed reduced expression level of three enzymes associated with 
the TCA cycle at earlier time points of the NASH inducing diet (10-30 days)212. Also 
other pathways can contribute to the reduction of urinary citric acid and 2-KG 
amounts. 2-KG is a product of AA transamination and L-AA intake was lower with the 
steatosis and NASH inducing diets than with the standard diet. The distinct decrease 
in citrate excretion can be further supported by an elevated expression of ATP-citrate 
lyase (ACL) found in relation to the development of NAFLD. ACL metabolizes citrate 
to acetyl-CoA and links therewith glucose catabolism with lipogenesis213. In the 
NASH mouse model, fed a high sugar content, the citrate levels were decreased 
more moderately than in the steatosis group when compared to controls, 
respectively. This was also observed for the other TCA cycle metabolites and threo-
ICA was even elevated in the NASH group when compared to controls. This 
suggests metabolic changes in mitochondria when inflammation progresses, which 
was supported by the report on mitochondrial abnormality observed in some NASH 
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patients214. The elevated threo-ICA amounts could be a protective response on 
inflammation. Inflammation can inhibit the production of red cells. ICA was shown to 
reduce chronic inflammation caused anemia by lessening the erythroid iron restriction 
response215. Indeed Thomas et al. found ICA dehydrogenase to be down regulated in 
the first 30 days of a NASH inducing diet212. The lack of a linear relation between L-
threo-ICA γ-lactone and threo-ICA (r= -0.1) responses suggested either a biological 
source of the lactone, which is independent from the open form, or a concentration 
dependent lactonization. In contrast baseline separated 2-HG enantiomers showed 
high linear correlation with the related lactone enantiomers, respectively (rD-form=0.97; 
rL-form=0.96). This correlation was based on a high, concentration independent and 
therefore constant, lactonization rate (65 %) during derivatization and either 
spontaneous lactonization during sample storage or enzyme catalyzed lactonization 
in mouse organisms. D- and L-2-HG enantiomer (lactone+open form) abundances 
behaved similar with lower levels in the diseased groups than in controls while their 
amounts in NASH were respectively higher than in the steatosis group. D-2-HG was 
the predominant form in mouse urine. It was reported that both D- and L-2-HG can be 
converted to 2-KG by two different stereo specific enzymes namely D- and L-2-HG 
dehydrogenase that were found to be active in rat tissues such as liver, kidney, heart 
and brain97, 99.The relation of 2-HG enantiomers to 2-KG is visible in comparable 
trends between the groups. Similar trends were detected also for the baseline 
separated NAA enantiomers. Many reports on NAA do not account for its chiral 
character. It was found to serve as an important source for acetate in the brain and 
the liver, that is required e.g. for lipid synthesis216. My data showed reduced urinary 
excretion of D- and L-NAA, which could indicate a higher requirement of the acetyl 
moiety of NAA in tissues during NAFLD, and suggests that both enantiomers could 
serve as acetyl donors. However, a decreased synthesis of NAA enantiomers in 
NAFLD mice could not be excluded. I found for the low abundant baseline separated 
D-Malate similar trends than for its antipode. A comparable metabolism for 
administrated labeled D- and L-Malate in rats was observed already in 196996. For 
proteinogenic L-AAs that can be catabolized to Krebs cycle intermediates or their 
precursors, comparable trends were observed as for TCA metabolites with lower 
amount found in the NAFLD groups than in controls. A study investigating the early 
development of NASH in mice, revealed moderately elevated expression levels of 
proteins involved in the degradation of L-AAs179.The reduced protein ratios in the 
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here applied steatosis (18.5%) and NASH (16.1%) inducing diets when compared to 
the standard diet (33%) contributed to reduced L-AA excretion in the NAFLD mice 
albeit could not explain the increased urinary levels of most detected L-AAs in NASH 
when compared to steatosis. Reduced urinary D-AA excretion was not a dietary 
effect as proteins typically do not contain D-AAs. The interpretation of D-AAs trends 
remains difficult, as their metabolism and functions in mammals are not completely 
understood. So far two enzymes are known to synthesize D-AAs in mammals namely 
Ser and Asp racemase and two enzymes were found to catalyze D-AA degradation 
being D-AA oxidase (DAO) and D-Asp oxidase52-54, 56, 57. The findings of elevated gut 
permeability and prevalent small intestinal bacterial overgrowth (SIBO) in steatosis 
189
 and a high release of D-AAs by bacteria at stationary phase conditions18 as well 
as increased D-AA serum level found in patients with liver cirrhosis (chapter 7.3.4) 
encourage the expectation of increased urinary D-AA excretion. However, only D-Val 
levels were slightly albeit not significantly increased in the steatosis group. These 
observations cannot be explained by changed DAO activity in the liver as contrary to 
other mammals, mice do not express DAO in the liver. Nevertheless, DAO 
expression might be regulated in the kidney and the brain of NAFLD mice52, 53. 
Citramalate is a bacterial metabolite and showed significantly elevated levels in 
steatosis and NASH, probably due to SIBO and changed permeability of the gut189. 
Phenylacetylglycine (PAG), phenylacetic acid and 4-hydroxyphenylacetic acid (4-
HPA) are also gut flora related metabolites that were significantly increased in the 
steatosis vs. controls comparison (Table 7, S1 and S2). The most distinct increase 
was observed for PAG that was also found to be grossly elevated in long term treated 
obese rats. An et al also found slightly increased 4-HPA levels after 80 days of the 
steatosis inducing diet211. I found phenylacetic acid to be slightly decreased in the 
NASH vs. controls comparison whereas PAG and HPA were significantly increased.  
Contrary to reports on elevated urinary excretion of saturated and unsaturated 
medium-chain dicarboxylic acids at disordered FA metabolism202, 203 adipic acid 
amounts were decreased in both diseased groups and suberic acid was only 
increased in the steatosis group albeit not significantly when compared to controls. 
Nevertheless, the three features identified as hexenedioic acid isomers were grossly 
increased in the steatosis vs. controls comparison with fc >10.5. They were more 
moderately increased in the NASH vs. controls comparison (fc >1.5, see Table 7, 
Table S1and Table S2). Therefore, they were distinctly decreased in the NASH mice 
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when compared to steatosis. Finally an octendioic acid isomer was tentatively 
identified. It was detected exclusively in urine of all six members of the steatosis 
group at quantifiable levels. These results can denote a selective activation of FA 
metabolism. Furthermore, my results did not support the reported supposition that 
trans-2-Hexenedioic acid originates from dehydrogenation of adipic acid203, 217. Most 
of the here discussed small organic acids and the 2-HG γ-lactone had already been 
identified previously as urinary metabolites of healthy individuals as methyl ester 
derivatives after non-chiral GC-MS analysis218. 
 
 8.3.7 RELEVANCE OF THE CHIRAL DIMENSION  
The combination of MeOH/MCF derivatization and a γ-cyclodextrin derivative chiral 
GC column yielded generally excellent enantioselectivity with resolution values 
between 1.9 and 17.2 for baseline-separated enantiomers. Besides ten proteinogenic 
AAE pairs, the method allowed the baseline separation of nine identified enantiomer 
pairs including two- and three-fold derivatized malic acid enantiomers and 2-HG 
latcone and open form enantiomers (Table 8). An obverse trend was found for D-Val 
in the steatosis vs control comparison when compared to its antipode L-Val, which 
underlines the importance of enantiomer resolution. Also D-Thr showed converse 
trends to its antipode in both diseased groups when compared to controls (see 
quantitative data in Figure 26). The discriminating allo-Ile was further specified as the 
D-enantiomer whereas the L- allo-Ile was not detected in any of the urine specimens. 
Hamase et al. also found high urinary amounts of D-allo-Ile in rats, mice and dogs 
whereas only traces of L-allo-Ile were detected in urine of rats51. In sum, 16 
separated enantiomers of chiral metabolites, including nine newly identified 
enantiomers and seven AAEs, significantly discriminated the groups in at least one 
group comparison. D-Val, D-allo-Ile and D-2-HG (lactone+open form) were baseline-
separated enantiomers that significantly differentiated NASH from steatosis (FDRs 
were 5.55E-03, 1.32E-02, and 2.92E-02, respectively), which demonstrated the 
relevance of the chiral dimension for the classification of NAFLD stages in this murine 
model. Whether these metabolites are also suited for the differential diagnosis of 
steatosis and NASH in human patients needs to be evaluated. 
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9 CONCLUSIONS AND PERSPECTIVES 
Quantitative GC-qMS and GC×GC-TOFMS for AAE analysis using MeOH/MCF 
derivatization and a γ-CD derivative as chiral selector were implemented, optimized, 
validated and finally applied to mammalian urine, serum and liver. Quantitative AAE 
analysis by GC-qMS offered superior repeatability, shorter run times and less time-
consuming data analysis compared to GC×GC-TOFMS. It allowed accurate 
quantification of four D-AAs in human control serum, six in mouse serum and eight in 
human control urine as well as five in mouse liver. GC×GC-TOFMS, on the other 
hand, showed improved enantiomer resolution and resolution from serum and urine 
matrix molecules as well as lower LLOQs when compared to the GC-qMS method. 
The chiral GC×GC method allowed the accurate quantitation of up to seven D-AAs in 
human urine and serum. Therefore, the application of GC×GC-TOFMS clearly 
increased the number of quantifiable D-AAs in human serum. However, it slightly 
decreased the number of quantifiable D-AAs in urine. Therefore, the chiral GC×GC 
method for AAE analysis is recommended for the analysis of serum whereas the 
related GC-qMS method for AAEs quantitation is recommended for urinary 
metabolome analysis due to its superior repeatability as well as faster analysis. Chiral 
GC-qMS analysis of AAEs in mouse liver revealed distinctly differing concentrations 
when D-AA levels were compared to L-AA levels. Thus, the GC×GC method will 
most probably provide more quantifiable AAE peaks due its broader linear ranges 
compared to GC-qMS. However, AAE analysis of liver tissues by GC×GC was not 
tested and therefore a definite recommendation is not possible as the disturbance by 
liver matrix compounds was not assessed for the two-dimensional method. Though 
chiral GC-qMS enabled the quantification of nine D-AAs in some analyzed human 
and mouse urine specimens, both methods had insufficiently low LLOQs and a lack 
of selectivity to allow quantification of all (in respect of the antipode) baseline 
separated D-AAs in all specimens of interest. Thus, further improvement of LLOQs 
and selectivity is required to provide more efficient AAE analysis in physiological 
fluids. This can be achieved by the application of an IS mix that does not impede 
sensitive AAE analysis by the generation of blank values. Here blank values limited 
LODs of both methods, LLOQs of both methods for early eluting (high abundant) 
AAEs and LLOQs of GC×GC analysis for all detected AAEs. Another drawback of the 
here applied IS mix, gained from algae, was that AA abundance varied widely, with 
labeled Ser and Met being the least abundant. Since these two amino acids also 
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yielded low peak abundances after MeOH/MCF derivatization and chiral analysis, 
dilution of the IS mix was limited by the abundance of these AA types. Therefore, a 
synthetic equimolar mixture of labeled racemic AAs would help to improve LLOQs 
and repeatability of the here presented GC-MS based methods. Furthermore, the 
here established methods were not able to baseline separate all proteinogenic AAEs 
in a single chromatographic run as Phe enantiomers were not separated by the γ-CD 
derivative and nine proteinogenic AA types did not elute from the chiral column. 
However, the final goal of chiral AA analysis in metabolomics is to establish a method 
that allows the monitoring of all proteinigenic D-AAs in physiological fluids and 
tissues to investigate their potential as biomarkers efficiently and to learn more about 
their biological relevance. Therefore, direct or indirect chiral LC-MS approaches, and 
thereby in particular the application of LC-MS/MS because of its excellent 
sensitivity120, should be considered to enlarge the quantifiable analyte spectrum for 
the analysis of physiological fluids and tissues. 
The here presented chiralomics approach demonstrates the relevance of the chiral 
dimension in the differentiation of experimental groups. Eighteen of the N=106 
significantly differentiating features detected could be assigned to stereoisomers in 
addition to the known AAEs, of which seven and D+L-Phe discriminated the study 
groups significantly. From the 18, three corresponded to cis/trans isomers and 12 
corresponded to enantiomers of small hydroxy diacids, non-proteinogenic AAs and 
AA derivatives as well as lactones. Principal component analyses separated murine 
hepatic steatosis from NASH along both PC1 and PC2 (Figure 25). Additionally, both 
diseased groups were perfectly separated from controls along PC1. The loadings plot 
(Figure S3) showed that from the identified and standard confirmed enantiomers, all 
stereoisomers of hydroxy dicarboxylic acids clearly contributed to the separation by 
PC 1 and D-Val and D-allo-Ile contributed to the separation by PC 2. This was 
reflected by p-values and FDRs obtained from statistical analysis for the steatosis vs. 
NASH comparison. D-Val, D-allo-Ile and D-2HG significantly differentiated NASH 
from steatosis (FDRs were 5.55E-03, 1.32E-02, and 2.92E-02 respectively), which 
further depicted the relevance of the chiral dimension for the classification of NAFLD 
stages in mouse models. Next, the application of chiralomics to human urine in the 
differentiation of NASH from hepatic steatosis needs to be explored in patients, for 
whom definite diagnosis based on liver biopsies is available. Such an approach will 
reveal if the aforementioned D-enantiomers are also diagnostic in human. 
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There were assigned 15 stereoisomers to 18 differentiating feature. This was a 
consequence of MeOH/MCF derivatization artifacts, specifically the incomplete 
modification of hydroxy moieties and the promotion of lactonization. Moreover, the 
highly exothermal reaction with MeOH/MCF, under acidic conditions, promoted 
racemization of N-Acetyl-Ala enantiomers as well as cis-trans-conversion in case of 
aconitate and fumaric acid/maleic acid. Thus, alternative, more gentle derivatization 
protocols or chiral LC- based methods requiring no derivatization at all should be 
investigated. 
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11 APPENDIX 
 
 
Figure S1. Overlaid chromatogram section of late eluting MeOH/MCF AAEs of MM I, 
after GC-qMS measure in SIM mode, accomplished with three different splitless 
times and remaining GC-MS parameters installed like in method II. 
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Figure S2. Characteristic calibration curves for MeOH/MCF L-Ala and Gly generated 
by chiral GC-qMS analysis of a dilution series of MM II with method II and a splitless 
time of 1.0 minutes except for the highest calibration point that was generated using 
method II and a splitless time of 0.5 minutes. 
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Figure S3. Loadings plot of PCA of discriminating metabolites shown in Figure 29 of chapter 8. Dots were marked by numbers given 
in Table 7, Table S1, Table S2 and Table S3. 
P
C
 
2
PC 1
136 
 
Table S1. Identification results of ‘Unknowns’ subjected to sf analysis: Retention times, picked m/z and sf results of 88 features, 
significantly differentiating the groups in at least one comparison after repeated univariate statistical analysis.
 
Nr assigned metabolite(s) identified by ret.t 
(GC-qMS)
picked 
m/z(GC-qMS) 
Elemental 
composition  
derivative+H
calculated 
m/z of M+H ∆ [mDa] mSigma
1 unknown - 10.83 89 - - - -
2 Fumaric acid (or Maleic acid) NIST; sf; std 11.55 113 C6H9O4 145.0501 0.03 24.6
3 Benzaldehyde NIST; sf 11.89 106 C7H7O 107.04969 -2.45 43.7
4 Malonic acid NIST; sf; std 12.77 101 C5H9O4 133.0501 -0.32 8.2
6 unknown - 13.38 105 - - - -
- df: Succinic acid NIST; sf; std 14.43 115 C6H11O4 147.0657 -0.69 7.8
7 Succinic acid NIST; sf; std 14.44 115 C6H11O4 147.0657 -0.69 7.8
8 unknown - 15.14 127 - - - -
9
DL-1-Acetoxy-1-ethoxyethane, 4,4-Dimethoxy-2-
butanone, S- or 1-Butanol, Isobutanol, Erythronilic
acid, 3-Hydroxy-2-methyl-[R-(R,S)]-butanoic acid, 
DL-3/4-Hydroxyisovaleric acid, DL- 2-Hydroxy-2/3-
methylbutyric acid,  2-Methylpropan-2-ol 
(hydroxyacids and alcohols as 1-fold derivatives)
sf 16.21 87 C6H13O3 133.0865 -0.54 71.9
10 see feature above sf 16.23 74 C6H13O3 133.0865 -0.54 71.9
11 Itaconic acid NIST; sf; std 16.37 127 C7H11O4 159.0657 -0.72 22.4
12 2-Methylbutylamine, 3-Methylbutylamine sf 16.44 88 C7H16NO2 146.1181 -0.96 13.3
13
Glutaric acid, D(L)-Methylsuccinic acid, 
Dimethylmalonic acid, DL-2-Aceto-2-
hydroxybutanoic acid (1-fold derivative)
sf 16.85 100 C7H13O4 161.0814 -0.76 6.9
14 Phenylacetic acid NIST; sf; std 16.88 91 C9H11O2 151.0759 -0.25 4.9
15 Adipate semialdehyde, 2/3-Oxohexanoic acid,DL-2/(3)-Methyl-3/(2)-oxovaleric acid, Ketoleucine sf 17.53 114 C7H13O3 145.0865 -1.03 20.3
16
cis/(trans)-2-Hexenedioic acid, cis-3-Hexenedioic 
acid, trans-2-Methylglutaconic acid, trans-3-
Methylglutaconic acid
sf, sf, sf; 
NIST, sf;NIST 18.66 107 C8H13O4 173.0814 -0.51 21.6
17 unknown - 19.08 87 - - - -
18 Carbamic acid or 3/2-Furoic acid sf 19.36 99 C4H8NO4 or C6H7O3
134.0453  or 
127.0395
-1.12 or 
1.00 14.4 or 6.2
19 see feature above sf 19.37 98 C4H8NO4 or C6H7O3
134.0453  or 
127.0395
-1.12 or 
1.00 14.4 or 6.2
21 Benzylamine sf 20.04 72 C9H12NO2 166.0868 2.53 58.5
22 DL-Citramalic acid (2-fold derivative) NIST; sf; std 20.13 117 C7H13O5 177.0763 -0.18 6
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Nr assigned metabolite(s) identified by ret.t (GC-
qMS)
picked 
m/z(GC-qMS) 
Elemental 
composition  
derivative+H
calculated 
m/z of M+H ∆ [mDa] mSigma
23 trans-2-Hexenedioic acid NIST; sf; std 20.27 74 C8H13O4 173.0814 -0.17 10.8
24
cis/(trans)-2-Hexenedioic acid, cis/trans-3-
Hexenedioic acid, cis/trans-1-Carboxycyclopropane-
2-acetic acid, cis/trans-2-Methylglutaconic acid, 
cis/trans-3-Methylglutaconic acid, (Succinylacetone)
NIST; sf 20.51 98 C8H13O4 173.0814 -0.89 18.2
25 Ethyl-2-furoate, Ethyl-3-furoate, Furfuryl acetate, 5-Methylfuran-2-carboxylic acid sf 20.82 99 C7H9O3 141.0552 0.26 24.4
27 Diethanolamin (1-fold derivative) sf 22.14 111 C6H14NO4 164.092284 -3.15 39.9
- L-Malic acid (2-fold derivatized) NIST; sf; std 22.26 71 C6H11O5 163.06065 -1.7 1
29
3-Hydroxymethylglutaric acid (2-fold derivative), 2/3-
DL-Hydroxyadipic acid (2-fold derivative), 2-
Hydroxy-2-ethylsuccinic acid (2-fold derivative)
sf;NIST, sf, sf, 
sf 22.42 117 C8H15O5 191.092 -0.32 12.5
30 Pimelic acid NIST; sf; std 22.57 125 C9H17O4 189.112685 0 18.6
31 Isopropylmaleate sf 22.87 84 C9H15O4 187.097035 0.3 20.6
32
3-Aminopropionaldehyde, Aminoacetone, (N-
Acetylglycine) or (DL-Ile,) (D-allo-Ile), DL-Norleucine, 
β-Leucine
sf 23.49 88 C5H10NO3 or C9H18NO4
132.0661 or 
204.1236
-0.27 or -
1.49 12.1 or 20.3
- df: α-Ketoglutarate NIST; sf; std 24.41 87 C7H11O5 175.0607 -0.72 91.7
34 α-Ketoglutarate NIST; sf; std 24.42 115 C7H11O5 175.0607 -0.72 91.7
36 unknown - 25.22 112 - - - -
37 (2/)3-Hydroxyglutaric acid (2-fold derivative),(DL-Citramalic acid (2-fold derivative)) sf 25.83 102 C7H13O5 177.0763 -0.12 26.3
38 Acetamidopropanal (1-fold derivative) sf 26.14 114 C7H12NO4 174.0766 -0.73 14.6
42 trans/cis-2/3/4-Octenedioic acid sf 27.51 136 C10H17O4 201.1127 -1.4 24.9
43 4-Aminobutyraldehyde (, N-Acetyl-DL-Ala), Propionylglycine sf 27.72 86 C6H12NO3 146.081719 -1.11 11.8
44 2-Keto-3-deoxy-DL-gluconic acid (1fold derivative) sf 27.75 116 C7H13O6 193.0712 -0.31 7.1
45 Nonic acid, Azelaic acid sf 28.29 88 C11H21O4 217.144 -0.25 8.5
46 1,2,3-Propanetricarboxylic acid NIST; sf 29.49 187 C9H15O6 219.086865 -0.88 52.8
47 N-Acetylserine, O-Acetylethanolamine sf 29.62 105 C6H12NO4 162.0766 0.9 62.7
48 cis (/trans)-Aconitic acid NIST; sf; std 29.80 153 C9H13O6 217.0712 -2.14 9.6
Table S1. continued. 
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Nr assigned metabolite(s) identified by ret.t (GC-qMS)
picked 
m/z(GC-
qMS) 
Elemental 
composition  
derivative+H
calculated m/z 
of M+H ∆ [mDa] mSigma
50 2,4,6-Trihydroxybenzoic acid methyl ester (underivatized),  2,4,6-Trihydroxybenzoic acid (1-fold derivative) sf 31.25 152 C8H9O5 185.045 -0.5 8.4
51
N-Acetylvaline, Valerylglycine, 5-Acetamidovalerate, 2-
Methylbutyrylglycine, Isovalerylglycine, 3-
Dehydrocarnitine 
sf 31.78 109 C8H16NO3 174.113 0.79 8
52 Benzoquinone acetic acid sf 31.82 145 C9H9O4 181.0501 0.18 20.7
53
2/3(/4)-Hydroxyphenylacetic acid, 4-Hydroxy-3-
methylbenzoic acid, p-Anisic acid, (DL-Mandelic acid), 
Homovanillin (without derivatized OH-groups)
sf 31.99 153 C9H11O3 167.07082 0.28 56.5
54 see feature above sf 32.05 143 C9H11O3 167.0708 0.28 56.5
55 unknown - 32.29 94 - - - -
56
cis/trans-2-Hydroxy-2-penteneglutaric acid (Enol 
byproduct of MCF derivatization of 2-Ketoglutaric acid, 2-
fold derivative)
sf; std 32.89 115 C7H11O5 175.06065 -0.75 7.2
57 see feature above sf; std 33.28 115 C7H11O5 175.06065 -1.49 5.9
58 unknown - 34.31 121 - - - -
59 Citric acid (3-fold derivative) NIST; sf; std 34.73 175 C9H15O7 235.08178 -3.57 19.6
60 Isovaleryl-DL-alanine, Isovalerylsarcosine, Hexanoylglycine, N-Acetyl-DL-Leu sf 35.02 131 C9H18NO3 188.128669 0.1 58.7
62 unknown - 35.96 151 - - - -
63 Hexanoylglycine,DL-Isovalerylalanine, Isovalerylsarcosine sf 36.46 131 C9H18NO3 188.1287 -1.79 7
- D-2-HG-γ-lactone (1-fold derivative) sf; std 37.47 85 C6H9O4 145.0501 -0.37 8.5
66 DL-(threo)-Isocitric acid (3-fold derivatized) sf 37.55 139 C9H15O7 235.0818 0.1 59.8
67 N-Acetyl-D-Asp NIST; sf; std 37.85 102 C8H14NO5 204.087199 -1.82 50.8
68
Ethyl hydrogen fumarate, 3-Hydroxyadipic acid 3,6-
lactone(, Itaconic acid)(, Citraconic acid), Mesaconic acid, 
Glutaconic acid
sf 38.51 90 C7H11O4 159.0657 -0.97 4.7
69 N-Acetyl-L-Asp NIST; sf; std 38.62 102 C8H14NO5 204.0872 -0.9 11.8
70 DL-β-aspartyl-glycine sf 38.79 224 C10H17N2O7 277.1036 3.05 25.4
71 unknown - 38.82 67 - - - -
72 (DL-Malic acid (3fold derivative)),DL-1-Deoxy-erythro-hexo-2,3-diulose (1fold derivative), DL-1,5-Anhydrofructose sf 38.99 101 C8H13O7 221.0661 -0.2 37.5
73 Phenylglyoxylic acid sf 39.00 105.18 C9H9O3 165.06 -0.7 56.5
74
2/3(/4)-Hydroxyphenylacetic acid, 4-Hydroxy-3-
methylbenzoic acid, p-Anisic acid, (DL-Mandelic acid), 
Homovanillin (all without derivatized OH-groups)
sf 39.20 98 C9H11O3 167.0708 -0.5 6
75 4-Hydroxyphenylacetic acid (1-fold derivative) NIST; sf, std 39.50 107 C9H11O3 167.0708 -0.4 6.4
76
(DL-3-Phenyllactic acid)(, Desaminotyrosine), 3-(3-
Hydroxyphenyl)propanoic acid, 4-Methoxyphenylacetic 
acid, Coniferyl alcohol (without derivatized OH-groups)
sf 39.53 121 C10H13O3 181.08647 -3.96 16.1
Table S1. continued. 
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Identification by NIST database relied on a match >65% for resolved peaks and a match >50% for disturbed and low abundant peaks (S/N<50). 
Identification by sf relied on ∆m <5mDa and mSigma <50 for separated peaks and mSigma <100 for disturbed and low abundant peaks. 
Identification by standard (std) relied on similar relative ret.t. (relative to IS) and similar mass spectra. Metabolites given in brackets were rejected 
after standard injection. df refers to double feature. Double features were not assigned to a feature Nr as they were not used for PCA analysis. 
Metabolites yielding two derivatization products were not assigned to a feature Nr as only their summed areas, listed in Table S3, were used for 
PCA analysis. Feature Nr refer to the numbers in the loadings plot (Figure S3). 
Nr assigned metabolite(s) identified by ret.t (GC-
qMS)
picked 
m/z(GC-qMS) 
Elemental 
composition  
derivative+H
calculated m/z 
of M+H ∆ [mDa] mSigma
77
(DL-Malic acid (3fold derivative)),DL-1-Deoxy-erythro-
hexo-2,3-diulose (1fold derivative), DL-1,5-
Anhydrofructose
sf 40.02 101 C8H13O7 221.0661 -1.3 22.3
78 unknown - 40.21 238 - - - -
79 Elenolic acid sf 40.22 135 C12H17O6 257.1025 1.23 11.7
80 Phenylglyoxylic acid sf 40.27 78 C9H9O3 165.0552 -2.75 21
81 Vanilpyruvic acid sf 40.28 224 C11H13O5 225.0763 0.67 69.4
- L-2-HG-γ−lactone (1-fold derivative) sf; std 40.33 85 C6H9O4 145.0501 -1.32 13
82 Acetyl citrate sf 40.47 115 C10H13O8 261.061 -0.8 15.3
83 Austdiol (underivatized), Dillapional sf 41.58 90 C12H13O5 237.0763 -0.39 29.7
84 (Phe) unknown sf 41.76 149 C12H16NO4 238.1079 -0.08 9.8
86 N-cyclohexylcarbonyl-Gly, Neotussilagine NIST; sf, sf 42.38 83 C10H18NO3 200.128669 -3.33 6.9
87 DL-5-Amino-3-oxohexanoic acid,  DL-2-Amino-6-
oxohexanoate,  6-Amino-2-oxohexanoic acid sf 43.17 121 C9H16NO5 218.1028 -0.77 8.6
88 see feature above sf 43.18 120 C9H16NO5 218.1028 -0.77 8.6
89 (D)L-threo-Isocitric acid (4-fold derivative) sf; std 44.25 129 C11H17O9 293.0873 -0.4 7.5
- df: (D)L-threo-Isocitric acid (4-fold derivative) sf; std 44.27 101 C11H17O9 293.0873 -0.4 7.5
90
N-Formyl-DL-Glu, cis(/trans)-4-D(L)Hydroxy-Pro (2-
fold derivative), cis/trans-3-Hydroxy-DL-Pro (2-fold 
derivative), 5-Amino-2-oxopentanoic acid, 5-
Aminolevulinic acid, DL-Glutamic-g-semialdehyde
sf 45.78 115 C8H14NO5 204.0871 0.25 6.9
91 Isovalerylglutamic acid, Suberylglycine, N-Heptanoylglycine sf 46.34 108 C12H22NO5 260.1498 0.96 25.3
92 see feature above sf 46.35 109 C12H22NO5 260.1498 0.96 25.3
93 3-Succinoylpyridine (, Hippuric acid) sf 47.49 131 C10H12NO3 194.081719 -2.54 15.4
94 Hippuric acid NIST; sf; std 48.79 77 C10H12NO3 194.0817 -0.4 6.8
95 unknown - 53.31 143 - - - -
96 Phenylacetylglycine NIST; sf 53.88 88 C11H14NO3 208.0974 -1.7 8.6
Table S1. continued. 
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Table S2. Adjusted P-values (FDRs) for t-tests of the three group comparisons and 
respective fcs of the 88 differentiating features of which identification results were 
shown in Table S1. For metabolites for which less than three quantifiable values 
(S/N>8) were detected in a group, the respective counts per group were noted in 
brackets. 
 
steatosis/ controls NASH/ controls NASH/ steatosis
Nr ret.t (GC-qMS) fc FDR fc FDR fc FDR
1 10.83 0.30 1.79E-02 0.43 4.98E-02 1.40 >0.05
2 11.55 0.04 2.94E-02 0.13 3.21E-02 3.45 >0.05
3 11.89 0.56 3.29E-02 0.40 7.87E-03 0.71 >0.05
4 12.77 0.55 2.97E-06 0.67 1.41E-04 1.21 >0.05
6 13.38 0.34 ( 6/ 6 ) 3.89E-06 0.09 ( 2/ 6 ) 1.43E-05 0.28 ( 2/ 6 ) >0.05
- 14.43 0.14 1.62E-06 0.41 1.62E-04 2.93 4.63E-02
7 14.44 0.14 1.62E-06 0.41 1.62E-04 2.93 4.63E-02
8 15.14 not av. ( 6/ 0 ) not av. not av. ( 0/ 0 ) not av. not av. ( 0/ 6 ) not av.
9 16.21 0.86 >0.05 0.30 4.55E-03 0.35 3.24E-02
10 16.23 2.39 4.89E-05 1.16 >0.05 0.49 4.59E-04
11 16.37 0.16 ( 1/ 6 ) 1.69E-02 0.33 ( 6/ 6 ) 2.60E-03 2.12 ( 6/ 1 ) >0.05
12 16.44 0.28 2.87E-03 0.26 3.48E-03 0.93 >0.05
13 16.85 0.09 3.25E-05 0.27 5.53E-04 3.08 >0.05
14 16.88 1.72 8.54E-04 0.80 >0.05 0.46 2.56E-04
15 17.53 0.20 4.34E-05 0.11 2.20E-04 0.51 >0.05
16 18.66 18.97 1.61E-05 2.82 >0.05 0.15 8.90E-05
17 19.08 not av. ( 0/ 6 ) not av. not av. ( 0 / 6 ) not av. not av. ( 0/ 0 ) not av.
18 19.36 6.74 1.14E-10 0.99 >0.05 0.15 1.12E-10
19 19.37 9.22 1.75E-08 1.05 >0.05 0.11 1.59E-09
21 20.04 not av. ( 0/ 6 ) not av. 0.18 ( 3/ 6 ) >0.05 not av.( 3/ 0 ) not av.
22 20.13 1.38 1.24E-02 1.92 1.84E-05 1.39 3.93E-03
23 20.27 10.52 1.59E-07 1.52 >0.05 0.14 2.27E-07
24 20.51 71.03 ( 6/ 1 ) 1.50E-07 1.90 ( 6/ 1 ) >0.05 0.03 ( 6/ 6 ) 4.28E-10
25 20.82 0.07 ( 5/ 6 ) 3.99E-06 0.02 ( 1/ 6 ) 3.95E-04 0.33 ( 1/ 5 ) >0.05
27 22.14 0.23 8.18E-05 0.15 8.97E-05 0.67 >0.05
- 22.26 0.04 1.06E-02 0.11 2.01E-02 2.87 >0.05
29 22.42 0.05 6.66E-04 0.32 4.55E-03 6.19 >0.05
30 22.57 0.44 9.82E-06 0.16 5.85E-07 0.38 1.45E-02
31 22.87 9.55 1.50E-14 0.65 >0.05 0.07 8.03E-15
32 23.49 1.96 4.02E-05 1.02 >0.05 0.52 1.55E-04
- 24.41 0.06 2.83E-03 0.17 8.09E-03 2.94 >0.05
34 24.42 0.05 2.67E-03 0.16 8.05E-03 3.25 >0.05
36 25.22 0.15 9.82E-06 0.11 8.97E-05 0.70 >0.05
37 25.83 not av. ( 0/ 6 ) not av. not av. ( 0/ 6 ) not av. not av. ( 0/ 0 ) not av.
38 26.14 0.10 ( 1/ 6 ) 2.46E-02 0.09 ( 1/ 6 ) 2.80E-02 0.85 ( 1/ 1 ) >0.05
42 27.51 not av. ( 6/ 0 ) not av. not av. ( 0/ 0 ) not av. not av. ( 0/ 6 ) not av.
43 27.72 0.22 4.87E-07 0.21 1.27E-06 0.96 >0.05
44 27.75 1.84 5.29E-03 2.15 8.89E-04 1.17 >0.05
45 28.29 not av. ( 0/ 6 ) not av. not av. ( 0/ 6 ) not av. not av. ( 0/ 0 ) not av.
46 29.49 0.25 ( 6/ 6 ) 2.23E-05 0.03 ( 1/ 6 ) 7.23E-04 0.11 (  1/ 6 ) >0.05
47 29.62 0.18 ( 6/ 6 ) 2.37E-05 0.03 ( 1/ 6 ) 1.39E-03 0.18 ( 1/ 6 ) >0.05
48 29.80 0.33 9.82E-06 0.57 1.19E-03 1.75 >0.05
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Table S2. continued. 
 
not. av. refers to not available for the calculation of fcs due to less than three quantifiable 
values in one of the two compared groups. The R ‘limma’ package was able to determine 
adjusted p-values (FDRs) if at least one value was available as it estimates a SD from the 
SDs of the other features.  
 
 
steatosis/ controls NASH/ controls NASH/ steatosis
Nr ret.t (GC-qMS) fc FDR fc FDR fc FDR
50 31.25 0.28 ( 6/ 6 ) >0.05 not av. ( 0 / 6 ) not av. not av. ( 0/ 6 ) not av.
51 31.78 0.14 ( 1/ 6 ) >0.05 not av. ( 0 / 6 ) not av. not av. ( 0 / 1 ) not av.
52 31.82 0.35 6.43E-03 0.15 1.63E-03 0.43 >0.05
53 31.99 4.35 1.61E-05 1.00 >0.05 0.23 4.95E-05
54 32.05 13.56 2.31E-06 1.80 >0.05 0.13 1.06E-05
55 32.29 0.13 ( 1/ 6 ) >0.05* not av. ( 0/ 6 ) not av. not av. ( 0/ 1 ) not av.
56 32.89 0.04 2.67E-03 0.16 8.05E-03 3.59 >0.05
57 33.28 0.04 2.67E-03 0.16 8.05E-03 3.60 >0.05
58 34.31 3.08 2.19E-04 0.69 >0.05 0.22 2.07E-04
59 34.73 0.05 1.12E-06 0.33 8.97E-05 6.67 >0.05
60 35.02 0.82 >0.05 0.55 1.84E-03 0.68 >0.05
62 35.96 0.61 ( 6/ 6 ) 2.85E-02 0.08 ( 1/ 6 ) 1.08E-02 0.13 ( 1/ 6 ) >0.05
63 36.46 0.49 5.13E-05 1.02 >0.05 2.10 1.00E-04
- 37.47 0.22 1.61E-05 0.57 4.31E-03 2.61 3.09E-02
66 37.55 3.03 2.73E-03 1.58 >0.05 0.52 4.63E-02
67 37.85 0.18 8.40E-06 0.25 5.06E-05 1.34 >0.05
68 38.51 3.41 1.95E-07 0.43 4.01E-02 0.13 1.70E-08
69 38.62 0.10 5.00E-06 0.25 7.79E-05 2.39 >0.05
70 38.79 0.13 7.22E-09 0.06 1.46E-08 0.50 >0.05
71 38.82 3.51 ( 6/ 2 ) 3.77E-03 0.61 ( 1/ 2 ) >0.05 0.18 ( 1/ 6 ) 2.07E-02
72 38.99 0.02 9.82E-06 0.30 4.98E-04 14.46 >0.05
73 39.00 0.10 ( 4/ 6 ) >0.05 not av. ( 0/ 6 ) not av. not av. ( 0/ 4 ) not av.
74 39.20 0.45 1.66E-04 0.55 1.78E-03 1.24 >0.05
75 39.50 2.89 7.10E-05 1.83 3.38E-02 0.63 2.15E-02
76 39.53 0.08 5.37E-07 0.02 1.28E-06 0.31 >0.05
77 40.02 0.02 8.40E-06 0.30 4.25E-04 14.59 >0.05
78 40.21 0.03 1.59E-07 0.003 1.88E-06 0.12 >0.05
79 40.22 0.03 1.30E-07 0.004 1.32E-06 0.15 >0.05
80 40.27 0.58 7.45E-04 0.34 3.01E-05 0.59 >0.05
81 40.28 1.10 >0.05 0.66 >0.05 0.61 4.24E-02
- 40.33 0.08 5.42E-04 0.31 6.55E-03 3.93 >0.05
82 40.47 0.03 7.56E-06 0.28 2.68E-04 8.68 >0.05
83 41.58 0.33 6.07E-04 0.32 9.47E-04 0.97 >0.05
84 41.76 0.56 1.69E-03 0.80 >0.05 1.42 >0.05
86 42.38 42.37 1.92E-16 1.15 >0.05 0.03 2.03E-16
87 43.17 0.07 ( 6/ 6 ) >0.05 not av. ( 0/ 6 ) not av. not av. ( 0/ 6 ) not av.
88 43.18 0.08 ( 6/ 6 ) 1.04E-05 0.01 ( 2/ 6 ) 2.26E-04 0.17 ( 2/ 6 ) >0.05
89 44.25 0.88 >0.05 1.46 8.20E-03 1.66 4.09E-03
- 44.27 0.89 >0.05 1.45 8.05E-03 1.62 4.18E-03
90 45.78 2.22 2.97E-06 2.54 7.08E-07 1.15 >0.05
91 46.34 45.94 1.14E-11 1.28 >0.05 0.03 9.80E-13
92 46.35 41.26 1.50E-14 1.19 >0.05 0.03 8.03E-15
93 47.49 not av. ( 6/ 0 ) not av. not av. ( 1/ 0 ) not av. 0.04 ( 1/ 6 ) >0.05*
94 48.79 0.21 7.89E-08 0.02 1.46E-08 0.11 4.63E-02
95 53.31 0.02 2.25E-02 0.12 2.76E-02 6.44 >0.05
96 53.88 3.30 1.95E-07 1.58 3.13E-02 0.48 1.15E-05
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Table S3. Identification results, retention times (ret.t.), integrated m/z, adjusted P-values (FDRs) and fcs for three group comparisons 
of 11 additional features of interest. For metabolites for which less than three quantifiable values (S/N>8) were detected in minimum 
one of the groups, the respective counts of compared groups were noted in brackets. 
 
 n. av. refers to not available for the calculation of fcs due to less than three quantifiable values in one of the two compared groups. The R ‘limma’ 
package can determine adjusted p-values (FDRs) if at least one value was available as it estimates a SD from the SDs of the other features. 
steatosis/ controls NASH/ controls NASH/ steatosis
Nr assigned metabolite(s) identified by ret.t (GC-qMS)
Integrated
m/z(GC-qMS) 
calculated
m/z 
of
M+H ∆[mDa] fc FDR fc FDR fc FDR
5 DL-3-Methyl-2-
oxovalerate std 13.36 85 - - 0.92 >0.05 0.66 8.05E-03 0.71 >0.05
20 Adipic acid std 19.59 114 175.0970 -0.07 0.52 1.67E-02 0.74 >0.05 1.43 >0.05
33 D-allo-Ile sf; std 23.53 144 204.1236 -1.49 0.86 >0.05 0.22 1.78E-03 0.26 1.42E-02
39 N-Acetyl-L-Ala std 26.58 86 - - 0.21 ( 1/4) n.av. n.av. ( 0/4) n.av. n.av. ( 0/1) n.av.
40 Suberic acid NIST; std 26.87 129 203.1283 -0.17 1.40 >0.05 0.63 >0.05 0.45 3.47E-02
41 N-Acetyl-D-Ala std 27.06 86 - - 0.28 ( 4/5) n.av. n.av. ( 0/5) n.av. n.av. ( 0/4) n.av.
-
L-threo-Isocitric acid-γ-
lactone std 49.3 143 203.0556 -0.34 1.22 >0.05 1.23 >0.05 1.01 >0.05
97 D-Malate (2-fold+3fold ) std + std 22.00; 29.30 103; 75 221.0661(2-fold) - 0.06 ( 1/6) >0.05 0.12 ( 4/6) >0.05 1.93 ( 4/1) >0.05
98 L-Malate (2-fold+3fold ) NIST; sf; std + std 22.20; 30.73 103; 75
221.0661
(2-fold ) -1.7 0.09 4.78E-03 0.22 1.41E-02 2.30 >0.05
99 D-2-HG (3-fold +lactone) std + sf; std 33.52; 37.47 71; 85 145.0501(lactone) -0.37 0.21 1.27E-05 0.56 3.48E-03 2.62 2.92E-02
100 L-2-HG (3-fold +lactone) std + sf; std 34.24; 40.34 71; 85 145.0501(lactone) -1.32 0.10 6.07E-04 0.33 7.27E-03 3.22 >0.05
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14 SUMMARY 
Chirality is not a rare phenomenon in metabolomes. Nevertheless, common 
metabolomics approaches still detect enantiomers as a single signal. However, they 
are individual metabolites due to different stereospecific enzymes catalyzing their 
metabolism. The here presented methods consider the configuration of chiral 
metabolites in the interpretation of metabolomics data to investigate the following 
biomedical hypotheses. D-AAs, albeit much lower abundant than their antipodes, are 
potential diagnostic markers for diseases affecting the liver, the gut and the gut flora. 
The other assumption of this thesis was that the comprehensive resolution of 
stereoisomers from metabolomes, providing more detailed metabolic fingerprints than 
conventional approaches, would facilitate the differentiation of groups. 
In order to investigate the former hypothesis two different GC-MS techniques were 
used for the implementation, optimization and validation of quantitative AAE analysis, 
primarily in urine and serum. The GC-qMS method using MeOH/MCF derivatization 
and a γ-CD derivative for enantiomer separation was chosen, among several tested 
derivative/chiral selector combinations, in my diploma thesis as the most effective 
GC-qMS method for quantitative AAE analysis with respect to the number of baseline 
separated proteinogenic AAE pairs and peak intensities. Sample preparation was 
optimized to allow the accurate quantification of exclusively free AAEs. In addition 
injection parameter and IS contents were optimized to decrease LLOQs and the 
method was validated by comparison to a non-chiral GC-qMS method for AA 
quantification. Finally, the method was subjected to biomedical applications that 
underlined the potential of D-AAs as diagnostic markers due to changed D-AA levels 
found in mouse serum and mouse liver tissues as a consequence of pathological 
changes of the liver. The method separated ten pairs of AAEs, but it failed to 
separate Phe enantiomers, D-Ile/L-Leu, L-Thr/L-Asp, and L-Ser/D-Met. For L-Thr, L-
Asp and D-Met a specific m/z enabled their accurate quantification in SIM mode but 
the quantification of the other coeluting enantiomers was impeded. Moreover, not 
each D-AA that was baseline separated from its antipode could be quantified in all 
samples of interest due to insufficient LLOQs. Thus, the potential of comprehensive 
GC×GC-TOFMS was tested for quantitative AAE analysis in urine and serum. The 
same derivative/chiral selector combination was used and a ZB-AAA column 
provided best AAE resolution as the second dimension selector from two different 
 148 
 
selectors tested. Upon optimization of the temperature program, baseline separation 
was accomplished for all detected AAEs except for Phe enantiomers. The method 
was validated by comparison to the chiral GC-qMS method and pros and cons of 
both approaches were discussed. The application of chiral GC×GC-TOFMS revealed 
increased D-AA serum levels in patients with liver cirrhosis when compared to 
respective serum levels of healthy individuals. Finally, performing a chiral 
fingerprinting approach, it was demonstrated that comprehensive enantiomer 
resolution assisted with the differentiation of different NAFLD stages in the analysis of 
urine samples from respective mouse models. There was observed a clear group 
separation of the three investigated groups after PCA of differentiating features and 
D-Val, D-2-HG and D-allo-Ile levels significantly differentiated NASH from hepatic 
steatosis. There were identified further enantiomers of hydroxydiacids and AA 
derivatives that significantly differentiated the diseased groups from controls and 
besides D-Val six other separated AAEs differentiated the experimental groups. This 
chiral GC-qMS based fingerprinting approach introduced a new field of investigation 
that I named ‘chiralomics’ as it expanded metabolomics to the chiral dimension. 
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15 ZUSAMMENFASSUNG 
Viele Stoffwechselprodukte sind chiral, werden aber in der Metabolomik meist nicht 
getrennt bestimmt. Stereoisomere sind jedoch auf Grund der Stereospezifizität der 
meisten Enzyme, die für ihren Auf- und Abbau verantwortlich sind, eigenständige 
Stoffwechselprodukte und Veränderungen in ihrer Abundanz können Aufschluss über 
gestörte Stoffwechselwege geben. So sind D-Aminosäuren (D-As), die zwar in 
deutlich geringeren Mengen vorkommen als ihre Spiegelbilder, potenzielle 
diagnostische Marker für Krankheiten, die beispielsweise die Funktion der Leber, des 
Darms und der Darmflora beeinträchtigen. Die zweite Annahme der Arbeit war, dass 
die Auflösung von allen erfassbaren Stereoisomeren, detailliertere metabolische 
Fingerabdrücke generiert, die die Differenzierung von Gruppen erleichtern. 
Initiales Ziel der Dissertation war die Optimierung der GC-MS basierten, quantitativen 
Analysen von Aminosäure-Enantiomeren in biologischen Proben wie Blut und Urin. 
Ausgangspunkt war die Derivatisierung der Aminosäuren mit Methylchloroformat und 
Methanol, gefolgt von deren Trennung auf einer γ-CD basierten stationären Phase 
und anschließender Detektion mittels Quadrupol-Massenspektrometrie. Diese 
Kombination hatte sich im Rahmen meiner Diplomarbeit als die effektivste unter den 
getesteten Derivat/ Säule Kombinationen für die quantitative Bestimmung von 
Aminosäure-Enantiomeren erwiesen. Durchgeführte Verbesserungen betrafen die 
Probenvorbereitung (Vorabtrennung von Proteinen und Durchführung der 
Derivatisierung ohne Einsatz von NaOH, um die Bestimmung von protein- und 
peptidgebundenen AsE zu unterbinden), die Injektion und die Konzentration der 
internen Standards, wodurch eine bis zu 16-fache Verbesserung der unteren 
Bestimmungsgrenzen erzielt werden konnten. Die optimierte Methode wurde über 
einen Methodenvergleich mit einer etablierten achiralen GC-qMS Methode für 
quantitative As Analytik in Serum und Urin validiert. Die Methode ermöglichte die 
Trennung von zehn Aminosäure-Enantiomerenpaaren, schaffte es jedoch nicht Phe 
Enantiomere, sowie D-Ile/L-Leu, L-Thr/L-Asp, und L-Ser/D-Met aufzulösen. Von 
diesen konnten im SIM-Modus, anhand von charakteristischen m/z Werten L-Thr, L-
Asp und D-Met quantifiziert werden, während die Bestimmung der anderen 
überlappenden Enantiomere gestört war. In der Anwendung an Serum und 
Leberproben aus Mausmodellen zur Fettleber erwiesen sich überdies die 
Bestimmungsgrenzen ungenügend, um alle D-As, die von ihrer L-Form getrennt 
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waren, in allen Proben zu quantifizieren. Deshalb wurde die Leistungsfähigkeit der 
allumfassenden zweidimensionalen Gaschromatographie (GC×GC-TOFMS) für die 
Bestimmung von AsE in Urin und Serum getestet. Es wurde die gleiche As Derivat/ 
chirale Säule Kombination verwendet und zudem eine ZB-AAA Säule, welche die 
beste Enantiomerenauflösung, von den zwei für die zweite Dimension getesteten 
Säulen, ermöglichte. Über die Optimierung des Temperaturprograms erreichte ich die 
Basislinien-Trennung aller erfassten AsE mit Ausnahme der Phe Enantiomere. Die 
Methode wurde über einen Methodenvergleich mit der chiralen GC-qMS validiert und 
Vor- und Nachteile beider Methoden wurden diskutiert. Die GC×GC Methode fand 
erhöhte D-As Serum Gehalte in Leberzirrhose Patienten im Vergleich zum D-As 
Serum Gehalt in gesunden Probanden und bekräftigte damit die untersuchte 
Hypothese. Die zweite Annahme dieser Arbeit wurde mit Hilfe eines erstmalig 
durchgeführten chiralen Fingerprintings untersucht. Es wurde gezeigt, dass die 
allgemeine Trennung von Enantiomeren zur Unterscheidung verschiedener NAFLD 
Stufen, anhand von Urin der entsprechenden Mausmodelle, beiträgt. Eine deutliche 
Gruppentrennung war mit Hilfe von PCA der differenzierenden Peaks sichtbar und D-
Val, D-allo-Ile und D-2-HG Gehalte unterschieden NASH von der hepatischen 
Steatose deutlich. Es wurden weitere Enantiomere von Hydroxydisäuren und As 
Derivaten identifiziert, die die kranken von den gesunden Mäusen unterschieden und 
weitere sechs AsE differenzierten die experimentellen Gruppen. Dieser 
allumfassende enantioselektive Ansatz mittels GC-qMS eröffnete ein neues 
Wissenschaftsgebiet, welches ich „Chiralomics“ nannte, da es das Gebiet der 
„Metabolomics“ um die chirale Dimension erweitert. 
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